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1.1 The role of Cell-Mediated immunity in the immune system 
The immune system can be divided in two main branches, the Humoral and the Cell-
mediated immunity. Humoral immunity is responsible for the production of antibodies while the 
cell-mediated immunity protects the body using several mechanisms. It can activate antigen-
specific cytotoxic T-lymphocytes that are able to induce apoptosis in body cells displaying 
epitopes of foreign antigens on their surface, such as virus-infected cells, cells with intracellular 
bacteria, and cancer cells displaying tumour antigens. The cell-mediated immunity also activates 
macrophages and natural killer cells, enabling them to destroy intracellular pathogens, and it can 
stimulate cells to secrete a variety of cytokines that influence the function of other cells involved 
in adaptive and innate immune responses. Intracellular microorganisms may elicit the production 
of antibodies or activate specific T-cells. Activation of T-cells takes place exclusively under the 
so-called Major Histocompatibility Complex (MHC) restriction (Figure 1.1). The MHC is 
basically a set of molecules displayed on cell surfaces that are responsible for lymphocyte 
recognition and "antigen presentation". T-cells recognize, by the T-cell Receptor (TCR, on the T-
cell surface), only specific antigenic peptides bound to an MHC molecule presented by Antigen 
Presenting Cells (APCs). This recognition is "MHC-restricted" because the TCR also requires 
interactions with MHC. Into the APCs family, among others, belong also Dendritic Cells (DCs).  
The MHC molecules control the immune response through recognition of "self" and "non-self" 
and, consequently, serve as targets in transplantation rejection. There are several classes of MHC 
molecules. Class I and Class II belong to a group of molecules known as the Immunoglobulin 
Supergene Family, which includes immunoglobulins, T-cell receptors, CD4, CD8, and others. 
 
 
Figure 1.1 Schematic representation of the major histocompability complex (MHC)1 
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Class I molecules are found on virtually every cell in the human body and present "endogenous" 
antigens to cytotoxic T-cells (CTLs). An endogenous antigen might be a fragment of viral 
proteins or tumour proteins: presentation of such antigens would indicate internal cellular 
alterations that if not contained could spread throughout the body. Hence, destruction of these 
cells by CTLs is advantageous to the body as a whole.  
Class II molecules are only found on professional APCs like B-cells, macrophages and dendritc 
cells and present "exogenous" antigens to helper T-cells (TH-cells). Exogenous antigens might be 
fragments of bacterial cells or viruses that are engulfed and processed by e.g. a macrophage and 
then presented to helper T-cells. The TH-cells, in turn, could activate B-cells to produce antibody 
that would lead to the destruction of the pathogen. 
Professional APCs can internalize antigens very efficiently, either by phagocytosis or by 
receptor-mediated endocytosis. After internalisation APCs usually migrate to the lymph vessels 
and are carried via lymph flow to the draining lymph nodes. During the migration, DCs and 
other APCs undergo maturation, mainly by loosing most of their ability to further engulf 
pathogens, and developing an increased ability to communicate with T cells. In the lymph nodes 
APCs such as dendritc cells can interact with T cells. 
Within the DC lysosomal compartment the internalized pathogen can be digested by proteolytic 
enzymes, reactive oxygen intermediates (ROI) and nitrogen monoxide (NO) into smaller pieces, 
and only a few of them are epitopes stable enough to migrate toward the cell surface and to be 
presented to T cells as MHC II complex.2  
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Figure 1.2 Antigen presentation of dendritic cell to the T-cell by MHC molecule3 
 
DCs express a range of Pathogen-Recognition Receptors (PRRs), including Toll-like 
receptors (TLRs) and C-type lectins that can recognize molecular patterns expressed by 
pathogens.4 PRRs recognize characteristic molecular patterns in microbial cell-wall components, 
such as carbohydrate structures (C-type lectins), nucleic acids (TLRs) and lipids.  
The DC response is modulated depending on the type or form of a microorganism that is 
recognized by different TLRs and C-type lectins. TLRs relay the information about the 
interacting pathogen to DCs through intracellular-signalling cascades, thereby eliciting 
appropriate cellular processes that lead to DC maturation and the induction of inflammatory 
cytokines, whilst C-type lectins internalize pathogens for degradation in lysosomal 
compartments to enhance antigen processing and presentation by DCs. Carbohydrate structures 
on self glycoproteins are also recognised by C-type lectins, thus allowing tolerance to self 
antigens and helping to mediate cellular processes, such as cell signalling, cell adhesion and 
migration.  
There have been described many different C-type lectins expressed by DCs, such as the 
mannose receptor (CD206), DEC205 (CD205), DC-SIGN (CD209), blood DC antigen 2 
(BDCA2), dectin-1, DC immunoreceptor (DCIR), DC-associated lectin 1 (DCAL1), C-type 
lectin receptor 1 (CLEC1), Langherhans-cell-specific C-type lectin (Langherin, CD207) and DC-
asialoglycoprotein receptor (DC-ASGPR) / macrophage galactose N-acetyl-galactosamine 
specific lectin 1 (MGL1). Many of these C-type lectins have been shown to function as antigen 
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receptors. Monocyte-derived DCs and interstitial DCs express the highest diversity of C-type 
lectins. By contrast, only a few C-type lectins have been identified on DCs from the blood and 
Langherhans cells. Langherhans cells specifically express Langherin, whereas plasmacytoid DCs 
express BDCA2 and dectin-1.  
 
1.2 DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-
Grabbing Non-integrin) 
 
DC-SIGN is a C-type lectin receptor (CLR) expressed exclusively on dendritic cells.5 It fulfils 
several functions: as adhesive molecule it enables DC migration, pathogen/antigen recognition 
and antigen presentation to T-Cells. After ligand binding, DC-SIGN initiate a signal pathway, 
which modulates DC maturation and cytokine-expression profile.6 
CLRs contain one or more carbohydrate recognition domains (CRDs). The CRD of DC-SIGN 
is a globular structure consisting of 12 β-strands, two α-helices and three disulphide bridges.7,8 
DC-SIGN also contains a neck region composed of four associated chains, each composed of 
seven complete and one incomplete tandem repeats, and a transmembrane region followed by a 
cytoplasmic tail containing recycling internalisation and intracellular signalling motifs, i.e. a di 
leucine (LL) motif, tri-acidic (EEE) clusters, and an incomplete immunoreceptor, tyrosine-based, 
activation motif (Figure 1.3).  
 
Figure 1.3 The structure of DC-SING and the tetramerisation through association of the neck 
domains9 
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DC-SIGN undergoes tetramerisation which is initiated by the neck domain10 which has an 
impact on the binding affinity of the receptor and also provides specificity, thereby defining the 
set of pathogens that are recognized by DC-SIGN. The tetramerisation depends highly on pH; in 
acidic media the tetramer falls apart to monomers and thus pathogen release can occur in the 
acidic endosomal environment, where its degradation takes place.11  
DC-SIGN recognises mannose and fucose-containing glycans which makes this receptor a target 
for a great number of important pathogens such as bacteria, parasites, fungi and viruses.2,7, 12 One 
of the characteristics of some bacterial pathogens is that they use DC-SIGN to increase their 
infectivity and host survival, which leads to chronic infectious states: during the pathogen - DC-
SIGN interaction an inappropriately polarized T-cell response is developed, which can not 
ensure complete clearance of the pathogen. An example of pathogen which uses DC to spread 
itself is the HIV-1 virus.13 HIV infects DCs (in mucosal tissues and blood) which then carry the 
virus to the lymphoid tissue where it infects the CD4+ T cells. The first contact between DC-
SIGN and HIV-1 occurs via its envelop gp120 protein, and the DCs are immature during this 
state.  The formed DC-SIGN-HIV-1 complex is internalised to the endosomes where the acidic 
media causes dissociation.14 Most of the ligands are lysed and processed via degradation 
pathways, but HIV-1 probably remains bound to DC-SIGN and the small amount of HIV-1 that 
enters DCs remain protected from the host immune system and retains its infectiveness.15,16 HIV-
1 stays hidden in multivesicular bodies for days until it reaches the T cell and infects them. 
However, HIV-1 adhesion to DCs may also occur in a receptor-independent way so HIV-1 may 
adhere to DCs by a variety of modes depending on the DC type and maturation status. A number 
of other pathogens besides HIV-1 bind to DCSIGN. Viruses (HCV, CMV, Dengue, Ebola, 
SARS-CoV, HSV, coronaviruses, H5N1, West Nile virus, measles virus), bacteria (M. 
Tuberculosis, H.pylori, L. interrogans), fungi (C. albicans, A.fumigatus) and several parasites 
(Leishmania, S. mansoni) use DC-SIGN as their main cellular entry mechanism.4  
 
1.3 Langherin 
As it was described in the previous section HIV-1 virus is transmitted to T-cells by DCs through 
DC-SIGN. However, pathogens like HIV-1 interact also with epithelial Langherhans cells (LCs), 
which are the first DC subset to encounter HIV-1 virus.17 LCs interacts with the pathogen via 
Langherin receptor. While interaction of HIV-1 with DC-SIGN enables HIV-1 to survive a host 
immune system, Langherin mediates HIV-1 internalisation into Birbeck granules where viral 
particles are degraded,18 thus interaction of the pathogen with Langherin is desired since it helps 
to prevent the infection.  
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Langherin is structurally similar to DC-SIGN; the extracellular domain consists of a C-type 
carbohydrate-recognition domain (CRD) and a neck region, which induces oligomerisation. 
While DC-SIGN exists as tetramer, Langherin is a trimer (Figure 1.4).19 
 
 
 
Figure 1.4 The monomeric and trimetric structure of Langherin18 
 
The binding site of the CRD contains a calcium atom which can coordinate mannose or glycans 
containing mannoses However, as it will be discussed in chapter 2, the binding site is structurally 
different from the binding site of DC-SIGN,20 allowing development of ligands which selectively 
binds to DC-SIGN but not Langherin.    
 
1.4 Natural DC-SIGN ligands 
 
Pathogens are using heavily glycosylated envelopes to bind DC-SIGN. A study from 2004 using 
glycan arrays probed with fluorescent-labelled DC-DIGN and DC-SIGNR showed that the most 
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potent fucose based natural ligands are Lewis a, b, x and y, and blood group A and B (Figure 
1.5).21 
 
Figure 1.5 Fucose and mannose based natural oligosaccharides and their affinity to binds DC-
SIGN21 
 
Among the mannose based ligands, the oligomannoside Man9 was found as progenitor of the 
high-Man family and exhibited the highest affinity with DC-SIGN (Scheme 1.1). 
 
Scheme 1.1 The structure of Man9 
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Another study, using a recent version of the Consortium for Functional Glycomics glycan array 
with human DC-SIGN, found that the three most active ligands belong to the high-Man family 
followed by some fucosylated Lewis-type structures (Figure 1.7).22 
 
Figure 1.6 Natural DC-SIGN ligands arranged by the potency to bind DC-SIGN22 
 
Binding assays to high density glycan-arrays functionalized with the complete epitope and its 
fragments allowed to detect that simpler linear fragments of Man9 have similar binding affinities 
DC-SIGN as Man9 itself (Scheme 1.2).23  
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Scheme 1.2 The structure of Man9 and its fragments and their potency to bind DC-SIGN23 
 
1.5 DC-SIGN as therapeutic target 
As it was mentioned above, DC-SIGN binds a large number of different pathogens and some of 
them use this receptor as a Trojan horse to reach T-Cells and spread the infection. This suggests 
that DC-SIGN can be an interesting therapeutic target,24 since inhibition of the DC-SIGN – 
pathogen interaction could prevent the localised infection of DCs and also the pathogen 
A 
C 
D 
E 
F 
G 
B 
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dissemination. Numerous publications deal with DC-SIGN as a possible target for anti-infective 
therapy25,26,27,28 and several distinct strategies are used to accomplish this goal:  
• inhibition of pathogen binding to DC-SIGN by DC-SIGN specific ligands – small molecule 
DC-SIGN antagonists or mAbs against DC-SIGN.22,29,30,31,32  
• inhibition of pathogen binding to DC-SIGN by carbohydrate-specific ligands23 
• inhibition of pathogen binding to DC-SIGN by PAMP (Pathogen-Associated Molecular 
Patterns)-specific ligands/ antibodies25 
• use of specific DC-SIGN targeted vectors that encode pathogen proteins to induce 
immunisation33 
 
The use of small molecules as DC-SIGN antagonist can be a promising methodology, and there 
have been already reported many molecules with different structural properties as potential DC-
SIGN ligands. The natural monovalent DC-SIGN ligands as mannose and fucose bind only with 
low affinity and this prevent them in use for therapeutic treatment. Moreover, the high ligand 
promiscuity of DC-SIGN requires specific molecules which bind selectively this target receptor. 
The high polarity of mono and polysaccharides is not in accordance with the common drug-like 
structures and therefore the design of therapeutically useful DC-SIGN antagonists is still a 
challenging task.    
In the design of potent and selective DC-SIGN antagonists three main concepts have been used  
1. the design of monovalent glycomimetics based on the DCSIGN-binding 
oligosaccharides34,35,36,37,38,39,40 
2. multimeric presentation of monosaccharides/oligosaccharides or glycomimetics41,42,43,44,40,45 
3. screening of compound libraries to obtain non-carbohydrate DC-SIGN antagonists31,32 
 
1.6 Monovalent glycomimetics as DC-SIGN ligands 
The CRD of DC-SIGN contains a calcium atom which is able to coordinate mannose and fucose 
molecules. With proper modification of natural sugar containing ligands the affinity and 
selectivity towards DC-SIGN can be improved. Furthermore, by changing from sugar to “sugar 
like” structures higher metabolical stability against sugar hydrolysing enzymes can be achieved. 
In general, the monovalent sugar anchor is used unchanged (since it primarily binds to calcium) 
and is decorated with structures which help to gain further interaction with the binding site 
and/or improve its overall properties.  
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1.6.1 Carbohydrate based DC-SIGN ligands 
1.6.1.1 Fucose based 
Bernardi et. al, by mimicking the Lewis-X trisacharide 1.1, designed α-fucosylamides as DC-
SIGN ligands.35,34 The α-amidic bond is used as a surrogate for the metabolically unstable α-
glycosidic bond.  In the first generation of fucosyl amides the full Lewis-X mimic 1.2 showed 
higher affinity than the natural Lewis X. The structurally simpler mimic 1.3 was found to be 
almost as potent as compound 1.2 (Scheme 1.3). STD-NMR experiments showed that only the 
fucose part of the molecule has strong interaction with the CRD of DC-SIGN.  
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Scheme 1.3 Structure of natural and synthetic fucose based DC-SIGN ligands35 
 
Further, a set of 30 compounds was synthesised with general structure 1.4 and binding affinities 
similar to compound 1.3, regardless on the R group and configuration of the central scaffold. A 
replacement of the aminocyclohexanecarboxylic acid ring by the simpler and more flexible β-
alanin gave compounds with general structure 1.5 which exhibited affinities similar to Lewis X 
(Scheme 1.4).  
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Scheme 1.4 General structures of fucose based ligands developed by Bernardi et al.34 
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1.6.1.2 Mannose based 
Mannose based DC-SIGN ligands have been studied more extensively than those based on 
fucose, probably due to the fact that most of the natural DC-SIGN ligands contain mannose or 
higher mannose structures.  
In 2007 a group of 2-C-substituted branched D-mannose analogues 1.6a-d was reported as better 
DC-SIGN binder than D-mannose.36 In particular 2-C-aminomethyl-D-mannose 1.6c showed 48-
fold higher affinity to DC-SIGN (Ki=0.35 mM, Ki(mannose)=17.1 mM), as determined using a 
surface plasmon resonance (SPR)-based competition assay that measures inhibition of DC-
SIGN-HIV gp120 binding (Scheme 1.5). 
 
Scheme 1.5 Branched D-mannose analogues as potent DC-SIGN inhibitor36 
 
Reina et al. published a mimic of the Manα1-2Man dimannoside, where the reducing end is 
substituted with a conformationally constrained cyclohexane derivative.37 The molecule is also 
functionalised either with a methyl (1.7a), azidoethyl (17b) or aminoethyl (17c) group which 
represents a linker and makes the molecule suitable for multivalent presentations (Scheme 1.6). 
The activity of these compounds was tested on Ebola virus entry into DC-SIGN expressing 
Jurkat cells and it was found that compound 1.7c (IC50 = 0.62 mM) is 3 times more active than 
the natural disaccharide 1.8 (IC50 = 1.91 mM).  
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Scheme 1.6 Structures of the natural dimannoside derivative 1.8 and its mimic 1.7a-c37 
 
STD-NMR of 1.7b with the extracellular domain of DC-SIGN confirmed that 1.7b is in close 
contact with the protein and the mannose mimic at the reducing and also makes interactions with 
the binding site.   
The same research group reported also a trimannoside mimic 1.9, where the central mannose is 
replaced with the functionalised cyclohexane used in compounds 1.7a-c (Scheme 1.7).38 The 
prepared DC-SIGN ligands were tested by SPR experiments (competition assay) and it was 
found that the trimannoside mimic 1.9 is an order of magnitude more active than the 
corresponding dimannoside 1.7b. 
 
O
O
MeOOC
MeOOC
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OH
OH
HO
HO
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O
O
N3
HO
HO
HO
1.9
 
Scheme 1.7 Pseudo trimannoside derivative 1.938 
 
Compound 1.9 showed improvement in activity in comparison with 1.7 but, on the other hand, 
the trimannoside mimic is synthetically less accessible. In order to gain further interaction with 
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the binding site the structure of 1.7 was modified by replacement of the methyl esters by amide 
groups which allowed to introduce lyophilic moieties into the molecule (Scheme 1.8).  
 
Scheme 1.8 Bisamides 1.10 derived from the dimannoside mimic 1.7c 
 
A small library of pseudo dimannoside-based bisamides 1.10 was prepared and tested using a 
DC adhesion assay to mannan-coated plates.39 It was found that the majority of synthesized 
compounds inhibit DC adhesion at low micromolar concentrations, which makes them more 
potent than the starting compound 1.7b by up to two orders of magnitude (Scheme 1.9). 
 
Scheme 1.9 Bis-amides 1.10a-c showing IC50 values at low micromolar range39 
 
Garber et al used Shikimic acid as a mannose mimic since the hydroxyl groups at position 2, 3 
and 4 have the same configurations.40 They designed a DC-SIGN ligand 1.11 based on Shikimic 
acid and synthesised a library of 192 compounds which were screened using a fluorescence-
based, high-throughput competition assay that assesses the ability of compounds to compete with 
immobilized mannan for binding to the fluorophore labelled DC-SIGN extracellular domain 
(Scheme 1.10). Compound 1.11a had the highest affinity with IC50 = 3.2 mM while the activity 
of N-acetylmannosamine was at 11.5 mM.  
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Scheme 1.10 Development of Shikimic acid derived DC-SIGN ligands 1.1140 
 
More importantly, it was found that these compounds are much more selective for DC-SIGN 
than for mannose binding protein A, which is a C-type lectin found in serum that participates in 
the innate inflammatory response in defence against a variety of bacterial, fungal and viral 
pathogens.   
1.6.2 Non-carbohydrate based DC-ligands 
Kiessling in a publication from 2007 describes a structurally new class of DC-SIGN ligands.31 
The potential DC-SIGN inhibitors were found after a screening of two libraries of small organic 
molecules (32 000 compounds). By high throughput screening using immobilised DC-SIGN, 7 
compounds 1.12-1.18 were found with activities in the low micromolar range (Scheme 1.11).  
The molecules have no similarities with native carbohydrates or carbohydrate mimics, proving 
that sugars are not essential in the design of potential DC-SIGN inhibitors.  
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Scheme 1.11 Non-carbohydrate based DC-SIGN ligands developed by the group of Kiessling, 
and their activities determined by the screening assay (IC50) and cell adhesion assays (IC50*)31 
 
In a more recent publication from the same group an optimisation of structure 1.12 and 1.14 is 
described.32 The most potent ligand 1.19 among the prepared compounds exhibited activity in 
the nanomolar range (IC50 = 310nM) demonstrating that small and highly potent non 
carbohydrate based DC-SIGN ligands are achievable targets (Scheme 1.12).   
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Scheme 1.12 The most potent non-carbohydrate or carbohydrate mimic based DC-SIGN ligand32 
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1.7 Multivalent presentation of carbohydrate based DC-SIGN ligands.  
Despite the fact that improvements were achieved in the development of monovalent DC-SIGN 
ligands, the activities are still too low in comparison with the natural ligands. Nature uses highly 
glycosylated structures to achieve multivalent interactions with DC-SIGN and this helps 
significantly to improve its binding activity. This strategy is successively used also in the design 
of poly or multivalent structures as DC-SIGN ligands.  
The first example of using multivalent scaffolds to inhibit DC-SIGN is from the group of Dr. 
Rojo and Delgado.41 They used a Boltorn type dendrimer 1.20 functionalised with 32 copies of 
mannose (1.20a) which was tested in cis and trans DC-SIGN mediated Ebola virus infection 
studies and the IC50 was found to be in the nanomolar range (IC50 = 337 nm), proving the 
efficiency of multivalent systems (Scheme 1.13). The pseudo-di and pseudo-trimanmoside 
mimics 1.7c and 1.9 were also conjugated to the Boltorn H30 dendrimer (1.20b, 1.20c) and 
tested in cis DC-SIGN mediated Ebola virus infection studies showing activities in low 
nanomolar range (IC50 = 20 nm, Scheme 1.13).42,43 
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Scheme 1.13 Boltorn type dendrimer decorated with mannose-based DC-SIGN inhibitors41,42,43 
 
Further, a tetravalent dendron was developed to reduce the loading of the multivalent structures 
(Scheme 1.14).43 This dendron was conjugated with 1.17c and 1.19 and tested in trans infection 
experiments where the IC50 value for 1.21a and 1.21b was 1.22 µM and 203 nM respectively. 
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Scheme 1.14 Dendrons bearing sugar mimics 1.17c and 1.1943 
 
The tetrameric Dendron 1.21 represents a structurally simpler compound in comparison with the 
3rd generation Boltorn type dendrimer 1.20, while the IC50 affinity towards DC-SIGN can be still 
in the nanomolar range.   
Another type of glycodendron bearing 25 copies of Man4 and Man9 oligosaccharides was 
developed by Wang et al.46 Using a glycan array assay that measures binding to HIV-1-
neutralizing monoclonal antibody and recombinant dimeric DC-SIGN, these glycodendrons 
exhibited potent inhibition of binding in the low nanomolar range. 
Glycopolymers 1.22 functionalised with α-mannose and β-galactose in different ratios have been 
synthesised by Becer et al (Scheme 1.15).44 The activities of these polymers were determined 
using an SPR assay that measures inhibition of DC-SIGN-gp120 binding, and it was found that 
the potency highly depends on the mannose content; an IC50 of 37 nM was obtained for a 
glycopolymer with 100% mannose.  
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Scheme 1.15 Polymer 1.22 as multivalent scaffold functionalised with α-mannose and β-
galactose44 
 
The glycomimetic 1.11a derived from Shikimic acid was also prepared in multivalent 
presentation as it was conjugated with a scaffold prepared by ring-opening methathesis (Scheme 
1.16).40 Polymer 1.23 functionalised with 29 copies of 1.11a has IC50 = 2.9 µM and its length 
should be enough to reach two CRDs of DC-SIGN.   
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Scheme 1.16 Polymer prepared by ring opening metathesis and functionalised with 1.11a40 
 
Nanoparticles were also used as potential multivalent system to block HIV-1 gp120 binding to 
DC-SIGN. Martinez-Alvila designed a small library of manno-glyconanoparticles (manno-
GNP), where the gold nanoparticles were functionalised with truncated (oligo)mannosides of the 
high-mannose oligosaccharide ligand for DC-SIGN (undecasaccharide Man9GlcNAc2, scheme 
1.17).45 Three different types of nanoparticles 1.24, 1.25 and 1.26 were prepared and tested both 
in SPR based competition assay and by in vitro assay that measures DC-SIGN mediated HIV-1 
trans-infection of human T lymphocytes. The results indicate that HIV-1 infection can be 
successfully inhibited by all GNPs, but the carbohydrate density on the gold surface has a 
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noticeable effect on the inhibition. In particular, GNP bearing 56 copies of Manα1-2Manα1-
2Manα1-3Manα showed remarkable inhibitory potency, with an IC50 of 0.34 nM to 0.83 nM, 
depending on the type of recombinant virus.  
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Scheme 1.17 Three types of gold nanoparticles bearing different mono and polysaccharides45 
 
 A significant drawback of gold nanoparticles is their toxicity caused by gold accumulation, 
however topical use should overcome this problem.  
From the previous examples, it is clear that the strategy to obtain potent and selective DC-SIGN 
antagonists is based on the development of small molecules which are then conjugated to 
multivalent scaffolds. The effect of multivalency helps significantly to improve the activity of 
the molecules giving chance for the development of antimicrobial agents which target DC-SIGN.   
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The synthesis of small organic molecules that bind to DC-SIGN in monovalent fashion is 
an important step in the development of potent and selective DC-SIGN inhibitors.1,2,3,4 
Compounds mimicking native carbohydrates5,6,7,8,9 showed promising results to achieve this goal 
and therefore this project focused mainly on the optimization of the pseudodimannoside (ps-
diMan) structures previously developed in the group of professor Anna Bernardi10,11 in 
collaboration with the European network CARMUSYS.12   
The first part of this chapter describes the synthesis of a library of appropriately functionalized 
ps-diMan based bisamides as well as the activity determination studies that allowed us to select 
one of the molecules for further elaboration. In the second part of the chapter a modification of 
the mannose residue in the ps-diMan structure is discussed. A synthetic pathway which allows to 
introduce a nitrogen atom to the position 6 of this ring is established and SPR measurement show 
that the modification has positive effect on the activity of some of the prepared ligands.  
2.1 Synthesis and activity determination of Pseudodimannoside based 
bisamides 
In a recent publication from the group of Anna Bernardi a library of dimannoside mimics of 
general formula 1.10 (Scheme 2.1) functionalized with two lipophilic amide groups is 
described.11  
 
 
Scheme 2.1 Bisamides 1.10b,d,e derived from the dimannoside mimic 1.7c showing IC50 values 
in the low micromolar range 11 
 
The prepared bisamides were tested using a DC adhesion assay to mannan-coated plates, and 
selected compounds were also tested by a SPR technique in which a competition experiment was 
used. The ligands were tested for their ability to inhibit binding of DC-SIGN to Man-BSA 
immobilized on the surface of an chip (for details about SPR see section 2.1.4.1). Some of tested 
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molecules showed improved activity in comparison with the parent methyl ester 1.7c.13 These 
studies allowed to establish that tertiary amides were not effective binders, and that among the 
molecules studied N-benzyl amides such as 1.10b,d,c (Scheme 2.1) were the most promising 
ones. These results were encouraging, since multivalent presentations of the most active 
bisamides could result in high affinity DC-SIGN ligands. In order to understand the binding 
mode of the compounds from the 1.10 series with DC-SIGN and to establish what is the 
contribution of each part of the molecule in the binding process, NMR experiments were 
performed using STD method (group of professor Pedro Nieto, Seville). The experiments 
showed relatively high saturation of the allyl function which suggests that this group has non 
specific interaction with DC-SIGN. This can be reflected in the activity of the compounds as a 
decrease of the IC50 value which may not correspond to a real antagonistic activity. Moreover, 
these molecules don’t contain a functional group which could be used to connect them with 
multivalent scaffolds. In order to eliminate the problem regarding the non specific interaction 
and to obtain a potent monovalent DC-SIGN ligand which can be connected to multivalent 
scaffolds, three main goals were set for my research (Scheme 2.2): 
1. Establish a synthetic pathway for the synthesis of DC-SIGN ligands 2.2 functionalized 
with an azide-terminated linker which allows conjugation via “click” chemistry (1,3 
dipolar cycloaddition) 
2. Prepare a small library of ligands and test them in biological assays to evaluate their 
activities 
3. Finally, select the most promising monovalent ligand and synthesize it in large scale for 
further elaboration towards multivalent systems.  
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Scheme 2.2 Schematic representation of the strategy used for the development of a potent and 
selective DC-SIGN inhibitor 
 
2.1.1 Synthesis using pentafluorophenol ester activation 
The synthetic approach used for the preparation of compounds 2.2 (Scheme 2.3) is 
similar to the previously described methodology.11 It starts from the enantiomerically pure diacid 
2.1.14 The first step was a di-ester formation with pentafluoro phenol (PFP). This transformation 
protects the acid in the following two steps, and at the same time provides the required activation 
of the carboxyl groups for reaction with the amines. The activation was followed by oxidation of 
the double bond (MCPBA) to afford epoxide 2.4 (Scheme 2.3).  
As shown in Scheme 2.3 epoxide 2.4 can be opened with neat chloroethanol using 
copper(II)triflate (Lewis acid) as a promoter. Cu/OTf)2 was previously selected as the most 
efficient catalyst in order to open epoxides of these kind.14 In former procedures epoxide 2.4 (or 
the methyl ester analogue) was opened with allylic alcohol11 or 2-bromoethanol.10 Allylic 
alcohol allows opening the epoxide with excellent yield (>90%) but unfortunately this linker is 
not suitable for an easy conjugation to multivalent supports (as mentioned above). 
Bromoethanol, on the other hand, does not dissolve copper triflate and dichloromethane had to 
be used as solvent in this reaction, which, in turn, slowed down the process and resulted in low 
yields (40%) of the corresponding alcohol.13 Furthermore, purification of the product from the 
excess of bromoethanol was difficult. Substituting bromoethanol by chloroethanol led to a great 
improvement of yields (from 40% to 94%) mostly because there is no need of additional solvents 
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since choroethanol is able to dissolve both the substrate and the promoter.13 2-azidoethanol 
(which was used later, see section 2.1.2) was not considered initially as an option for safety 
reasons.15 In summary, during this reaction chloroethanol was used as a nucleophile and solvent 
to open the epoxide 2.4 in the presence of a catalytic amount of copper(II) triflate. The activated 
esters are fully stable under these conditions and only one isomer is formed, compound 2.5, 
which represents a mannose mimic where the conformationaly constrained cyclohexane14 is 
substituted with four functional groups mimicking the α-1,2-mannose configuration.  
 
Scheme 2.3 Reactivity determination of the PFP activated ester containing compound 2.5 
 
An attempt to replace the chloride of 2.5 by an azide using sodium azide in DMF as 
solvent failed. Within one hour the starting material was consumed and several products were 
observed in the reaction mixture (TLC). One main product was isolated from the reaction 
mixture but the NMR signals did not correspond to the desired product 2.6. Also, the fast 
reactant consumption indicates that chloride exchange by the azide group did not take place. 
Most probably the PFP esters are more reactive towards sodium azide than the primary chloride 
(Scheme 2.3) 
The second attempt was the replacement of PFP esters in molecule 2.5 with p-
methoxybenzyl amine, which was selected as a model amine leading to a potentially active 
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ligand. This reaction worked well, and the primary chloride was not substituted by the amine 
confirming that the activated esters are indeed more reactive than the chloride (Scheme 2.3) 
 Having established that the p-methoxybenzyl amine reacts chemoselectively with PFP-
esters we set to obtain the mannosylated scaffold 2.9 by glycosylation of compound 2.5. The 
glycosyl donor in this reaction is mannose 2.8 activated with trichloroacetimidate in the 
anomeric position and protected by benzoyl groups in all other positions (Scheme 2.4).16 
Trichloroacetimidate (TCA) is a relatively stable functional group and its stability depends on 
the nature of neighbouring hydroxyl function protecting groups.17 However, upon a treatment 
with an acidic catalyst, TCA becomes a powerful leaving group leading to a Sn reaction in the 
presence of a glycosyl acceptor with a free hydroxyl moiety. Previous studies showed that tetra-
O-benzoylmannose-TCA is a better donor than the corresponding tetra-O-acetate giving higher 
glycosylation yield and reducing the formation of the orthoester byproduct.13 In this reaction, 
trimethylsilyltriflate (TMSOTf) was used in catalytic amount as Lewis acid and the product 2.9 
was isolated in 50% yield. Then, the exchange of PFP by p-methoxybenzyl amine in molecule 
2.9 was made under the same conditions described for 2.7. Finally, product 2.10a was treated 
with sodium azide in DMF to afford 2.11a in 86% yield. The mannose moiety in compound 
2.11a was deprotected under Zemplen conditions giving the final product 2.2a, and establishing 
the full sequence for the synthesis of the first library.   
 
Scheme 2.4 Synthesis of final ligand 2.2a starting from compound 2.5 
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In fact in Scheme 2.4 p-methoxybenzylamine was used as a model nucleophile but this synthetic 
strategy allows to use different amines. The general synthesis of ligands 2.2 summarizing the 
reactions from Scheme 2.3 and 2.4 is shown in Scheme 2.5. This strategy was later improved by 
replacing chloroethanol with azidoethanol, but it served us well for the preparation of the first 
group of bisamides. 
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Scheme 2.5 The full synthetic route for the preparation of DC-SIGN ligands 2.2 starting from 
diacid 2.1 
 
Among the ligands reported in the previous paper,11 those with substituted benzyl amides 
showed high activity (Scheme 2.1). Therefore, a small library of benzylamides substituted with 
hydrogen bond donor and/or acceptor on the aromatic ring was suggested using docking studies 
and prepared following the reaction pathway shown in Scheme 2.5. The group of ligands initially 
suggested is shown in Scheme 2.6.  
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Scheme 2.6 DC-SIGN ligands 2.2a-i prepared by the method using PFP activation showed in 
Scheme 2.5 
 
Benzylamines 2.12a-d used for the synthesis of ligands 2.2a-d were commercially available 
(Scheme 2.7) whereas  amines 2.12e-i had to be prepared in 1-3 steps.  
 
 
Scheme 2.7 Commercially available and not available benzylamines 2.12a-i used for the 
synthesis of DC-SIGN ligands 2.2a-i 
 
The synthesis of benzyl amines 2.12e-h used for the preparation of final ligands 2.2e-i is 
summarized in Scheme 2.8 
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Scheme 2.8 Synthesis of benzylamines 2.12a-h used for the preparation of final ligands 2.2e-i 
 
The synthesis of the bis p-acetylbenzylamide derivative 2.2i required an additional step in 
comparison with the general procedure shown in Scheme 2.5. The acetal groups in compound 
2.10h (intermediate during the preparation of 2.2h) were hydrolyzed using a catalytic amount of 
pyridinium 4-toluenesulfonate (PPTS) leading to compound 2.10i (Scheme 2.9). The last two 
steps (exchange of chloride by an azide and deprotection) were identical to those showed in 
Scheme 2.5. 
 
Scheme 2.9 Synthesis of final ligand 2.2i starting from compound 2.10h 
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In an effort to establish if polymannosylation of the scaffold could be beneficial for DC-
SIGN binding, also sugar moieties were introduced into the pseudo-disaccharide scaffold 
through amide bonds. An α-O-mannosyl ethanolamine was used as the carbohydrate residue 
(Scheme 2.10). 
 
 
Scheme 2.10 Structure of mannose derivative 2.12j used for the  synthesis of ligand 2.2j 
 
The synthesis of 2.2j started with the preparation of α-O-mannosyl ethanolamine 2.12j 
(Scheme 2.11) following an established protocol.18,19 The first step is a reaction between penta-
O-acetyl mannose 2.21 and 2-chloroethanol, in the presence of excess BF3.OEt2. The resulting 
compound 2.22 was treated with NaN3 in DMF in order to substitute the chloride by an azide 
group. The azide derivative 2.23 was then deprotected using sodium methoxide. The last step 
was the reduction of the azide 2.24 to the corresponding amine 2.12j (Pd/C, quant). 
  
 
 
Scheme 2.11 Synthesis of mannose derivative 2.12j 
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Condensation of the O-mannosyl ethanolamine 2.12j with the PFP-activated scaffold 2.9 was not 
successful when 2.5 molar equivalents of amine 2.12j, diisopropylethylamine (DIPEA) and 0.1 
M concentration of scaffold 2.9 in THF/water mixture was used. Under these conditions only the 
undesired imide 2.25 was isolated (Scheme 2.12). However, if the amount of amine 2.12j was 
increased to 6 molar equivalents, no DIPEA was used and the concentration of 2.9 was 0.3M, the 
desired bis amide 2.26 was isolated from the reaction mixture. Slow addition (8h) of a solution 
of 2.9 to the concentrated solution of 2.12j afforded 2.26 in 82% yield. 
 
 
Scheme 2.12 Reaction condition optimization for the synthesis of 2.32 
 
Compound 2.26, after chloride to azide transformation and deprotection, gave the final 
product 2.2j (Scheme 2.13). 
 
Scheme 2.13 Transformation of intermediate 2.26 to the final ligand 2.2j 
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2.1.2 Optimized synthesis of the bisamide ligands  
The reaction route shown in the previous section has some drawbacks, most notably: a) 
the low reaction yield in the glycosylation step of the pentafluorophenyl ester derivative 2.5, b) 
the nucleophilic substitution of the Cl atom in 2.10 by NaN3, which must be performed after the 
transformation of the activated esters and therefore individually for each final derivative 2.2 
from building block 2.9, and c) the relatively high prize of pentafluorophenol.  
For these reasons, a new sequence was suggested which involves p-nitrophenol, as a 
cheaper activating ester in comparison with the pentafluorophenol ester (Scheme 2.14). The first 
two steps in the reaction sequence, the activated ester formation and epoxidation, were analogous 
to those performed with pentafluorophenol. In the following step 2-azidoethanol 2.3320 was used 
to open the epoxide 2.29 (Scheme 2.14). Azidoethanol can be prepared via a reaction in which 2-
cloroethanol 2.32 is treated with sodium azide in water media and the resulting reaction mixture 
is extracted with DCM. The product is not dried due to the volatility and possible explosive 
properties of 2.33.15 Azide derivative 2.33 was prepared several times in small scale with 
attention on safety issues, and no hazardeous character was observed. The reaction between 
epoxide 2.29 and alcohol 2.33 resulted in the important intermediate 2.30, with the activated 
ester still on, and the azide-terminated linker already installed in the molecule. This compound 
was glycosylated using trichloroacetimidate activated and benzoyl protected mannose,16 using 
the same conditions described in section 2.1.1, and resulting in building block 2.31 which is a 
common starting material for all final molecules 2.2. The last two steps in the synthesis are the 
treatment of scaffold 2.31 with the corresponding amine in acetonitrile and the subsequent 
deprotection of the mannose moiety. It was found that these two reactions can be performed in 
one pot (see general procedure 5 in the experimental part) and thus accelerating and simplifying 
the synthesis of the final ligands (Scheme 2.14).  
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Scheme 2.14 Improved synthesis of compounds 2.2 using PNP activation 
 
The first set of ligands 2.2a-j, described in the previous section, was tested by single point SPR 
experiments (discussed in details in section 2.1.4.2) in which compound 2.2f was found to be the 
most interesting one for further modifications. For this reason, another small focused library of 
molecules was designed and prepared (using the optimized synthesis) including derivatives of 
compound 2.2f as well as some ligands with different aromatic groups (Scheme 2.15).  
 
Scheme 2.15 Ligands 2.2k-s prepared by the method showed in scheme 2.14 
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Aromatic amines used for the synthesis of 2.2k-m were commercially available (Scheme 2.16).  
 
Scheme 2.16 Amines 2.12k-s used for the synthesis of ligands 2.2k-s 
 
Amines 2.12n-q used for the synthesis of 2.2n-q can be prepared from commercially available 
materials using strong reductive conditions (Scheme 2.17, see general procedure 1 in the 
experimental part).  
 
Scheme 2.17 Synthesis of benzylamines 2.12n-q by reduction with LiAlH4 
 
Amines 2.12r-s used for the preparation of compounds 2.2r-s were prepared in multistep 
synthesis. The key step in the following reactions is the palladium catalyzed bromide substitution 
by a cyanide group.21 In this reaction K4[Fe(CN)6] . 3H2O as a non toxic cyanide source was 
used in the presence of sodium carbonate and catalytic amount of Pd(OAc)2. As solvent 
dimethylacetamide (DMAC) was used which allows to perform the reactions at high 
temperatures.   
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Scheme 2.18 Synthesis of benzylamines using multistep synthesis 
 
Compound 2.39 was obtained in good yield using only 0.5% of Pd(OAc)4 at 80°C. The synthesis 
of 2.12s started from aromatic derivative 2.40. The acid in compound 2.40 was converted to an 
ester since there are no examples of carboxylic acids as substrates in the article describing the 
palladium catalyzed bromide substitution.21 The subsequent introduction of the cyanide group in 
2.41 required higher amount of palladium catalyst (5%) and elevated temperature (130°) but the 
product 2.42 was obtained in a remarkable yield despite the significant sterical hindrance caused 
by the bulky methoxy substituents in the ortho positions. The last reaction for both 2.39 and 2.42 
is the reduction of ester and cyanide functions using LiAlH4 (Scheme 2.18). 
To analyze the effect of the stereochemistry of the cyclohexane scaffold on the activity of 
ligands 2.2, a stereoisomer of 2.2f, compound 2.2t was also prepared. During a large scale 
synthesis of 2.2f, the diacid 2.1 was used as a 4:1 mixture of the two enantiomers (commercially 
available, the resolution of (+)2.1 is described in the experimental part, section 2.4.2.1). 
Following the reaction path described in Scheme 2.14 an approximately 4:1 mixture of 
diastereoisomers 2.31 and 2.43 was obtained and treated with amine 2.12f (Scheme 2.19). This 
led to two diastereoisomers 2.11f and 2.44 which were partially separable by flash 
chromatography. Deprotection of these compounds gave the final DC-SIGN ligands 2.2f and its 
diastereoisomer 2.2t, respectively (Scheme 2.19).  
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Scheme 2.19 Schematic representation of the synthesis of diastereoisomers 2.2f and 2.2t 
 
In order to investigate the scope of the amide synthesis we also examined the reaction of 2.31 
with bis-bezylamines 2.45a-c (Scheme 2.20). The working hypothesis was that compounds with 
general structure 2.46 could be obtained. The initial approach using orto, meta or para 
xylylenediamine 2.45a-c in the reaction with 2.31 led mostly to complex mixtures. However, in 
the case of p-xylilendiamine one major product could be isolated in moderate yield by 
chromatography. MS and 13C-NMR analysis revealed that the dimeric macrocyclic structure 2.47 
had been formed, as a 1:1 mixture of regioisomers 2.47a and 2.47b that could not be separated 
by chromatographic methods.  
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Scheme 2.20 Synthesis of macrocycles 2.47a and b 
 
Sugar containing macrocycles are synthetically challenging structures,22,23 and this approach 
gives a relatively easy access to the preparation of this kind of molecules. Compound 2.47 
represents a bivalent presentation of DC-SIGN ligands 2.2 and the potential metal chelating 
properties24 of the macrocyclic structure could be a target of further investigations.  
2.1.3 Large scale synthesis of 1.7b and 2.2f 
It was found during my thesis that compounds 1.7b and 2.2f represent pseudo dimannose 
derivatives with good DC-SIGN inhibition activity and therefore these compounds are currently 
used as standards in biological assays throughout the CARMUSYS network. As it will be 
described in the following chapter, ligands 1.7b and 2.2f were also used in the synthesis of 
multivalent systems meaning that these compounds had to be available in a relatively large scale. 
The small scale synthesis of molecule 1.7b was optimized by Sara Sattin;13 the scaled up 
synthesis works just as well, with similar yields. From diacid 2.1 the final compound was 
obtained in 6 steps with 60% over all yield. 
Ligand 2.2f was prepared twice in hundred milligram scales.. Starting from the diacid 2.1 
in 6 steps the final compound was obtained in 31% overall yield (Scheme 2.21).    
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Scheme 2.21 Large scale synthesis of DC-SIGN ligands 1.7b and 2.2f both prepared from the 
enantiomerically pure diacid 2. 
 
2.1.4 Activity determinations  
2.1.4.1 Surface Plasmon Resonance (SPR) 
Binding studies on the isolated receptor DC-SIGN, exploiting the SPR (Surface Plasmon 
Resonance) biosensor, allowed to assess the affinity of the glycomimetic structures. Biosensors  
used in drug discovery usually require at some point labeling (fluorescent or radiolabelling) of at 
least one of the components involved in the interaction process to report the binding of a ligand 
to its receptor. This labeling step demands extra time and cost, and can, in some cases lead to 
false negatives or false positives. SPR, as well as other optical biosensors, exploits the 
evanescent-wave phenomenon to characterize interactions between receptors that are usually 
attached to the biosensor surface and ligands that are in solution above the surface. The response 
signal is directly proportional to the amount in weight of bound ligand. In figure 2.1 is a 
schematic view of a SPR biosensor.  
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Figure 2.1 Schematic representation of the principles of SPR 25 
 
Surface plasmon resonance (SPR) detects changes in the refractive index in the immediate 
vicinity of the surface layer of a sensor chip. SPR is observed as a sharp shadow in the reflected 
light from the surface at an angle that is dependent on the mass of material at the surface. The 
SPR angle shifts (from I to II in the lower left-hand diagram) when (bio)molecules bind to the 
surface and change the mass of the surface layer.25 
There are several different possible experimental set up, depending on the molecules we are 
handling, where the immobilized molecule can be the ligand, the receptor or a binding 
competitor. Low molecular weight ligands (as in the case of monovalent carbohydrates binding 
to a lectin) are difficult to detect in general, and therefore we chose to immobilize the binding 
competitor. In our particular case, a highly mannosylated glycoprotein was immobilized on the 
SPR chip and a fixed concentration of DC-SIGN extra-cellular domain (ECD) was flowed within 
a) increasing concentration of the tested ligand in order to determine its IC50 value, or b) fixed 
concentration of the ligand in the case of single point SPR experiment when the inhibition 
potency of the ligand is measured at certain (fixed) concentration. More in detail, for this assay, a 
CM4 SPR chip was used. Two flow cells were activated as previously described26 with an EDC-
NHS mixture. Flow cell one was then blocked with 1M ethanolamine (50 µL) and served as a 
control surface. The second one was treated with Man-BSA (Bovine serum albumin - 
Mannotriose, Dextra, 60 µg/mL) in acetate buffer (10 mm, pH 4). The Man-BSA used to 
functionalize the CM4 chips harbors 15 glycosylation sites (according to the manufacturer) 
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displaying the Manα1-3[Manα1-6]Man trisaccharide. Remaining activated groups were blocked 
with ethanolamine (1M, 50 µL). The DC-SIGN ECD was expressed and isolated by the Fieschi 
laboratory27 using a previously described protocol.5 The ECD exhibited good affinity (in the μM 
range) for this surface. This was determined for each chip by a titration curve obtained by 
flowing increasing protein amount (DC-SIGN ECD) and reporting the response signal as a 
function of protein concentration 
2.1.4.2 Single point SPR experiments 
DC-SIGN ligands 2.2a-j synthetized using the PFP activation sequence (see section 
2.1.1) were initially tested by single point SPR experiments in which 150 µM solutions of ligand 
and a 20 µM solution of DC-SIGN were flown over mannosylated-BSA immobilized on the chip 
and the competitive inhibition of DC-SIGN was measured. In this experiment the ligands were 
also compared to the dimethyl ester analogs of the bi and tri-mannoside mimics (1.7b, 1.9, 
Scheme 2.22), that represent two standards with well-known levels of inhibition.8,10 These 
experiments were performed in Grenoble in the group of professor F. Fieschi. The results are 
shown in graph 2.1 as % of DC-SIGN binding inhibition.   
 
Scheme 2.22 Structures of reference molecules 1.7b and 1.9 and bisamides 1.10f and 2.2a-j 
measured in single point SPR experiments 
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Graph 2.1 DC-SIGN Inhibition activities of molecules 1.7b, 1.9, 1.10f and 2.2a-j (shown as a, 
b, …) at 150 µM concentration determined by single point SPR measurement with a Man-BSA 
chip 
 
The single point experiments showed that substitution of the benzyl group in para 
position by -CHx-O-R groups (2.2c,e-i) improves the activity and the best ligands showed 
inhibition between 32-35 % (c = 150 µM) which is a clear improvement over the activity of the 
parent dimethyl ester and approaches the activity of the much more synthetically demanding 
pseudo-trisaccharide 1.9. On the other hand, the polymanosylated compound 2.2j had practically 
the same activity as the reference diester 1.7b showing that in this case the number of mannose 
moieties in the molecule has a minor impact on the activity of the ligand. A possible explanation 
could be that the hydroxyl groups in the mannose residues have to undergo desolvatation before 
the interaction with the binding site and this process is energetically demanding.  
In the single point experiment also the analog of 2.2a, compound 1.10f, was tested in 
which the azidoethanol linker is replaced with an allyl group. This compound had been 
previously prepared and tested by DC-SIGN adhesion experiment (IC50 = 111 µM).11 In the SPR 
experiment, derivative 2.2a showed lower activity than 1.10f and this confirms that the allyl 
group has non specific interaction with DC-SIGN. As we have noted above this was also 
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observed in STD measurements by NMR (Pedro Nieto, Seville). Among the tested ligands 
compound 2.2f showed the most promising properties from the viewpoint of activity, solubility 
and synthesis. 
2.1.4.3 IC50 determination by SPR 
After the single point SPR experiments showed promising results, the library of bisamides was 
expanded (see section 2.1.2) and finally, the activities of all bis-amides 2.2a-t and of the 
macrocycle 2.47 was measured by determining their IC50 in SPR experiments described above, 
where the ability of the ligand to inhibit DC-SIGN binding to mannosylated BSA (Man-BSA) 
was tested. In the assay, Man-BSA is immobilized on a CM4 chip and DC-SIGN is flown in the 
chamber in the presence of increasing concentrations of the inhibitors thus allowing the 
determination of the IC50 value. The data were obtained as in several campaigns and compounds 
1.7b and 1.9 were always used as standards. Since these standards exhibited very similar 
activities in all the SPR experiments (IC50 = app. 0.6 mM for 1.7b and 0.1 mM for 1.9) the 
results can be summarized in table 2.1 and graph 2.2. 
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(Scheme 2.19) 
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Table 2.1 DC-SIGN ligands 2.2a-t and 2.47 with IC50 values. a. In SPR competition test with 
immobilized Man-BSA. b. Low solubility in water. c. Not tested for IC50 due to low stability. d. 
Insoluble in water  
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Graph 2.2 IC50 values of final DC-SIGN ligand 2.2a-g,i-k,n-t (showed as a, b…) and 2.47 
compared to the activity of ligands 1.9 and 1.7b 
 
Many of the bis-amides prepared showed a remarkable increase in inhibitory activity compared 
to 1.7b and some approached the affinity observed for 1.9 a molecule of significantly higher 
structural and synthetic complexity. Low solubility remains a problem for some of the structures. 
Molecules 2.2l-m precipitated in water and their IC50 couldn’t be determined. Structures 2.2a 
and 2.2d had some solubility problems too, which was reflected also in their activities. However, 
the majority of compounds displayed good solubility in water at the concentration required for 
the assay. The group of bisamides 2.2b-c,e-g,i,n-r all showed a remarkable activity, as they were 
found to be only approximately 1.5 fold less potent than 1.9. As it was already mentioned 2.2f, 
featuring an hydroxymethylene group in the para position, was selected for structural 
modifications. The hydroxy group appears to play a role as a H-bond acceptor, since the 
corresponding methyl ether 2.2e shows the same inhibition power (cfr 2.2f and 2.2e). Addition 
of fluorine atoms on the ring (2.2o, 2.2p) or of additional lipophylic groups in the proximity of 
the acceptor (2.2g) did not improve significantly the affinity. On the contrary, two methoxy 
group meta to the hydroxymethylene, as in compound 2.2s, had a marked negative effect, 
possibly as a result of a different orientation of the aromatic residue around the N-benzylic bond. 
Similarly, compound 2.2t with the opposite configuration (1R, 2R, 4R, 5R)- of the cyclohexane 
ring interacts poorly with DC-SIGN.  Remarkably, dimer 2.47 (1:1 mixture of isomers) with an 
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IC50 of 16 μM turned out to be the most potent inhibitor of the series, and one of the most 
effective reported so far. Given that the dimension of the macrocycle in 2.47 is too short to span 
two consecutive DC-SIGN binding sites (which are separated by ca. 38 Å)28, the strong activity 
of this compound is likely derived from a protein aggregation mechanism, which effectively 
inhibits Man-BSA binding under the assay conditions in this particular model, but may not be 
relevant in real physiological settings.  
Among the tested compound 2.2f remains the representative of the amide series and the most 
promising candidate for further elaboration towards multivalent systems. Though the p-
methylenehydroxy benzyl moiety can show instability in biological systems, further substitution 
of the benzyl ring (i.e. with fluorine, 2.2o-p) or substitution of the benzylic position (2.2g) could 
improve its resistance against degradation without significant change in the activity of the ligand. 
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2.2 Modification of 1.7b at position 6 of the mannose residue  
Modification of 1.7b, by a replacement of its methylester moieties by amides (2.2a-t), was 
proved to be an efficient way to improve the activity and selectivity of the ligand (the selectivity 
of ligands 2.2a-t will be discussed in section 2.3). In order to continue on this line and to find 
further possibilities to enhance the potency of pseudodimannoside based ligands, another 
modification of 1.7b was sought. Since the mannose residue of molecule 1.7b  has a close 
contact with the binding site, a proper modification of its structure could have positive effect on 
the activity. Based on the available X-ray structure of the DC-SIGN : 1.7b complex29 an 
interesting point to modify would be position 2 of the mannose ring (Figure 2.2).  
 
Figure 2.2 X-ray structure of the 1.7b : DC-SIGN complex. Blue circle: position 2 of the 
mannose residue. Red circle: carboxylic group of the side chain of glutamic acid E354 
 
The hydroxyl group in position 2 of the mannose ring has axial configuration and therefore a 
substituent of the hydrogen of the -CH- group at this position would be equatorial allowing it to 
interact with the side chain of glutamic acid E354. This hypothesis would also explain the 
remarkable improvement of the activity of compound 1.6c (ki = 0.35 mM) in comparison with 
D-mannose (ki = 17.1 mM, Scheme 2.23) reported by the Fleet group.7  
 
Scheme 2.23 branched D-mannose analogue as potent DC-SIGN inhibitor7 
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However, such a modification would be synthetically very demanding and not very practical. A 
second point which lends itself to modifications is position 6 in the structure of mannose moiety.  
A recent publication from Winssinger et. al.30,31 describes a small library of native mannobioside 
derivatives, among which a compound with an amino group in position 6 of the non-reducing 
end was found to be a potent DC-SIGN binder. Docking studies performed within the 
CARMUSYS network suggests that an amino group at this position could interact efficiently 
with carboxylic side chains in the vicinity of the Ca2+ binding site. Moreover, based on structural 
studies reported by Feinberg et. al.32 this position on the non reducing end of Man1-2Man 
disaccharide 1.8 (see introduction) is relatively close to lysine299 of the binding site of 
Langherin (Figure 2.3).  
 
 
Figure 2.3 Interaction of a Manα1-2Man disaccharide with the binding site of Langherin 32 
 
   A functional group at position 6 exhibiting repulsive interaction  (i. e. a protonated amine 
group, Scheme 2.24) with lysine299 may result in lower binding activity of the ligand with 
Langherin and thus improve its selectivity towards DC-SIGN. Furthermore, giving the fact that 
position 6 is the only primary alcohol in the molecule its modification could be easier in 
comparison with the secondary alcohols in positions 2-4.  
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Scheme 2.24 Modification of compound 1.7b in position 6 of the mannose residue 
 
2.2.1 Synthesis 
The synthesis of the pseudodimmanoside derivatives 2.2a-t involves a glycosylation step where 
the secondary hydroxyl group of the cyclohexyl derivative 2.5 or 2.30 (glycosyl acceptor) is 
connected with a tetra-O-benzoyl mannose derivative 2.8 (glycosyl donor) activated in anomeric 
position via a trichloroacetimidate (TCA) (Scheme 2.5 and 2.14). This strategy can also be used 
to synthesize derivative 2.48, bearing a protected or masked amine group in position six of the 
Man residue (Scheme 2.25). After the glycosylation a primary amine could be obtained, which 
can be further functionalized (secondary and tertiary amines, amides, carbamates, 
sulfonamides…). For this transformation we envisaged two possible strategies involving either a 
carbamate or an azide to mask the primary amine function in the manosyl donor 2.49 (Scheme 
2.25). So far, only the strategy using an azide (glycosyl donor 2.49b) as a source of the primary 
amine has been investigated. To allow orthogonal modification of Man-C6 and of the 
azidoethanol linker, glycosyl acceptors 2.5 and 2.30 were replaced with the corresponding 
chloride 2.50 which had been previously obtained.  
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Scheme 2.25 Synthetic strategy for the preparation of molecules 2.48a,b,… 
 
The concept of introducing an azide group in position 6 of different aldohexoses has been 
previously described. The used strategies commonly starts with selective activation of position 6 
of an unprotected or partially protected sugar by a tosyl group (Ts) using tosyl chloride in the 
presence of a base. This reaction has been described among others for β-D-galactose33 and α-D-
glucose34 both substituted only at the anomeric position (positions 2-5 are unprotected). The 
synthesis of native mannobiosides modified in position 6 described by Wissinger et. al.30 also 
starts with the activation of position 6 of D-mannose (fully unprotected). Since this strategy is 
used with success in literature, we decided to adopt it with some modification. 
The synthesis starts with D-mannose 2.52 (Scheme 2.26) which is selectively activated with a 
tosyl group in position six using tosyl chloride and pyridine as a base and solvent. This group is 
substituted by an azide moiety in the following reaction leading to compound 2.53, which is then 
fully benzoylated (2.54). The anomeric position of 2.54 is deprotected using methylamine giving 
the α and β mixture of the product. In the subsequent reaction the free hydroxyl group at position 
1 is activated using trichloroacetonitrile and DBU as a bulky base. Product 2.49b represents a 
glycosyl donor which is treated in the glycosylation step with the glycosyl acceptor 2.50,8 which 
comes from the synthesis of 1.7b and was available in the laboratory. As a promoter in this step, 
trimethylsilyl trifluoromethansulfonate (TMSOTf) was added  at -30°C and after 1 hour at -20°C 
the product 2.51b was isolated in 88% yield. The last step in this reaction sequence is the 
deprotection of the mannose moiety using sodium methoxide in methanol (Scheme 2.26).  
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Scheme 2.26 Synthesis of building block 2.55 starting from D-mannose 
 
In order to prepare the desired final ligands, product 2.55 can be modified in several different 
ways.  
In the first route (Scheme 2.27) compound 2.55 is reduced using hydrogen and a catalytic 
amount of palladium on carbon in the presence of Boc2O which gives the protected amine in 
position 6 of  mannose, 2.56. In the following steps the chloride on the ethylene tail is substituted 
by an azide group and the Boc protecting moiety is removed in acidic condition. Product 2.48a 
represents one of the desired final ligands, however, it can be further functionalized, for instance 
by treatment with mesylchloride which gives derivative 2.48b, another ligand ready to be tested 
with DC-SIGN or other lectins .  
 In the second approach (Scheme 2.27) compound 2.55 is reduced with Pd/C without 
Boc2O and hence without subsequent protection. The primary amine can be then functionalized 
with an acetyl group. During this reaction undesired protections of the free hydroxyl groups were 
observed and therefore the mixture of products was treated with sodium methoxide in order to 
remove the acetyls from the oxygens. In the last step sodium azide was used to replace the 
chloride to an azide, resulting in final ligand 2.48c (Scheme 2.27).    
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Scheme 2.27 Synthesis of ligands 2.48a-c starting from building block 2.55 
 
Compound 2.55 contains an azide function which can be exploited for copper catalysed 
1,3 dipolar cycloadition, so called “click” reaction (the concept and principle of the used click 
reaction will be described more in details in the following chapter).35,36,37  Propargyl alcohol was 
the first substrate used for this reaction (Scheme 2.28). As a copper source CuSO4. 5 H2O was 
selected, and sodium ascorbate was used to reduce Cu(II) to Cu(I) in situ.  Tris-
(Benzyltriazolylmethyl)amine (TBTA)38 is a ligand which efficiently coordinates copper(I) 
preventing its oxidation and thus enhances the reaction. The final compound 2.48d was obtained 
by the treatment of 2.58 with sodium azide which substitutes the Cl function to an azide (Scheme 
2.28).  
N-Boc protected propargyl amine was also used in the click reaction with 2.55. The first 
two steps are similar to those described above (giving products 2.59 and 2.60) but one additional 
reaction was done where the primary amine was deprotected using trifluoroacetic acid resulting 
in final ligand 2.48e. As a structurally more complex alkyne donor (R)-N-Boc-propargylglycine 
was used in order to check the scope of the click reaction for our substrate. After one attempt, 
product 2.61 was obtained in lower yield and due to the little amount of this compound no 
further reactions were performed (Scheme 2.28).   
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Scheme 2.28 Synthesis of compounds 2.54d,e and 2.61 starting from 2.55 using “click” 
chemistry 
 
2.2.2 Activity determination of DC-SIGN ligands 2.48a-c and d 
The prepared ligands 2.48a-c and e where tested by SPR using the same experimental 
setup described in section 2.1.4. As standards, two molecules were used: the dimannoside mimic 
1.7b and its bisamide derivative 2.2f  Derivatives 2.48b,c and e exhibited slightly lower or very 
similar activity than the parent pseudo dimannoside 1.7b. The free primary amine 2.48a however 
showed improvement by a factor of two and an IC50 value at 453 μM (Graph 2.3). This 
observation proves that positive effect on the activity can be achieved by a proper modification 
of position 6 of the mannose residue, and suggests that a positively charged amino group in this 
position may have a positive influence also on the activity of 2.2f.  
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Graph 2.3 IC50 values of ligands 1.7b, 2.2f and 2.48a-c and d (showed as a,b…) 
 
In order to achieve further improvements in the activity, the library should be expanded 
since only a small number of molecules was prepared and tested. However, even these 4 
molecules gave us important hints regarding further derivatisation and modification.   
 
2.3 DC-SIGN/Langherin specificity of the pseudodimannoside based ligands  
Both DC-SIGN and Langherin are mannose binding lectins involved in the cell mediated 
immune response. While DC-SIGN acts as a transporter for the HIV virus,39 Langherin manages 
to internalize the virus into the Bierbeck granules and destroy it (see introduction).40 The binding 
sites of both these receptors contains a Ca2+ cation which can coordinate mannose or mannose-
containing molecules. However, the different structural environment of each binding site41,42 
should allow to develop ligands which can selectively bind DC-SIGN or Langherin.  
In order the investigate the selectivity of the prepared ligands, in the initial experiments single 
point SPR measurements were performed (group of prof. Frank Fieschi). In this experimental 
setup  150 µM solutions of ligand and 20 µM solution of lectin were flown over mannosylated-
BSA immobilized on the chip and the competitive inhibition of lectins (DC-SIGN or Langherin 
ECD) was measured. The inhibition activities are summarised in graph 2.4  
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Graph 2.4 Inhibition levels of DC-SIGN (blue) or Langherin (green) by compounds 1.7b, 1.9 
and 2.2a-j measured by single point SPR  experiment 
 
Substracting Langherin inhibition from DC-SIGN inhibition gives us an indication about the 
selectivity of the tested ligands.  
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Graph 2.5 Subtraction of Langherin inhibition from DC-SIGN inhibition of molecules 1.7b, 1.9 
and 2.2a-j measured by single point SPR  experiment 
 
Most of the bis-amides bind better DC-SIGN than Langherin. Compounds 2.2c and f showed the 
highest selectivity from the amide series in the single point SPR experiment. Practically the same 
inhibition of DC-SIGN and Langherin was observed in the case of 2.2a and b. On the other 
hand, the bis p-nitrobenzylamide derivative 2.2d exhibited better inhibition of Langherin, giving 
an interesting hint that the selectivity can be tuned by proper substitution of the benzylamide 
residues. Also, the branched pseudo tetrasaccharide 2.2j is a better Langherin binder. It was 
found that the pseudotrisaccharide 1.9 has significant selectivity towards  DC-SIGN.  
The initial SPR studies revealed, that selectivity towards either tested receptor can be achieved 
by relatively small modification in the structure. While the mannose moiety is the main 
farmacophore, its decoration has a significant impact on the binding activity and selectivity of 
the ligand. 
 
After the single point SPR experiments further studies were carried out (group of Franck Fieschi) 
and it was observed  that the measured DC-SIGN activity of our ligands does not change when 
SPR chips with different surface density of BSA-Man (competitive inhibitor) is used. However, 
significant differences were observed with Langherin when the SPR chips were functionalized 
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with different BSA-Man density. Therefore, it was difficult to determine the absolute IC50 
values for Langherin. To overcome this problem an approach was used which quantify the gain 
of DC-SIGN specificity from one ligand to another. The absolute selectivity of a particular 
compound (selcomp.) for DC-SIGN vs Langherin can be defined as a ratio of the IC50 values for 
Langherin and DC-SIGN (Equation 2.1). 
 
SIGNDC
Langherin
comp IC
IC
sel
−
=
50
50
.  
Equation 2.1 
 
To exclude the effect of the surface density a selectivity gain (selg) achieved by switching from 
one compound to another can be considered:  
1
2
21lg
comp
comp
compcomp sel
sel
se =→  
Equation 2.2 
This term provides a relative comparison of the improvement of selectivity between the two 
lectins when switching from one compound to another. Indeed, selgcomp.1Æcomp.2 > 1 means a gain 
of DC-SIGN selectivity vs. Langherin for compound 2 compared to compound 1 by a 
corresponding factor, while values <1 means a loss of selectivity for DC-SIGN. This approach 
revealed that the selectivity gain is surface density independent. 
The first determination of the DC-SIGN/Langherin selectivity gain was performed for the natural 
mannobioside Manα1-2Man 1.8 and its mimic 1.7b. It was found that 1.7b is a more specific 
DC-SING  binder than 1.8 by a factor of 3. 
 Preliminary studies have been carried out in order to determine the DC-SIGN/Langherin 
selectivity gain of 2.2f and 2.48a over 1.7b. Considering the obtained IC50 values of the ligands 
with both the tested lectins, it was calculated that 2.2f has a selectivity gain over 1.7b by a factor 
of 9 and ligand 2.48a was found to be more specific for DC-SIGN by a factor of 5.8. Further 
experiments will be performed in order to confirm the obtained data. Nevertheless, the 
preliminary results are clearly showing high selectivity of compounds 2.2f and 2.48a towards 
DC-SIGN and we can conclude that the novel structures derived from 1.7b have significantly 
improved DC-SIGN specificity in comparison with the parent molecule.   
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2.4 Experimental part 
2.4.1 General 
Dichloromethane (DCM), methanol (MeOH), N,N-diisopropylethylamine (DIPEA) and 
triethylamine (TEA) were dried over calcium hydride; THF was distilled over sodium, N,N-
dimethylacetamide (DMA) was dried over activated molecular sieves. Reactions requiring 
anhydrous conditions were performed under nitrogen. 1H and 13C spectra were recorded at 
400MHz on a Bruker AVANCE-400 instrument. Chemical shifts (δ) for 1H and 13C spectra are 
expressed in ppm relative to internal standard (CDCl3: 7.24 for 1H and 77.23 for 13C; CD3OD: 
3.31 for 1H and 49.15 for 13C, D2O: 4.80 for 1H). Signals were abbreviated as s, singlet; br s, 
broad singlet; d, doublet; t, triplet; q, quartet; m, multiplet. The numbering used in the NMR 
characterizations is indicated in the structures showed after the procedures. Sugar signals were 
numbered as customary; cyclohexane protons are indicated with the letter D followed by 
numbers. The unusual numbering of the pseudo-disaccharide derivatives in the NMR 
characterizations was adopted to facilitate comparison with the native disaccharide. In the names 
of the compounds the conventional numbering is used. Mass spectra were obtained with a 
ThermoFisherLCQapparatus (ESI ionization), or iontrap ESI Esquire 6000 from Bruker, or a 
Microflex apparatus (MALDI ionization) from Bruker, or Apex II ICR FTMS (ESI ionization—
HR-MS). Specific optical rotation values were measured using a Perkin-Elmer 241, at 589 nm, in 
a 1 dm cell. Thin layer chromatography (TLC) was carried out with pre-coated Merck F254 
silica gel plates. Flash chromatography (FC) was carried out with Macherey-Nagel silica gel 60 
(230–400 mesh). For selected compounds the 1H and 13C  NMR spectra are showed, the NMR 
spectra for the rest of the molecules can be found on the compact disc (CD) attached to the 
thesis.  
 
2.4.2 Synthesis of scaffold 2.9 – PFP method 
2.4.2.1 Resolution of (1S,2S)-4-Cyclohexene-1,2-dicarboxylic acid, (+)2.114, 43 
To a solution of diacid 2.1 (5.12 g, 30.10 mmol, 1 eq, 74% e.e.) in MeOH (35 ml) a solution of 
quinine (12.40 g, 38.22 mmol, 1.27 eq) in MeOH (13 ml) was added. The resulting solution was 
stirred at 40°C for 10 minutes then the solvent was removed under reduced pressure. In order to 
remove the excess of quinine, ethyl acetate was added (25 ml) and the resulting mixture was 
heated up to reflux for several minutes, then let to cool down to room temperature. The 
precipitates were filtered to obtain 15.6 g of diacid 2.1- quinine salt as a white solid.   
Chapter 2   Monovalent glycomimetic DC-SIGN ligands  
     75
To the quinine salt methanol (15 ml) was added and heated up to reflux for 20 minutes, then 
additional 5 ml of methanol was added every 20 minutes until the precipitates doesn’t dissolve 
completely. The mixture was let to cool down to room temperature, then transferred to the 
freezer to keep at -20°C overnight. The white precipitate was filtered off and washed with the 
filtrate to obtain 12.5 g of solid which was further recrystallized: methanol (12.5 ml) was added 
and the resulting mixture was heated to reflux then let to cool to room temperature and kept at -
20°C (freezer) for overnight. The recrystallized quinine salt was filtered to obtain 10.3 g of white 
solid.  
In order to liberate the desired diacid (+)2.1 the quinine salt was dissoved in aqueous HCl 
solution (10%, 500 ml) and extracted with ethyl acetate (3 x 240 ml). The combined organic 
phases were washed with aqueous HCl solution (10%, 2 x 50 ml), brine (2 x 40 ml) and water, 
then dried over sodium sulphate, filtered and concentrated under reduced pressure to obtain 3.08 
g of enantiomerically pure product. 
OH
O
OH
O
(+) 2.1
1
23
4
5
6
 
Yield = 82% 
[α]20 D  = + 142 (c = 1.1; EtOH) 
1H NMR (400 MHz, CDCl3): 5.73 – 5.66 (m, 2H, H4, H5), 2.86 – 2.75 (m, 2H, H1, H2), 2.53-
2.37 (m, 2H, H3eq, H6eq), 2.29 - 2.10 (m, 2H, H3ax, H6ax). 
 
2.4.2.2 4-cyclohexene-1,2-dicarboxylic acid bispentafluorophenylester, 
(1S,2S), 2.3 
To a solution of the diacid 2.114 (0.5 g, 2.938 mmol, 1 eq) in dry THF (25 ml) under nitrogen 
atmosphere EDC•HCl (0.74 g, 3.877 mmol, 3.3 eq.) was added. After 10 minutes 
pentafluorophenol (1.69 g, 8.815 mmol, 3 eq) was added. The solution was stirred at room 
temperature for 1 h and then at 40°C for 2 h. After completion of the reaction (TLC, EtOAc) the 
solvent was removed at reduced pressure and the crude residue was taken up in Et2O. The 
organic phase was washed with 1M HCl and saturated Na2CO3, then dried over sodium sulphate. 
The solvent was evaporated at reduced pressure obtaining 1360 mg of pure product as white 
solid 
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Yield = 92% 
[α]20 D  = + 53.6 (c = 0.5; CHCl3) 
1H NMR (400 MHz, CDCl3): 5.81 (app d, J= 2.68 Hz, 2H, H4, H5), 3.40-3.31 (m, 2H, H1, H2), 
2.80-2.68 (m, 2H, H3ps-eq, H6ps-eq), 2.50-2.38 (m, 2H, H3ps-ax, H6ps-ax). 
13C NMR (100 MHz, CDCl3): 170.5 (C7); 142.6 (m, CF); 141.2 (m, CF); 140.1 (m, CF); 139.4 
(m, CF); 138.7 (m, CF); 136.9 (m, CF); 124.7 (C4, C5); 40.8 (C1, C2); 27.8 (C3, C6). 
19F-NMR (282 MHz, CDCl3): -153.2 (d, 2F, Fortho, Jo-m= 20 Hz), -157.9 (t, 1F, Fpara, Jp-m= 22.5 
Hz), -162.4 (t, 2F, Fmeta). 
2.4.2.3 7-Oxabicyclo[4.1.0]heptane-3,4-dicarboxylic acid, 
bispentafluorophenyl ester (3S,4S), 2.4 
To a solution of the PFP ester 2.3 (1360 mg, 2.7 mmol, 1 eq.) in dry DCM (6 ml), 77% MCPBA 
was added (788 mg, 3.5 mmol, 1.3 eq). The reaction was stirred under nitrogen atmosphere at 
room temperature. After completion of the reaction (16 h, TLC 8:2 Hex:EtOAc), the solvent was 
removed at reduced pressure, the reaction mixture was diluted with Et2O and washed with sat. 
NaHCO3 and water. The organic phase was dried over sodium sulphate and the solvent was 
removed at reduced pressure. The crude product was purified by flash chromatography (8:2 
Hex:EtOAc) leading to 1162 mg of pure product. 
O
O
O
O7
2
16
3
4
5 F5
F5
O
2.4
 
Yield: 83% 
[α]20 D  = + 37.7 (c = 0.5; CHCl3) 
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MS (FAB) calculated for [C20H9F10O5]+: 519; found = 519. 
1H NMR (400 MHz, CDCl3): 3.43-3.34 (m, 2H, H4 or H5, H2 or H1), 3.32 (dd, 1H, H5 or H4, J5-4  
= J5-6 or J4-3 = 4 Hz), 3.14 (dt, 1H, H2 or H1, J2-3eq or  J1-6eq = 6.8 Hz, J2-3ax or J1-6ax = J2-1 = 10.0 
Hz), 2.76 (ddd, 1H, H3eq o H6eq, J3eq-4 or J6eq-5 = 1.6 Hz, J3eq-2 or J6eq-1 = 5.2 Hz, Jgem = 14.8 Hz), 
2.61 (ddd, 1H, H6eq or H3eq, J6eq-1 or J3eq-2 = 4.4 Hz, Jgem = 15.6 Hz), 2.37 (dd, 1H, H6ax or H3ax), 
2.16 (ddd, 1H, H3ax or H6ax, J3ax-4 or J6ax-5 = 2.0 Hz). 
13C NMR (100 MHz, CDCl3): 170.6, 169.4 (C7); 142.6 (m, CF); 141.1 (m, CF); 140.0 (m, CF); 
139.4 (m, CF); 138.7 (m, CF); 137.3 (m, CF); 51.5, 50.1 (C4, C5); 39.4, 37.5 (C1, C2); 26.9, 26.2 
(C3, C6). 
19F-NMR (282 MHz, CDCl3): -153.1 (dd, 2F, Fortho, Jo-m= 84.6 Hz, Jo-p= 16.9 Hz), -157.6 (m, 
1F, Fpara), -162.3 (m, 2F, Fmeta).                                                                                                                             
 
2.4.2.4 1,2-Cyclohexanedicarboxylic acid, 5-(2-chloroethoxy)-4-hydroxy, 1,2-
bispentafluorophenyl ester, (1S,2S,4S,5S), 2.5 
To a solution of the epoxide 2.4 (1162 mg, 2.24 mmol, 1 eq) in minimum amount of dry DCM (1 
ml) under nitrogen atmosphere 2-chloroethanol (0.75 mL, 115.1 mmol, 50 eq.) and Cu(OTf)2 
(162 mg, 0.448 mmol, 0.2 eq.) were added. The solution was stirred at room temperature. After 
completion of the reaction in (16 h, TLC 7:3 Hex:EtOAc) the solvent was removed under 
reduced pressure and the crude residue was purified by flash chromatography (8:2 Hex:EtOAc) 
obtaining 1266 mg of pure product as colorless wax which later solidified. 
 
 
Yield: 94% 
[α]20 D  = +3.93 (c = 0.57; CHCl3) 
MS (FAB) calculated for [C22H13ClF10O6Na]+: 621; found: 621. 
1H NMR (400 MHz, CDCl3): 4.13 (m, 1H, H2), 3.92 (m, 1H, H7b), 3.77 (m, 1H, H7a), 3.66 (m, 
2H, H8), 3.63 (m, 1H, H1) 3.62 - 3.50 (m, 2H, H4, H5), 2.34 - 2.27 (m, 2H, H6), 2.27 - 2.22 (m, 
2H, H3), 1.82 (br s, 1H, OH). 
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13C NMR (100 MHz, CDCl3): 170.4, 170.4 (C9); 142.4 (m, CF); 141.1 (m, CF); 139.9 (m, CF); 
139.3 (m, CF); 138.6 (m, CF); 136.8 (m, CF); 76.6 (C1); 69.8 (C7); 66.58 (C2); 43.3 (C8); 39.1 
(C4); 38.6 (C5); 30.6 (C3); 27.4 (C6). 
2.4.2.5 1,2-Cyclohexanedicarboxylic acid, 4-(2-chloroethoxy)-5-[(2,3,4,6-tetra-
O-benzoyl-α-D-mannopyranosyl)oxy]-, 1,2- bispentafluorophenyl ester, 
(1S,2S,4S,5S), 2.9  
A mixture of the acceptor 2.5 (300 mg, 0.5 mmol, 1 eq.) and the donor 2.8 (445 mg, 0.6 mmol, 
1.2 eq.) was co-evaporated with toluene three times, then acid washed and powdered molecular 
sieves 4Å were added; the mixture was kept under vacuum for few h and then dissolved in dry 
CH2Cl2 (4 ml). After cooling at -20°C, TMSOTf (18 μL, 0.1 mmol, 0.2 eq.) was slowely added 
and the reaction mixture was stirred at that temperature. The reaction completition (1 h, TLC 
Hex:EtOAc = 7:3) the reaction was quenched with NEt3. The mixture was warmed to room 
temperature, filtered through a celite pad and concentrated at reduced pressure. The crude 
product was purified by flash chromatography (silica, hexane with gradient of ethyl acetate from 
10 to 20 %) affording 407 mg of pure product.  
O
O
ClPFP
O
PFP
O
O
OBz
BzO
OBz
BzO
D1
D2D3
D4
D5
D6
123
4 5
6
7
8
9
2.9  
Yield: 67 %. 
[α]20 D  = -26.7 (c = 0.55; CHCl3) 
MS (FAB): calculated for[C56H39ClF10O15Na]+: 1199; found: 1199 
1H NMR (400 MHz, CDCl3): 8.08 (m, 4H, HBz), 8.99 (d, 2H, HBz, J = 7.2 Hz), 7.84 (d, 2H, HBz, 
J = 7.2 Hz), 7.66 - 7.50 (m, 3H, HBz), 7.49 - 7.34 (m, 6H, HBz), 7.34 - 7.23 (m, 3H, HBz), 6.08 (t, 
1H, H4, J4-3 = J4-5= 10.0 Hz), 5.92 (dd, 1H, H3, J3-4 = 10 Hz, J3-2= 3.2 Hz), 5.77 (dd 1H, H2, J2-3 = 
3.2 Hz, J2-1= 1.2 Hz, 5.34 (d, 1H, H1, J1-2= 1.2 Hz), 4.72 (dd, 1H, H6b, J6-5 = 2.8 Hz, J6a-6b = 12.0 
Hz), 4.57 (dd, 1H, H6a, J6-5 = 5.2 Hz, J6a-6b = 12.0 Hz), 4.49 (m, 1H, H5), 4.21 (m, 1H, D2), 3.87 
(m, 1H, D1), 3.79 (m, 1H, H7a), 3.66 (m, 1H, H7b), 3.59 - 3.50 (m, 4H, H8a, H8b, D4, D5), 2.50 - 
2.40 (m, 2H, D3eq, D6eq), 2.28 - 2.17 (m, 2H, D3ax, D6ax). 
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13C NMR (100 MHz, CDCl3): 170.1, 170.1 (C9); 166.2, 165.7, 165.6, 165,5 (COBZ); 142.5 (m, 
CF); 141.1 (m, CF); 139.9 (m, CF); 139.2 (m, CF); 138.6 (m, CF); 136.8 (m, CF); 133.8, 133.7, 
133.5, 133.4 (CHBZ); 130,0 130.0, 129.9, 129.9 (CHBZ); 129.3, 129.1, 129.0, 129.0 (CquatBZ); 
128.8, 128.6, 128.6, 128.5 (CHBZ); 96.7 (C1); 74.7 (CD1); 72.3 (CD2); 70.8 (C2); 70.0 (C3); 69.9 
(C7); 69.8 (C5); 67.4 (C4); 63.4 (C6); 43.1 (C8); 38.8, 38.7 (CD4, CD5); 28.2 (CD3); 27.3 (CD6). 
 
2.5 1H NMR  
(400 MHz, CDCl3) 
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2.4.3 Synthesis of scaffold 2.31 – PNP methodology 
2.4.3.1 4-cyclohexene-1,2-dicarboxylic acid bis(4-nitro)phenylester, (1S,2S), 
2.28 
EDC·HCl (394 mg, 2.05 mmol, 3.5 eq.) was added to a solution of diacid  2.114 (100 mg, 0.59 
mmol, 1 eq.) in dry THF (5.8 ml) under stirring and under a nitrogen atmosphere. After 10 
minutes p-nitrophenol (245 mg, 1.76 mmol, 3 eq.) was added. The solution was stirred at room 
temperature for 2 h. After completion of the reaction the solvent was evaporated under reduced 
pressure, the residue was taken up in Et2O, washed with 1M HCl, saturated Na2CO3 (3x) and 
water; then dried over sodium sulphate. Solvent was evaporated under reduced pressure to yield 
pure product 2.28 as a pale yellow solid.  
O
O
O
O
NO2
NO2
87
2
16
3
4
5
9
10
11
2.28  
Yield: 70% 
2.5 13C NMR  
(100 MHz, CDCl3) 
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[α]D20  = + 129.6 (c = 1 in chloroform).  
1H NMR (400 MHz, CDCl3): δ = 8.28 - 8.22 (m, 4H, H10), 7.27 - 7.22 (m, 4H, H9), 5.83 (app d, J 
= 2.8 Hz, 2H, H4, H5), 3.27 - 3.19 (m, 2H, H1, H2), 2.78 - 2.68 (m, 2H, H3ps-eq, H6ps-eq), 2.48 - 
2.37 (m, 2H, H3ps-ax, H6ps-ax). 
 13C NMR (100 MHz, CDCl3): δ = 172.8 (C7); 155.4 (C11); 145.7 (C8); 125.5 (C10); 124.9 (C5, 
C4); 122.5 (C9); 41.5 (C1, C2); 28.0 (C3, C6).  
 
2.4.3.2 7-Oxabicyclo[4.1.0]heptane-3,4-dicarboxylic acid bis(4-
nitro)phenylester (3S,4S), 2.29 
MCPBA  (77%, 891 mg, 3.98 mmol, 1.2 eq.) was added to a solution of the PNP ester 2.28 
(1367 mg, 3.32 mmol, 1 eq.) in dry CH2Cl2 (11 ml) under stirring. The reaction was stirred under 
nitrogen at room temperature for 16 h. The solvent was evaporated at reduced pressure, the 
reaction mixture was diluted with EtOAc and washed with saturated NaHCO3 (3x) and with 
water. The organic phase was dried over sodium sulphate and the solvent evaporated under 
reduced pressure to yield of pure product 6 as white solid.  
O
O
O
O
NO2
NO2
87
2
16
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10
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O
4
5
2.29  
Yield: 96% 
[α]D20  = + 82.2 (c = 1.1 in chloroform). 
MS (ESI) calculated for [C20H16N2O9Na]+: 451.3; found: 452.0 
 1H NMR (400 MHz, CDCl3): δ = 8.28 - 8.22 (m, 4H, H10), 7.27 - 7.21 (m, 4H, H9), 3.43 – 3.36 
(m, 1H, H4 or H5), 3.35 - 3.31 (m, 1H, H4 or H5), 3.32 - 3.24 (m, 1H, H1 or H2), 3.08 - 3.00 (m, 
1H, H1 or H2), 2.79 – 2.71 (m, 1H, H3eq or H6eq), 2.63 – 2.54 (m, 1H, H3eq or H6eq),  2.42 – 2.33 
(m, 1H, H3az or H6az), 2.21 – 2.12 (m, 1H, H3ax or H6az). 
 13C NMR (100 MHz, CDCl3): δ = 172.6, 171.5 (C7); 155.4, 155.3 (C8); 149.9 (C11); 125.5 (C10); 
122.5, 122,6 (C9); 51.8, 50.3 (C4, C5); 40.1, 38.1 (C1, C2); 26.8, 26.3 (C3, C6).  
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2.4.3.3 1,2-Cyclohexanedicarboxylic acid, 4-hydroxy-5-(2-azidoethoxy)-, 1,2-
bis(4-nitro)phenyl ester, (1S,2S,4S,5S), 2.30 
To the solution of 2-azidoethanol 2.3320 (cca 600 mg, 7 mmol, 58 eq) in DCM (3 ml) epoxide 
2.29 (50 mg, 0.12 mmol, 1 eq) and Cu(OTf)2, (4 mg, 0.01 mmol, 0.1 eq.) were added and stirred 
under nitrogen at room temperature. After completion (16 h) the solvents were removed under 
reduced pressure and the crude was purified by flash chromatography (hexane with gradient of 
ethyl acetate from 20 % to 50 %) to yield pure product 2.30 as colourless wax.  
O
O
O
O
OH
O N3
O2N
O2N
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4
3
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7
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1213
2.30  
Yield: 70% 
[α]D20  = + 33.8 (c = 1.1 in chloroform) 
MS (ESI) calculated for [C22H21N3O10Na]+ =  [(M  – N2) + Na]+: 512.4; found: 512.0. 
1H NMR (400 MHz, CDCl3): δ = 8.27 - 8.17 (m, 4H, H12), 7.31 - 7.23 (m, 4H, H11),  4.19 - 4.14 
(m, 1H, H2), 3.88 – 3.82 (m, 1H, H7a), 3.73 – 3.63 (m, 2H, H7b, H1), 3.49 – 3.29 (m, 4H, H4, H5, 
H8a,b), 2.40 – 2.10 (m, 4H, H3, H6). 
 13C NMR (100 MHz, CDCl3): δ = 172.7, 172.6 (C9); 155.5 (C10); 145.8, 145.7 (C13); 125.5 
(C12); 122.6, 122,6 (C11); 76.5 (C1); 68.7 (C7); 66.3 (C2); 51.1 (C8); 39.4, 39.1 (C4, C5); 30.5, 
27.0 (C3, C6).  
 
2.4.3.4 1,2-Cyclohexanedicarboxylic acid, 4-(2-azidoethoxy)-5-[(2,3,4,6-tetra-
O-benzoyl-α-D-mannopyranosyl)oxy]-, 1,2- bis(4-nitro)phenyl ester, 
(1S,2S,4S,5S), 2.31  
A mixture of the acceptor 2.30 (37 mg, 0.071 mmol, 1 eq.) and the donor 2.816 (65 mg, 0.086 
mmol, 1.2 eq.) was coevaporated with toluene three times. Powdered and activated acid washed 
4Å molecular sieves were added; the mixture was kept under vacuum for a few h and then 
dissolved with dry CH2Cl2 (1 mL). After cooling at −20°C, TMSOTf (3μL, 0.014 mmol, 0.2 eq.) 
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was added to the reaction mixture under stirring. The reaction was stirred at -20°C for 1 h. The 
reaction was quenched with Et3N and the mixture warmed to room temperature and filtered over 
a celite pad. The filtrate was evaporated at reduced pressure and the crude product purified by 
flash chromatography (toluene with gradient of ethyl acetate from 0 % to 10 %) to yield pure 
product 2.31 as white foam.   
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Yield: 85 % 
[α]D20  = - 18.0 (c = 0.5 in chloroform).  
MS (ESI) calculated for [C56H47N5O19Na]+: 1117.0; found 1116.1. 
1HNMR (400 MHz, CDCl3): δ = 8.30 – 8.20 (m, 4H, H12), 8.09 – 8.00 (m, 4H, HBz), 7.99 – 7.94 
(m, 2H, HBz,), 7.83 – 7.79 (m, 3H, HBz), 7.63 – 7.48 (m, 3H, HBz), 7.46 – 7.20 (m, 12H, HBz, 
H11), 6.07 (t, 1H, H4, J4-3 = J4-5= 10.0 Hz), 5.90 (dd, 1H, H3, J3-4 = 10.0 Hz, J3-2 = 3.3), 5.75 (dd, 
1H, H2, J2-1 = 1.7 Hz, J2-3 = 3.3 Hz), 5.34 (d, 1H, H1, J1-2 = 1.7 Hz), 4.73 (dd, 1H, H6b, J6b-5 = 2.9 
Hz, J6a-6b = 12.0 Hz), 4.53 (dd, 1H, H6a, J6a-5 = 5.3 Hz, J6a-6b = 12 Hz), 4.48 - 4.40 (m, 1H, H5), 
4.23 - 4.18 (m, 1H, D2), 3.89 – 3.84 (m, 1H, D1), 3.74 – 3.67 (m, 1H, H7a), 3.60 – 3.52 (m, 1H, 
H7b), 3.44 - 3.34 (m, 2H, D4, D5), 3.35 - 3.23 (m, 2H, H8), 2.52 - 2.41 (m, 2H, D3eq, D6eq), 2.25 - 
2.09 (m, 2H, D3ax, D6ax). 13C NMR (100 MHz, CDCl3): δ = 172.3, 172.2 (C9); 166.3, 165.8, 
165.7 (COBZ); 155.5, 155.4 (C10); 145.8 (C13); 133.9, 133.8, 133.6, 133.5 (CHBZ); 130.1, 130.1, 
129.9, 129.9, 129.9 (CHBZ); 129.3, 129.2, 129.1, 129.0 (CquatBZ); 128.9, 128.7, 128.9, 128.4 
(CHBZ); 125.5, 125.4 (C12); 122.7, 122.6 (C11); 96.8 (C1); 74.9 (CD1); 72.3 (CD2); 70.9 (C2); 70.1 
(C5); 69.9 (C3); 68.7 (C7); 67.4 (C4); 63.5 (C6); 51.0 (C8); 39.4, 39.2 (CD4,CD5); 27.8 (CD3); 27.0 
(CD6). 
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2.31 1H NMR  
(400 MHz, CDCl3) 
2.31 13C NMR  
(100 MHz, CDCl3) 
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2.4.4 Synthesis of amines 2.12e-j,n-s 
 
 
 
2.4.4.1 General procedure 1:  reduction using LiAlH4 
To a 0.5 M solution of LiAlH4 (2 eq per functional group) in dry THF a 0.5 M solution of 
starting material (1 eq) in dry THF was added at 0°C dropwise under nitrogen atmosphere. After 
the complete addition the reaction mixture was heated up to reflux for 3 h. The reaction was 
cooled to 0°C and worked up by addition of water (1 ml per 1g of LiAlH4), 15% NaOH solution 
(1 ml per 1g of LiAlH4) and water (3 ml per 1g of LiAlH4) again. The precipitate was filtered off 
and washed with THF. The filtrate was concentrated under reduced pressure. The product was 
purified by flash chromatography (silica, DCM with gradient of methanol from 0 to 20%) or 
used without purification if the purity was sufficient.   
2.4.4.2 (4-(methoxymethyl)phenyl)methanamine, 2.12e 
 
Cl
Cl
NaOMe/MeOH
THF, N2
O
Cl
45 %
NaN3
TBAI, DMF
50deg
O
N3
80 % O
H2N
Pd/C/H2
EtOH
80 %
2.12e2.13 2.14 2.15  
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1-(chloromethyl)-4-(methoxymethyl)benzene, 2.1444: To a solution of 
1,4bis(chloromethyl)benzene 2.13 (200 mg, 1.14 mmol, 1.1 eq) in dry THF (1.3 ml) a 1 M 
solution of MeONa in methanol (0.9 ml, 1.01 mmol, 1 eq) was added  dropwise at 0°C under 
nitrogen atmosphere. The reaction was stirred at room temperature for 16 h. The reaction was 
diluted with diethylether washed with water and brine, dried over sodium sulphate and 
concentrated under reduced pressure. The crude product was purified by flash chromatography 
(hexane with gradient of DCM from 20% to 50%) to yield 45% of pure product 2.14.  
O
Cl
1
2
3
4
5
6
7
2.14
 
Yield: 45 %.  
1H NMR (400 MHz, CDCl3): δ = 7.39 (d, 2H, H3, J = 8.2 Hz), 7.34 (d, 2H, H4, J = 8.2 Hz), 4.60 
(s, 2H, H1), 4.48 (s, 2H, H6), 3.41 (s, 3H, H7).  
 
1-(azidomethyl)-4-(methoxymethyl)benzene, 2.15: To a solution of 2.14 (65 mg, 0.38 mmol, 1 
eq) in DMF (1.3 ml) NaN3 (198 mg, 3.05 mmol, 8 eq) and TBAI (14 mg, 0.04 mmol, 0.1 eq) 
was added. The reaction was heated up to 50°C and stirred for 16 h. The solvent was removed 
under reduced pressure and the residue was taken up with ether, washed with water and brine, 
dried over sodium sulphate and concentrated under reduced pressure.  The crude product was 
purified by flash chromatography (hexane with gradient of DCM from 30 % to 70 %) to yield 80 
% of pure product 2.15.  
O
N3
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2
3
4
5
6
7
2.15
 
Yield: 80 %.  
1H NMR (400 MHz, CDCl3): δ = 7.35 (d, 2H, H3, J = 8.1 Hz), 7.29 (d, 2H, H4, J = 8.1 Hz), 4.45 
(s, 2H, H6), 4.31 (s, 2H, H1), 3.38 (s, 3H, H7)  
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13C NMR (100 MHz, CDCl3): δ = 138.6 (C2); 134.9 (C5); 128.4, 128.2 (C3, C4); 74.4 (C6); 58.3 
(C7); 54.7 (C1). 
 
(4-(methoxymethyl)phenyl)methanamine, 2.12e45: To a solution of 2.15 (50 mg, 0.28 mmol, 1 
eq) in ethanol (9 ml) 10 % Pd/C was added in catalytic amount. The reaction was stirred under 
H2 (1 atm) at room temperature for 2 h. The catalyst was filtered off through a celite pad. The 
filtrate was concentrated under reduced pressure to yield 80 % of pure product. 
O
NH21
2
3
4
5
6
7
2.12e  
Yield: 80 %.  
1H NMR (400 MHz, CDCl3): δ = 7.30 - 7.24 (m, 4H, H3, H4), 4.41 (s, 2H, H6), 3.83 (s, 2H, H1), 
3.35 (s, 3H, H7).  
13C NMR (100 MHz, CDCl3): δ = 142.9 (C2); 136.9 (C5); 128.2, 127.3 (C3, C4); 74.6 (C6); 58.2 
(C7); 46.4 (C1).  
2.4.4.3  (4-(aminomethyl)phenyl)methanol, 2.12f46 
Using the general procedure 1 starting from methyl 4-(aminomethyl)benzoate hydrochloride  
NH2
HO
1
2
3
4
5
6
10h  
Yield: 95 %.  
1H NMR (400 MHz, CD3OD): δ = 7.32 (s, 4H, H3, H4), 4.58 (s, 2H, H6), 3.78 (s, 2H, H1). 
2.4.4.4 2-(4-(aminomethyl)phenyl)propan-2-ol, 2.12g 
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4-(2-hydroxypropan-2-yl)benzonitrile, 2.1847: To a solution of MeMgBr (3 M in Et2O, 2.3 ml, 
6.88 mmol, 5 eq) in THF (5 ml) a solution of 4-acetylbenzonitrile 2.17 (200 mg, 1.38 mmol, 1 
eq) was added dropwise at 0°C under nitrogen atmosphere. The reaction was stirred for 2 h at 
room temperature, then cooled down to 0°C and quenched by addition of water. The reaction 
was diluted with ether, washed with water and brine. The organic phase was dried over sodium 
sulphate and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (hexane with gradient of ethyl acetate from 10% - 30%) to yield pure product 
2.18.  
N
HO
1
2
3
2.18  
Yield: 67% 
1H NMR (400 MHz, CDCl3): δ = 7.65 – 7.55 (m, 4 H, H1, H2), 1.57 (s, 6H, H3). 
 
2-(4-(aminomethyl)phenyl)propan-2-ol, 2.12g47: Using general procedure 1 starting from 2.12g.  
HO
H2N 1
2
3
4
5
6 7
2.12g  
Yield: 70 %. 
1H NMR (400 MHz, CD3OD): δ = 7.46 (d, 2H, H4, J = 8.4 Hz), 7.29 (d, 2H, H3, J = 8.4 Hz), 
3.79 (s, 2H, H1), 1.52 (s, 6H, H7). 
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 13C NMR (100 MHz, CD3OD): δ = 149.2 (C2, C5); 128.4 (C3);, 126.0 (C4); 73.0 (C6); 47.3 (C1); 
32.1 (C7). 
 
2.4.4.5  (4-(2-methyl-1,3-dioxolan-2-yl)phenyl)methanamine, 2.12h 
 
 
4-(2-methyl-1,3-dioxolan-2-yl)benzonitrile, 2.2048: To the solution of 4-acetylbenzonitrile 2.19 
(300 mg, 2.06 mmol, 1 eq) in benzene (5 ml) under nitrogen atmosphere ethyleneglycol (0.35 
ml, 6.20 mmol, 3 eq)  was added in one portion and BF3.Et3 (0.08 ml, 0.62 mmol, 0.3 eq) 
dropwise. The solution was stirred at room temperature for 1 h then heated up to reflux for 5 h. 
The reaction was quenched by addition of triethylamine (few drops) and then diluted with 
diethyl ether. The mixture was transferred to a separatory funnel, washed with water and brine, 
dried over sodium sulphate and concentrated under reduced pressure. The crude was purified by 
flash chromatography (hexane : diethyl ether = 7 : 3) to yield 41 % of pure product. 
N
O
O
1
2
3
4
5
6
7
8
9
2.20
 
Yield: 41 % 
1H NMR (400 MHz, CDCl3): δ = 7.64 – 7.56 (m, 4H, H3, H4), 4.09 – 3.99 (m, 2H, H8, H9), 3.78 
– 3.68 (m, 2H, H8, H9), 1.61 (s, 3H, H7).  
13C NMR (100 MHz, CDCl3): δ = 148.9 (C5); 132.4 (C3); 126.4 (C4); 119.0 (C1); 112.0 (C2); 
108.4 (C6); 64.9 (C8, C9); 27.6 (C7) 
 
 (4-(2-methyl-1,3-dioxolan-2-yl)phenyl)methanamine, 2.12h49: Using general procedure 1 
starting from nitrile 2.20.  
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Yield: 95 %. 
1H NMR (400 MHz, CDCl3): δ = 7.45 – 7.21 (m, 4 H, H3, H4), 4.06 – 3.96 (m, 2H, H8, H9), 3.85 
(s, 2H, H1), 3.80 – 3.70 (m, 2H, H8, H9), 1.63 (s, 3H, H7).  
13C NMR (100 MHz, CDCl3): δ = 142.6, 142.0 (C2, C5); 127.2 (C3); 125.7 (C4); 109.0 (C6); 64.6 
(C8, C9); 46.3 (C1); 27.8 (C7). 
 
2.4.4.6 (2-aminoethyl)-α-D-mannopyranoside, 2.12j  
 
HO
Cl
BF3.OEt2,DCM
3day, 0°C to rt.
62%
O
OAc
AcO
AcO
OAc
O
Cl
O
OAc
AcO
AcO
OAc
O
N3
NaN3
DMF, 55°C
1day, quant.
NaOMe
MeOH, rt.
1h, quant.
O
OH
HO
HO
OH
O
N3
H2(1atm.)/Pd/C
EtOH, rt.
4h, quant.
O
OH
HO
HO
OH
O
NH2
O
OAc
AcO
AcO
OAc
OAc
2.22 2.23
2.24
2.21
2.12j
 
 
 (2-chloroethyl)-2,3,4,6-tetraacetyl-α-D-mannopyranoside, 2.22 
To a solution of the peracetylated mannose (100 mg, 0.256 mmol, 1 eq.) in dry DCM (8.5 mL) at 
room temperature under nitrogen atmosphere chloroethanol (22 µl, 0.333 mmol, 1.3 eq.) was 
added. The solution was cooled at 0°C and BF3 – Et2O (126 µl, 1.025 mmol, 4 eq.) was added. 
The reaction was kept at 0°C for 30 minutes, then warmed at room temperature and stirred 
overnight. After completion (TLC 6:4 Hex:EtOAc) the reaction mixture was diluted with DCM, 
poured into a ice-water mixture and extracted twice with DCM. Organic phases were collected, 
washed with sat. NaHCO3 and dried over sodium sulphate. The solvent was evaporated at 
reduced pressure obtaining 108 mg of crude that was purified by flash chromatography (silica, 
Toluene:EtOAc = 7:3) leading to 63 mg of pure product. 
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Yield: 60%. 
[α]20D= (c = 0.47, chloroform). 
MS (FAB) calculated for [C16H23ClO10Na]+: 433 ; found: 433. 
1H NMR (400 MHz, CDCl3): 5.33 (dd, 1H, H3, J3-4 =10.0 Hz, J3-2 = 3.4 Hz), 5.30 - 5.23 (m, 2H, 
H2, H4), 4.85 (d, 1H, H1, J1-2 = 1.3 Hz), 4.25 (dd, 1H, H6B, Jgem = 12.4 Hz, J6B-5 = 5.5 Hz), 4.15 - 
4.06 (m, 2H, H6A, H5), 3.95 - 3.86 (m, 1H, H7B), 3.84 - 3.76 (m, 1H, H7A), 3.66 (t, 2H, H8, J = 5.7 
Hz), 2.14 (s, 3H, CH3CO), 2.08 (s, 3H, CH3CO), 2.03 (s, 3H, CH3CO), 1.98 (s, 3H, CH3CO). 
13C NMR (100 MHz, CDCl3): 170.8 (COCH3); 170.2 (COCH3); 170.1 (COCH3); 170.0 
(COCH3); 98.1 (C1); 69.7 (C2); 69.2 (C3); 69.2 (C5); 68.9 (C7); 66.3 (C4); 62.7 (C6); 42.6 (C8); 
21.1 (CH3CO); 21.0 (CH3CO); 20.9 (CH3CO); 20.9 (CH3CO). 
 
(2-azidoethyl)-2,3,4,6-tetraacetyl-α-D-mannopyranoside, 2.23: To a solution of the chloroethyl 
derivative 2.22 (43.0 mg, 0.105 mmol, 1 eq.) in dry DMF (0.26 ml) under nitrogen atmosphere 
sodium azide (34 mg, 0.523 mmol, 5 eq.) was added. The reaction was warmed at 50°C and 
stirred at that temperature for 1 day. After completion (1H-NMR) the reaction mixture was 
diluted with EtOAc, washed with water. Aqueous phase was extracted again with EtOAc, the 
organic phases were collected, dried over sodium sulphate and the solvent was evaporated at 
reduced pressure, obtaining 43 mg of pure product as a colourless oil. 
 
Yield: quantitative. 
[α]20D= + 31.5 (c: 0.35, CHCl3). 
MS (FAB) calculated for [C16H24N3O10]+: 418; found: 418. 
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                   calculated for [C16H23N3O10Na]+: 440; found: 440. 
1H NMR (400 MHz, CDCl3): 5.34 (dd, 1H, H3, J3-4 =10.0 Hz, J3-2 = 3.2 Hz), 5.31 - 5.24 (m, 2H, 
H2, H4), 4.85 (d, 1H, H1, J1-2 = 1.2 Hz), 4.27 (dd, 1H, H6B, Jgem = 12.0 Hz, J6B-5 = 5.2 Hz), 4.11 
(dd, 1H, H6A, J6A-5 = 2.4 Hz), 4.06 - 4.00 (m, 1H, H5), 3.88 - 3.81 (m, 1H, H7B), 3.69 - 3.62 (m, 
1H, 
H7A), 3.51 - 3.38 (m, 2H, H8), 2.14 (s, 3H, CH3CO), 2.08 (s, 3H, CH3CO), 2.03 (s, 3H, CH3CO), 
1.97 (s, 3H, CH3CO). 
13C NMR (100 MHz, CDCl3): 170.8 (COCH3); 170.2 (COCH3); 170.0 (COCH3); 170.0 
(COCH3); 98.0 (C1); 69.6 (C2); 69.1 (C3); 69.1 (C5); 67.3 (C7); 66.3 (C4); 62.7 (C6); 50.6 (C8); 
21.1 (CH3CO); 21.0 (CH3CO); 20.9 (CH3CO); 20.9 (CH3CO). 
 
(2-azidoethyl)-α-D-mannopyranosid, 2.24: To a solution of the azidoethyl derivative 2.23 (3.26 
g, 7.81 mmol, 1 eq) in dry MeOH (53 ml), freshly prepared MeONa 1M in dry MeOH (1.25 ml) 
was added. The reaction was stirred at room temperature, monitoring by TLC (Hex:EtOAc = 
1:1). After 20 min the reaction mixture was neutralized with an acidic resin (Amberlite IRA 120 
H+) and the solvent was evaporated at reduced pressure, obtaining 1.95 g of the 
azidoethylmannoside 2.24, as a white solid, which was used without any other purification. 
O
OH
HO
HO
OH
O
N3
2.24
123
4
5
6
7
8
 
 
Yield = quantitative. 
[α]D20 = +55.64 (c: 1.2, MeOH). 
MS (ESI) calculated for [C8H15N3O6Na]+: 272.1; found: 272.6 
                 calculated for [C8H15N3O6K]+: 289.1; found: 288.4. 
1H NMR (400 MHz, D2O): 4.95 (d, 1H, H1, J1-2= 1.6 Hz), 4.01 (dd, 1H, H2, J2-3= 3.2 Hz), 3.98 - 
3.92 (m, 1H, H7B), 3.95 - 3-91 (m, 1H, H6B), 3.87 (dd, 1H, H3, J3-4= 9.4 Hz), 3.82 – 3.77 (m, 1H, 
H6A), 3.78-3.73 (m, 1H, H7A), 3.72-3.68 (m, 2H, H4, H5), 3.58 (ddd, 1H, H8B, Jgem= 13.6 Hz, 
J8B-7= 6.4 Hz, J8B-7’ = 3.2 Hz), 3.52 (ddd, 1H, H8A, J8A-7 = 6.0 Hz, J8A-7’ = 3.2 Hz). 
13C NMR (100 MHz, D2O): 99.6 (C1); 72.7 (C4); 70.2 (C3); 69.7 (C2); 66.5 (C5); 66.1 (C7); 60.7 
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(C6); 50.0 (C8). 
 
(2-aminoethyl)-α-D-mannopyranoside, 2.12j: To a solution of the azide 2.24 (20 mg, 0.08 
mmol, 1 eq) in EtOH (4 ml) a catalytic amount of Pd on carbon was added. The suspension was 
stirred under hydrogen atmosphere at room temperature. After completition (2 h, TLC 
CHCl3:MeOH = 8:2) the reaction mixture was filtered over a celite pad and the solvent was 
evaporated at reduced pressure, obtaining 17 mg of pure product. 
O
OH
HO
HO
OH
O
NH2
2.12j
123
4
5
6
7
8
 
Yield = 95% 
MS (ESI) calculated for [C8H18O6]+: 224; found: 224 
1H NMR (400 MHz, CD3OD): 4.81 (s, 1H, H1), 4.02 – 3.78 (m, 3H, H2, H6A, H7A) 3.75 – 3.56 
(m, 4H, H3, H6B, H7B, H4), 3.55 – 3.49 (m, 1H, H5), 3.15 – 3.06 (m, 2H, H8). 
13C NMR (100 MHz, D2O): 102.1 (C1); 75.3 (C5); 72.6 (C3); 71..9 (C2); 68.7 (C4); 66.0 (C7); 
63.1 
(C6); 41.0 (C8). 
2.4.4.7 (3-(aminomethyl)phenyl)methanol 2.12n50 
 Using general procedure 1 starting from 3-formylbenzonitrile. yield: 92%. 
OH
H2N 1
2
3
4
5
6
7
8
2.12n  
Yield: 92%. 
1H NMR (400 MHz, CD3OD): δ = 7.41 – 7.28 (m, 4 H, H3, H5, H6, H7), 4.68 (s, 2H, H8), 3.85 (s, 
2H, H1).  
13C NMR (100 MHz, CD3OD): δ = 143.9, 143.2 (C2, C4); 129.7(C3); 127.4, 127.1, 126.7 (C5, C6, 
C7);, 65.3 (C8); 46.8 (C1). 
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2.4.4.8 (4-(aminomethyl)-3-fluorophenyl)methanol 2.12o 
 Using general procedure 1 starting from 2-fluoro-4-formylbenzonitrile. 
 
Yield: 53 %. 
1H NMR (400 MHz, CD3OD): δ = 7.40 (t, 1H, H3, J7-6 = J3-F = 7.8 Hz), 7.19  - 7.09 (m, 2H, H6, 
H4), 4.63 (s, 2H, H8), 3.86 (s, 2H, H1).  
13C NMR (100 MHz, CD3OD): δ = 162.4 (d, C3, JC3-F = 244 Hz);  144.7 (d, C5, JC5-F = 7.2 Hz); 
130.7 (d, C7, JC7-F = 5.0 Hz); 129.17 (d, C2, JC2-F = 15.5 Hz);  123.7 (d, C4, JC4-F = 3.22 Hz); 114.5 
(d, C6, JC6-F = 22.4 Hz);  64.4 (d, C8, JC8-F = 1.6 Hz); 40.3 (d, C1, JC1-F = 3.9 Hz). 
 
2.4.4.9 (4-(aminomethyl)-2-fluorophenyl)methanol 2.12p 
 Using general procedure 1 starting from 4-cyano-2-fluorobenzoic acid; yield: 70 %. 
1
2
3
4
5
6
7
8
NH2
HO
F
2.12p  
1H NMR (400 MHz, CD3OD): δ = 7.44 (t, 1H, H4, J4-3 = J4-F = 7.8 Hz), 7.19  - 7.09 (m, 2H, H3, 
H7), 4.68 (s, 2H, H8), 3.81 (s, 2H, H1). 
13C NMR (100 MHz, CD3OD): δ = 162.1 (d, C6, JC6-F = 245 Hz);  145.8 (d, C2, JC2-F = 7.1 Hz); 
130.7 (d, C4, JC4-F = 4.9 Hz); 128.1 (d, C5, JC5-F = 15.2 Hz);  124.2 (d, C3, JC3-F = 3.16 Hz); 115.0 
(d, C7, JC7-F = 22.0 Hz);  58.8 (d, C8, JC8-F = 4.4 Hz); 46.2 (d, C1, JC1-F = 1.5 Hz). 
 
2.4.4.10 (5-(aminomethyl)-1,3-phenylene)dimethanol 2.12q 
Using general procedure 1 starting from 5-cyanoisophthalic acid. 
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Yield: 35 %. 
1H NMR (400 MHz, CD3OD): δ = 7.26 (s, 1H, H5), 7.23 (s, 2H, H3), 4.62 (s, 4H, H6), 3.88 (s, 
2H, H1).  
13C NMR (100 MHz, CD3OD): δ = 143.6 (C4); 141.5 (C2); 126.4 (C3); 125.9 (C5); 65.2 (C6); 
46.1 (C1). 
2.4.4.11 (4-(aminomethyl)-2-methoxyphenyl)methanol 2.12r 
 
methyl 4-cyano-2-methoxybenzoate 2.39: A flask charged with methyl 4-bromo-2-
methoxybenzoate 2.38 (200 mg, 0.82 mmol, 1 eq), K4[Fe(CN)6].3H2O (76 mg, 0.18 mmol, 0.22 
eq), Na2CO3 (87 mg, 0.82 mmol, 1 eq), Pd(OAc)2 (1 mg, 0.04 mmol, 0.05 eq) was degassed and 
nitrogen atmosphere was introduced (3 cycles), then the reagents were dissolved by addition of 
dry DMAC (1.4 ml). The reaction mixture was heated to 80°C and stirred under nitrogen 
atmosphere for 24 h. The TLC (hexane : AcOEt = 8:2), indicated presence of starting material so 
another portion of K4[Fe(CN)6].3H2O (172 mg, 0.408 mmol, 0.5 eq), Na2CO3 (87 eq, 0.82 mmol, 
1 eq), Pd(OAc)2 (1 mg, 0.04 mmol, 0.05 eq), and 1 mL of DMAC was added. The reaction 
mixture was stirred for additional 24 h at 70°C then cooled down to room temperature, diluted 
with ethyl acetate and filtered through a short silica pad. The filtrate was concentrated under 
reduced pressure and the crude residue was purified by flash chromatography (hexane : 
ethylacetate = 9 : 1)  to yield pure product 2.39.  
 
yield: 54 %  
1H NMR (400 MHz, CDCl3): δ = 7.83 (d, 1H, H4, J4-3  = 7.9 Hz), 7.29 (dd, 1H, H3, J3-4 = 7.9 Hz, 
J3-7 = 1.3 Hz ), 7.26 (d, 1H, H7, J7-3  = 1.3 Hz), 3.95 (s, 3H, H10) 3.93 (s, 1H, H9). 
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13C NMR (100 MHz, CDCl3): δ = 165.3 (C8); 159.0 (C2); 132.2 (C4); 124.8 (C5); 124.0 (C3); 
118.0 (C1); 116.6 (C6); 115.4 (C7); 56.3 (C9); 52.7 (C10). 
 
 (4-(aminomethyl)-2-methoxyphenyl)methanol 2.12r: Using the general procedure 1 starting 
from 2.39.  
HO
NH2
O
1
2
3
4
5
6
7
8
9
2.12r  
Yield: 70 %. 
1H NMR (400 MHz, CD3OD): δ = 7.30 (d, 1H, H4, J4-3  = 7.6 Hz), 6.96 (s, 1H, H7), 6.91 (d, 1H, 
H3, J3-4  = 7.6 Hz), 4.60 (s, 2H, H8) 3.88 (s, 3H, H9), 3.82 (s, 2H, H1).  
13C NMR (100 MHz, CD3OD): δ = 158.8 (C6); 143.8 (C2); 129.6 (C5); 129.4 (C4); 120.5 (C3); 
110.6 (C7); 60.5 (C8); 56.1 (C9); 46.8 (C1). 
2.4.4.12 4-(aminomethyl)-3,5-dimethoxyphenyl)methanol 2.12s 
 
methyl 4-bromo-3,5-dimethoxybenzoate 2.41: To a solution of 4-bromo-3,5-dimethoxybenzoic 
acid 2.40 (1,00 g, 3.83 mmol, 1 eq) in methanol (4 ml) H2SO4 (25 µL, 0.46 mmol, 0.12 eq).was 
added. The reaction was stirred under reflux for 16 h. The solvent was removed under reduced 
pressure and the crude residue was dissolved in DCM, washed with saturated NaHCO3 solution 
and water. The organic phase was dried over sodium sulphate and concentrated under reduced 
pressure to afford the pure product 2.41.   
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OO
OO 1
2
3
4
5
6
7
2.41
 
Yield: quantitative 
1H NMR (400 MHz, CDCl3): δ = 7.25 (s, 2H, H3), 3.96 (s, 6H, H7), 3.94 (s, 3H, H6).  
13C NMR (100 MHz, CDCl3): δ 166.8 (C5); 157.3 (C2); 130.2 (C4); 107.0 (C1); 105.6 (C3); 56.9 
(C7); 52.6 (C6). 
 
methyl 4-cyano-3,5-dimethoxybenzoate 2.42: A flask charged with 2.41 (200 mg, 0.73  mmol, 1 
eq), K4[Fe(CN)6].3H2O (307 mg, 0.73 mmol, 1 eq), Na2CO3 (77 mg, 0.727 mmol, 1 eq) and 
Pd(OAc)2 (3-5%) was degassed and nitrogen atmosphere was introduced (3 cycle), then the 
reagents were dissolved by addition of dry DMAC (1 ml). The reaction mixture was heated up to 
130°C and stirred under nitrogen atmosphere for 24 h. The reaction was cooled to room 
temperature, diluted with ethyl acetate and filtered through a short silica pad. The filtrate was 
concentrated under reduced pressure and the crude residue was purified by flash chromatography 
(hexane : ethylacetate = 9 : 1)  to yield pure product 2.42.  
 
Yield: 46 % 
1H NMR (400 MHz, CDCl3): δ = 7.22 (s, 2H, H4), 3.98 (s, 6H, H8), 3.96 (s, 3H, H7). 
13C NMR (100 MHz, CDCl3): δ = 166.4 (C6); 162.6 (C3); 136.1 (C5); 113.6 (C1); 105.0 (C4); 
56.9 (C8); 53.2 (C7).  
 
(4-(aminomethyl)-3,5-dimethoxyphenyl)methanol 2.12s: Using the general procedure 1 starting 
from 2.42.  
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7
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Yield: 28 %. 
1H NMR (400 MHz, CDCl3): δ = 6.66 (s, 2H, H4), 4.61 (s, 2H, H6), 3.93 (s, 2H, H1), 3.85 (s, 6H, 
H7).  
13C NMR (100 MHz, CDCl3): δ = 159.8 (C3); 145.4 (C5); 113.8 (C2); 103.0 (C4); 65.4 (C6); 56.6 
(C7) 34.1 (C1). 
 
2.4.5 Synthesis and characterization of 1,2-Cyclohexanedicarboxamides 4-
(2-chloroethoxy)-5-[(2,3,4,6-tetra-O-benzoyl-α-D-
mannopyranosyl)oxy]-, (1S,2S,4S,5S), 2.10a-j   
2.4.5.1 General procedure 2 
Amine 2.12 (3 eq) was added to a 0.1 M PFP-scaffold 2.9 (1 eq) in dry THF under stirring and 
under nitrogen atmosphere at room temperature. After completion (1-12 h, checked by TLC, hex 
: EtOAc) the solvent was evaporated under reduced pressure. The crude was purified by flash 
chromatography (hexane with gradient of ethyl acetate from 30% to 80%) 
 
 
O
O
Cl
O
O
O
OBz
BzO
OBz
Obz
D1
D2
D3
D4
D5
D6
123
4 5
6
7
8
9
NH
H
N
R
R
  
General structure and numbering of pseudobimannoside bis-amides 2.10a-j in the NMR 
characterizations   
2.4.5.2 N1,N2-bis(4-methoxybenzyl)amide, 2.10a 
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1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-methoxybenzyl)-4-(2-chloroethoxy)-5-[(2,3,4,6-
tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 2, using amine 2.12a. 
 
10
11
12
13
14
15
HN
R:
O
2.10a
  
Yield: 90% 
[α]20 D  = -35.62 (c = 0.45; CHCl3) 
MS (FAB):  calculated for [C60H60ClN2O15]+: 1083; found: 1083 
  calculated for [C60H60ClN2O15Na]+: 1105; found: 1105 
1H NMR (400 MHz, CDCl3): 8.07 (d, 2H, HBZ, J = 7.2 Hz), 8.02 (d, 2H, HBZ, J = 7.2 Hz), 7.97 
(d, 2H, HBZ, J = 7.2 Hz), 7.73 (d, 2H, HBZ, J = 7.2 Hz), 7.64-7.49 (m, 3H, HBZ), 7.48-7.35 (m, 
7H, HBZ), 7.25-7.16 (m, 6H, HBZ, H12), 6.91-6.71 (m, 5H, H13, NH), 6.17 (brs, 1H, NH), 6.13 
(dd, 1H, H4, J4-5 = 10.4 Hz, J4-3  = 8.0 Hz), 5.88 (dd, 1H, H3, J3-2  = 3.2 Hz, J3-4  = 10.4 Hz), 5.86-
5.79 (m, 1H, H8), 5.66 (dd, 1H, H2, J2-1 = 1.6 Hz, J2-3  = 3.2 Hz), 5.26 (d, 1H, H1, J1-2 = 1.6 Hz),  
4.73-4.65 (m, 1H, H6b), 4.55-4.46 (m, 2H, H5, H6a), 4.43-4.32 (m, 2H, H10a), 4.30-4.19 (m, 2H, 
H10b), 4.07 (m, 1H, D2), 3.79 (s, 3H, H15), 3.77 (m, 1H, D1), 3.73 (s, 3H, H15), 3.71-3.60 (m, 2H, 
H7a,b), 3.57-3.51 (m, 2H, H8a,b) 2.97-2.85 (m, 2H, D4, D5), 2.33-2.12 (m, 2H, D3eq, D6eq), 2.09-
1.94 (m, 2H, D3ax, D6ax). 
13C NMR (100 MHz, CDCl3): 174.2, 174.0 (C9); 166.2, 165.9, 165.9, 165.8 (COBZ); 159.1, 
159.0 (C14); 133.8, 133.7, 133.4, 133.3 (CHBZ); 130.7, 130.4, 130.0, 129.0, 129.0 (CquatBZ, C11); 
130.1, 130.0, 129.9, 129.2, 128.8, 128.6, 128.6, 128.5 (CHBZ, C12); 114.2, 114.2 (C13); 97.1 (C1); 
75.3 (CD1); 74.5 (CD2); 71.6 (C2); 70.3 (C3); 70.1 (C5); 69.7 (C7); 66.8 (C4); 63.1 (C6); 55.4, 55.4 
(C15); 43.3 (C8) 43.2, 43.1 (C10); 41.8, 41.1 (CD4, CD5); 28.8, 28.4 (CD3, CD6). 
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2.4.5.3 N1,N2-bis(3-methoxybenzyl)amide, 2.10b 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(3-methoxybenzyl)-4-(2-chloroethoxy)-5-[(2,3,4,6-
tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 2, using amine 2.12b. 
 
10
11
12
13 O14
15
16
17
HN
R:
2.10b
 
Yield: 96% 
MS (FAB):  calculated for [C60H60ClN2O15]+: 1083; found: 1083 
  calculated for [C60H60ClN2O15Na]+: 1105; found: 1105 
1H NMR (400 MHz, CDCl3): δ = 8.06 – 7.90 (m, 6H, HBz), 7.71 – 7.65 (m, 2H, HBz), 7.60 – 7.46 
(m, 3H, HBz), 7.43–7.32 (m, 7H, HBz), 7.25 – 7.13 (m, 4H, HBz, H15), 6.88 - 6.67 (m, 7H, H12, 
H14, H16, HNH), 6.17 (t, 1H, HNH, JNH-10 = 5.8 Hz), 6.10 (t, 1H, H4, J4-3 = J4-5= 10.0 Hz), 5.85 (dd, 
1H, H3, J3-4 = 10.0 Hz, J3-2= 3.3), 5.66 (brs, 1H, H2), 5.23 (brs, 1H, H1), 4.70 – 4.64 (m, 1H, H6a), 
4.51 – 4.30 (m, 4H, H6b, H10a, H5), 4.30-4.19 (m, 2H, H10b), 4.04 (m, 1H, D2), 4.75 (s, 3H, H17), 
3.69 (s, 3H, H17), 3.67 – 3.55 (m, 3H, D1, H7a,b), 3.53 - 3.45 (m, 2H, H8), 3.01 – 2.87 (m, 2H, D4, 
D5), 2.26 - 2.10 (m, 2H, D3eq, D6eq), 2.07 - 1.95 (m, 2H, D3ax, D6ax).  
2.4.5.4 N1,N2-bis(4-carbomethoxybenzyl)amide, 2.10c 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-carbomethoxybenzyl)-4-(2-chloroethoxy)-5-
[(2,3,4,6-tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 2, using amine 2.12c. 
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Yield: 63% 
MS (ESI):  calculated for [C62H59ClN2O17Na]+: 1162.6; found: 1162.6 
1H NMR (400 MHz, CDCl3): δ = 8.06 – 8.03 (m, 2H, HBz), 7.99 – 7.86 (m, 10H, HBz, H13), 7.68 
– 7.65 (m, 2H, HBz), 7.59 – 7.51 (m, 2H, HBz), 7.50–7.45 (m, 1H, HBz), 7.41 – 7.26 (m, 8H, HBz, 
H12), 7.22 – 7.17 (m, 2H, HBz), 7.06 (t, 1H, HNH, JNH-10 = 5.62 Hz), 6.41 (t, 1H, HNH, JNH-10 = 5.8 
Hz), 6.11 (t, 1H, H4, J4-3 = J4-5= 10.0 Hz), 5.87 (dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.3), 5.66 (dd, 
1H, H2, J2-1 = 1.7 Hz, J2-3= 3.3 Hz), 5.24 (d, 1H, H1, J1-2= 1.7 Hz), 4.72 – 4.62 (m, 1H, H6a), 4.51 
– 4.30 (m, 6H, H6b, H10a,b, H5), 4.09 - 4.04 (m, 1H, D2), 4.87 (s, 3H, H16), 3.84 (s, 3H, H16), 3.78 
– 3.74 (m, 1H, D1), 3.71 - 3.58 (m, 2H, H7a,b), 3.53 - 3.45 (m, 2H, H8), 3.08 – 2.98 (m, 2H, D4, 
D5), 2.26 - 2.10 (m, 2H, D3eq, D6eq), 2.07 - 1.95 (m, 2H, D3ax, D6ax).  
13C NMR (100 MHz, CDCl3): δ = 174.6, 174.5 (C9); 167.0, 167.0 (C15); 166.3, 166.1, 166.0, 
165.7 (COBZ); 143.8, 143.6 (C11); 133.9, 133.7, 133.6, 133.4 (CHBZ); 130.1, 130.1, 129.9, 129.9 
(CHBZ); 129.3, 129.3, 129.1, 128.9 (CquatBZ, C14); 128.8, 128.7, 128.7, 128.5 (CHBZ); 127.6, 
127.5 (C12, C13); 97.1 (C1); 75.3 (CD1); 74.4 (CD2); 72.9 (C2); 71.5 (C3); 70.4 (C5); 69.9 (C7); 66.7 
(C4); 63.0 (C6); 52.3, 52.2 (C16); 43.4 (C8); 43.3, 43.2, (C10); 41.7, 41.0 (CD4, CD5); 29.0 (CD3); 
28.6 (CD6).  
2.4.5.5 N1,N2-bis(4-nitrobenzyl)amide, 2.10d 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-nitrobenzyl)-4-(2-chloroethoxy)-5-[(2,3,4,6-tetra-
O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 2, using amine 2.12d. 
 
10
11
12
13
14
HN
R:
O2N
2.10d  
Yield: 91% 
MS (FAB):  calculated for [C58H53ClN4O17]+: 1013; found: 1013 
  calculated for [C58H53ClN4O17Na]+: 1135; found: 1135 
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1H NMR (400 MHz, CDCl3): δ = 8.14 – 7.90 (m, 10H, HBz, H13), 7.68 – 7.64 (m, 2H, HBz, H13), 
7.61 – 7.47 (m, 3H, HBz), 7.43 – 7.31 (m, 10H, H13, HBz), 7.26–7.11 (m, 4H, HNH, HBz), 6.52  (t, 
1H, HNH, JNH-10 = 6.1 Hz), 6.14 (t, 1H, H4, J4-3 = J4-5= 10.0 Hz), 5.84 (dd, 1H, H3, J3-4 = 10.0 Hz, 
J3-2= 3.3), 5.68 (dd, 1H, H2, J2-1 = 1.7 Hz, J2-3= 3.3 Hz), 5.25 (d, 1H, H1, J1-2= 1.7 Hz), 4.72 – 
4.62 (m, 1H, H6a), 4.60 – 4.35 (m, 6H, H6b, H10a,b, H5), 4.11 - 4.07 (m, 1H, D2), 3.78 – 3.74 (m, 
1H, D1), 3.71 - 3.66 (m, 2H, H7a,b), 3.56 - 3.52 (m, 2H, H8), 3.15 – 2.98 (m, 2H, D4, D5), 2.26 - 
2.00 (m, 4H, D3, D6).  
2.4.5.6 N1,N2-bis(4-(methoxymethyl)benzyl)amide 2.10e 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-(methoxymethyl)benzyl)-4-(2-chloroethoxy)-5-
[(2,3,4,6-tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 2, using amine 2.12e. 
 
10
11
12
13
14
HN
R:
O 15
16
2.10e  
 
Yield: 91% 
MS (ESI): calculated for [C62H63ClN2O15Na]+: 1134.6; found: 1134.7 
1H NMR (400 MHz, CDCl3): δ = 8.06 – 7.92 (m, 6H, HBz), 7.72 – 7.68 (m, 2H, HBz), 7.60 – 7.47 
(m, 3H, HBz), 7.42 – 7.32 (m, 7H, H13, HBz), 7.29 – 7.19 (m, 10H, H13, HBz), 6.86 (t, 1H, HNH, 
JNH-10 = 5.7 Hz), 6.34 (t, 1H, HNH, JNH-10 = 5.7 Hz), 6.19 (t, 1H, H4, J4-3 = J4-5= 10.0 Hz), 5.92 
(dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.3), 5.64 (dd, 1H, H2, J2-1 = 1.7 Hz, J2-3= 3.3 Hz), 5.24 (d, 1H, 
H1, J1-2= 1.7 Hz), 4.70 – 4.63 (m, 1H, H6a), 4.51 – 4.20 (m, 10H, H15, H6b, H10a,b, H5), 4.08 - 4.04 
(m, 1H, D2), 3.78 – 3.74 (m, 1H, D1), 3.71 - 3.58 (m, 2H, H7a,b), 3.53 - 3.45 (m, 2H, H8), 3.34 (s, 
3H, H16), 3.29 (s, 3H, H16), 3.01 – 2.86 (m, 2H, D4, D5), 2.26 - 2.10 (m, 2H, D3eq, D6eq), 2.07 - 
1.95 (m, 2H, D3ax, D6ax).  
13C NMR (100 MHz, CDCl3): δ = 174.4, 174.2 (C9); 166.3, 166.0, 165,9, 165.8 (COBZ); 137.9, 
137.5, 137.5, 137.4 (C11, C14); 133.9, 133.7, 133.5, 133.4 (CHBZ); 130.1, 130.0, 129.9, 129.9 
(CHBZ); 129.2, 129.0 (CquatBZ); 128.7, 128.5, 128.4, 128.2, 128.2 (CHBZ); 127.9, 127.9 (C12, 
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C13); 97.2 (C1); 75.3 (CD1); 74.6, 74.5 (C15); 74.5 (CD2); 71.5 (C2); 70.3 (C3); 70.1 (C5); 69.7 
(C7); 66.8 (C4); 63.1 (C6); 58.3, 58.2 (C16); 52.3, 52.2 (C16); 43.4 (C8); 43.3 (C10); 41.7, 41.0 
(CD4, CD5); 28.8 (CD3); 28.5 (CD6).  
2.4.5.7 N1,N2-bis(4-(hydroxymethylene)benzyl)amide, 2.10f 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-(hydroxymethylene)benzyl)-4-(2-chloroethoxy)-5-
[(2,3,4,6-tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
 
Prepared according to general procedure 2, using amine 2.12f. 
 
10
11
12
13
14
HN
R:
OH15
2.12f  
Yield: 86% 
MS (ESI): calculated for [C60H59ClN2O15Na]+: 1106.6; found: 1105.6 
1H NMR (400 MHz, CD3OD): δ = 8.15 – 7.92 (m, 6H, HBz), 7.80 – 7.75 (m, 2H, HBz), 7.70 – 
7.60 (m, 2H, HBz), 7.55 – 7.40 (m, 6H, H13, HBz), 7.38 – 7.20 (m, 12H, H12, HBz); 6.10 (t, 1H, H4, 
J4-3 = J4-5= 10.0 Hz), 6.00 (dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.3), 5.86 (dd, 1H, H2, J2-1 = 1.7 Hz, 
J2-3= 3.3 Hz), 5.39 (d, 1H, H1, J1-2= 1.7 Hz), 4.79 – 4.74 (m, 1H, H6a), 4.66 – 4.53 (m, 6H, H15, 
H6b, H5), 4.42 - 4.30 (m, 4H, H10a,b), 4.23 – 4.18 (m, 1H, D2), 3.92 – 3.87 (m, 1H, D1), 3.83 - 
3.76 (m, 1H, H7a), 3.72 - 3.63 (m, 1H, H7a), 3.60 - 3.57 (m, 2H, H8), 3.17 – 2.98 (m, 2H, D4, D5), 
2.13 - 1.99 (m, 2H, D3, D6).  
13C NMR (100 MHz, CD3OD): δ = 177.4, 176.8 (C9); 167.6, 167.2, 166.9, 166.9 (COBZ); 141.7, 
139.2, 139.0 (C11, C14); 134.9, 134.8, 134.7, 134.6 (CHBZ); 131.2 (CquatBZ); 130.9, 130.9  
(CHBZ); 130.7 (CquatBZ); 130.7 (CHBZ); 130.4 (CquatBZ); 130.0, 129.9, 129.7, 129.6 (CHBZ); 
128.6, 128.5 (C12, C13); 98.2 (C1); 76.5 (CD1); 74.3 (CD2); 72.2 (C2); 72.0 (C3); 71.0 (C5); 70.8 
(C7); 68.5 (C4); 65.1, 65.1 (C15); 64.2 (C6); 44.4 (C8); 43.9 (C10); 42.0, 42.0 (CD4, CD5); 30.1 
(CD3); 29.2 (CD6).  
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2.4.5.8 N1,N2-bis(4-hydroxy(α,α-dimethyl)methylenebenzyl)amide, 2.10g 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-hydroxy(α,α-dimethyl)methylenebenzyl)-4-(2-
chloroethoxy)-5-[(2,3,4,6-tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
 
Prepared according to general procedure 2, using amine 2.12g. 
 
10
11
12
13
14
HN
R:
HO 15 16
2.10g  
Yield: 95% 
MS (ESI): calculated for [C64H67ClN2O15Na]+: 1162.7; found: 1161.8 
1H NMR (400 MHz, CDCl3): δ = 8.06 – 7.92 (m, 6H, HBz), 7.74 – 7.66 (m, 2H, HBz), 7.60 – 7.46 
(m, 3H, HBz), 7.41 – 7.31 (m, 11H, HBz ,H13), 7.25 – 7.17 (m, 6H, H12, HBz), 6.90 (t, 1H, HNH, 
JNH-10 = 5.7 Hz), 6.33 (t, 1H, HNH, JNH-10 = 5.7 Hz),  6.11 (t, 1H, H4, J4-3 = J4-5= 10.0 Hz), 5.87 
(dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.1), 5.66 (dd, 1H, H2, J2-1 = 1.7 Hz, J2-3= 3.1 Hz), 5.24 (d, 1H, 
H1, J1-2= 1.7 Hz), 4.70 – 4.63 (m, 1H, H6a), 4.51 – 4.44 (m, 2H, H6b, H5), 4.42 - 4.32 (m, 2H, 
H10a), 4.31 – 4.19 (m, 2H, H10a), 4.08 – 4.04 (m, 1H, D2), 3.78 – 3.73 (m, 1H, D1), 3.77 - 3.55 
(m, 2H, H7), 3.52 - 3.47 (m, 2H, H8), 3.03 – 2.89 (m, 2H, D4, D5), 2.28 – 1.92 (m, 4H, D3, D6), 
1.51 (s, 3H, H16), 1.50 (s, 3H, H16), 1.46 (s, 3H, H16), 1.43 (s, 3H, H16).  
13C NMR (100 MHz, CDCl3): δ = 174.4, 174.3 (C9); 166.3, 165.9, 165.9, 165.8 (COBZ); 148.5, 
148.3 (C14); 136.8, 136.8 (C11); 133.9, 133.7, 133.5, 133.3 (CHBZ); 130.1, 130.0, 129.9, 129.9 
(CHBZ); 129.2, 129.0 (CquatBZ); 128.8, 128.7, 128.5 (CHBZ); 127.6, 127.6 (C12); 124.9, 124.9 
(C13); 97.2 (C1); 75.3 (CD1); 74.5 (CD2); 72.5, 72.5 (C15); 71.5 (C2); 70.3 (C3); 70.1 (C5); 69.7 
(C7); 66.8 (C4); 63.1 (C6); 58.3, 58.2 (C16); 52.3, 52.2 (C16); 43.3, 43.2 (C10 ,C8); 41.8, 41.1 (CD4, 
CD5); 31.9, 31.9, 31.9, 31.8  (C16); 28.8, 28.6 (CD3, CD6).  
 
2.4.5.9 N1,N2-bis(4-(2-methyl-1,3-dioxolan-2-yl)benzyl)amide, 2.10h 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-(2-methyl-1,3-dioxolan-2-yl)benzyl)-4-(2-
chloroethoxy)-5-[(2,3,4,6-tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
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Prepared according to general procedure 2, using amine 2.12h. 
 
10
11
12
13
14
HN
R:
1516
O
O
17
18
2.10h  
 
Yield: 80% 
MS (ESI): calculated for [C66H67ClN2O17Na]+: 1218.7; found: 1218.8 
1H NMR (400 MHz, CDCl3): δ = 8.06 – 8.02 (m, 2H, HBz), 8.01 – 7.96 (m, 4H, HBz,), 7.75 – 
7.70 (m, 2H, HBz), 7.60 – 7.46 (m, 3H, HBz), 7.43–7.32 (m, 11H, HBz, H12), 7.26 – 7.19 (m, 6H, 
HBz, H13), 7.01 (t, 1H, HNH, JNH-10 = 5.8 Hz), 6.38 (t, 1H, HNH, JNH-10 = 5.8 Hz), 6.10 (t, 1H, H4, 
J4-3 = J4-5= 10.0 Hz), 5.89 (dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.3), 5.67 (dd, 1H, H2, J2-1 = 1.7 Hz, 
J2-3= 3.3 Hz), 5.25 (brs, 1H, H1), 4.72 – 4.60 (m, 1H, H6a), 4.53 – 4.21 (m, 6H, H6b, H10a,b, H5), 
4.09 - 4.04 (m, 1H, D2), 4.03 - 3.96 (m, 4H, H18a, 17a), 3.78 – 3.74 (m, 1H, D1), 3.74 - 3.59 (m, 
6H, H7, H18b, 17b), 3.53 - 3.47 (m, 2H, H8), 3.03 – 2.87 (m, 2H, D4, D5), 2.26 - 2.10 (m, 2H, D3eq, 
D6eq), 2.10 - 1.95 (m, 2H, D3ax, D6ax), 1.60 (s, 3H, H16), 1.54 (s, 3H, H16). 
13C NMR (100 MHz, CDCl3): δ = 174.3, 174.3 (C9); 166.3, 166.0, 166.0, 165.9 (COBZ); 142.7, 
142.6 (C11); 138.1 (C14); 133.9, 133.8, 133.6, 133.4 (CHBZ); 130.1, 130.0, 129.9 (CHBZ); 129.2, 
129.0, 129.0 (CquatBZ); 128.8, 128.7, 128.7, 128.5 (CHBZ); 127.7 (C13); 125.8, 125.8 (C12); 108,9 
(C15); 97.3 (C1); 75.3 (CD1); 74.6 (CD2); 71.5 (C2); 70.4 (C3); 70.1 (C5); 69.8 (C7); 66.8 (C4); 
64.6, 64.6 (C16, C17); 63.9 (C6); 43.3, 43.2 (C8, C10);  41.9, 41.7 (CD4, CD5); 28.8 (CD3); 28.6 
(CD6); 27.8, 27.8 (C16);  
2.4.5.10 N1,N2-bis(4-acetylbenzyl)amide, 2.10i 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-acetylbenzyl)-4-(2-chloroethoxy)-5-[(2,3,4,6-tetra-
O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
The acetal 2.10h (60 mg, 0.05mmol, 1 eq) was dissolved in a mixture of acetone and water 
(10/1, 0.5ml) and to this solution pyridinium 4-toluenesulfonate (PPTS, 1.2 mg, 0.005 mmol, 0.1 
eq) was added. The reaction was stirred at 50°C for 4 h. The solvents were removed under 
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reduced pressure and the crude was purified by flash chromatography (hexane: EtOAc = 3:7) to 
afford 50 mg of product. 
10
11
12
13
14
HN
R:
O 15 16
2.10i  
Yield: 90%  
MS (ESI): calculated for [C62H59ClN2O15Na]+: 1129.6; found: 1129.6 
1H NMR (400 MHz, CDCl3): δ = 8.04 (d, 2H, HBz, J = 8.3 Hz), 7.98 (d, 2H, HBz, J = 8.3 Hz), 
7.93 (d, 2H, HBz, J = 8.3 Hz), 7.85 (d, 2H, H13, J13-12 = 8.1 Hz), 7.80 (d, 2H, H13, J13-12 = 8.1 Hz), 
7.65 (d, 2H, HBz, J = 8.3 Hz), 7.60 – 7.45 (m, 3H, HBz), 7.41 – 7.28 (m, 11H, H12, HBz), 7.22 – 
7.16 (m, 2H, HBz), 7.06 (t, 1H, HNH, JNH-10 = 5.8 Hz), 6.36 (t, 1H, HNH, JNH-10 = 5.8 Hz), 6.12 (t, 
1H, H4, J4-3 = J4-5= 10.0 Hz), 5.86 (dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.2), 5.66 (dd, 1H, H2, J2-1 = 
1.7 Hz, J2-3= 3.3 Hz), 5.24 (d, 1H, H1, J2-1 = 1.7 Hz), 4.73 – 4.63 (m, 1H, H6a), 4.53 – 4.32 (m, 
6H, H6b, H10a,b, H5), 4.10 - 4.06 (m, 1H, D2),  3.77 – 3.74 (m, 1H, D1), 3.72 – 3.60 (m, 2H, H7), 
3.54 - 3.50 (m, 2H, H8), 3.09 – 2.95 (m, 2H, D4, D5), 2.53 (s, 3H, H16), 2.45 (s, 3H, H16), 2.26 – 
1.99 (m, 4H, D3, D6).  
13C NMR (100 MHz, CDCl3): δ = 197.8, 197.8 (C15); 174.6, 174.5 (C9); 166.3, 166.1, 166.1, 
165.7 (COBZ); 144.0, 143.9 (C11); 136.4, 136.3 (C14); 134.0, 133.8, 133.7, 133.4 (CHBZ); 130.1, 
130.0, 129.9, 129.9 (CHBZ); 129.1, 128.9 (CquatBZ); 128.9, 128.9 (CHBZ), 128.8 (CquatBZ); 
128.7, 128.6 (CHBZ, C13); 127.7, 127,7 (C12); 97.2 (C1); 75.3 (CD1); 74.5 (CD2); 71.5 (C2); 70.4 
(C3); 70.1 (C5); 69.8 (C7); 66.7 (C4); 63.0 (C6); 43.4 (C8); 43.3, 43.2 (C10); 41.7, 41.0 (CD4,CD5); 
29.1 (CD3); 28.7 (CD6); 26.8, 26.7 (C16).  
2.4.5.11 N1,N2-bis(2-(α-D-mannopyranosyloxy)ehyl)amide, 2.10j 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(2-(α-D-mannopyranosyloxy)ehyl)-4-(2-
chloroethoxy)-5-[(2,3,4,6-tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
A solution of PFP scaffold 2.9 (45 mg, 0.0038 mmol 1 eq.) in H2O/THF (1:2, 0.1 mL) was added 
to the solution of 2.12j (51 mg, 0.23 mmol, 6 eq.) in H2O/THF (1:2, 0.1 mL) over 8 hours at 
35°C. The reaction was stirred for additional 16 h at 35°C. The solvent was evaporated under 
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reduced pressure. The crude was purified by flash chromatography (DCM with gradient of 
methanol from 0% to 20%,  10% H2O in methanol) to afford 40 mg of pure product. 
O
OH
HO
HO
OH
O
N
H2.10j
 
 
Yield = 83 %;  
[α]D20  = - 2.1 (c = 0.31 in ethanol) 
MS (ESI) calculated for: [C60H71ClN2NaO25]+: 1278.6; found: 1278.4 
 
2.10j 1H NMR  
(400 MHz, CD3OD) 
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2.4.6 Synthesis and characterization of 1,2-Cyclohexanedicarboxamides-4-
(2-azidoethoxy)-5-[(2,3,4,6-tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- 
(1S,2S,4S,5S), 2.11a-j   
2.4.6.1 General procedure 3 
 To a solution of the chloroethyl derivative 2.10 (1 eq) in DMF (0.3 M) sodium azide (5 eq) and 
tetrabutylammonium iodide (0.1 eq) were added. The reaction was warmed at 45°C and stirred 
for 3 days. The solvent was removed at reduced pressure and the crude residue was purified by 
flash chromatography (silica, hexane with gradient of EA from 30% to 50%) to afford the pure 
product.   
O
O
N3
O
O
O
OBz
BzO
OBz
Obz
D1
D2
D3
D4
D5
D6
123
4 5
6
7
8
9
NH
H
N
R
R
  
General structure and numbering of pseudobimannoside 2.11a-j bis-amides in the NMR 
characterizations   
 
2.10j 13C NMR  
(100 MHz, CD3OD) 
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2.4.6.2 N1,N2-bis(4-methoxybenzyl)amide, 2.11a 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-methoxybenzyl)-4-(2-azidoethoxy)-5-[(2,3,4,6-
tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 3, starting from chloride 2.10a. 
 
10
11
12
13
14
15
HN
R:
O
2.11a
 
Yield: 86%. 
[α]20 D  =  - 29.9 (c: 0.25, CHCl3). 
MS (FAB):  calculated for [C60H60N5O15]+: 1090; found: 1090 
  calculated for [C60H59N5O15Na]+: 1112; found: 1112 
1H NMR (400 MHz, CDCl3): 8.07 (dd, 2H, HBZ, Jo-p = 1.2 Hz, Jo-m = 8.4 Hz ), 8.02 (dd, 2H, 
HBZ, Jo-p = 1.2 Hz, Jo-m = 8.4 Hz ),7.97 (dd, 2H, HBZ, Jo-p = 1.2 Hz, Jo-m = 8.4 Hz ), 7.72 (dd, 2H, 
HBZ, Jo-p = 1.2 Hz, Jo-m = 8.4 Hz ), 7.64-7.49 (m, 3H, HBZ), 7.47-7.35 (m, 7H, HBZ), 7.26-7.16 
(m, 6H, HBZ, H12), 6.88-6.79 (m, 4H, H13), 6.74 (t, 1H, NH, JNH-10 = 5.2 Hz), 6.17 (t, 1H, NH, 
JNH-10 = 5.2 Hz), 6.13 (dd, 1H, H4, J4-5 = 10.4 Hz, J4-3  = 10 Hz), 5.88 (dd, 1H, H3, J3-2  = 3.2 Hz, 
J3-4  = 10.4 Hz), 5.67 (dd, 1H, H2, J2-1 = 1.6 Hz, J2-3  = 3.2 Hz), 5.27 (d, 1H, H1, J1-2 = 1.6 Hz),  
4.73-4.65 (m, 1H, H6b), 4.55-4.46 (m, 2H, H5, H6a), 4.42-4.33 (m, 2H, H10a), 4.30-4.19 (m, 2H, 
H10b), 4.08 (m, 1H, D2), 3.78 (s, 3H, H15), 3.77 (m, 1H, D1), 3.73 (s, 3H, H15), 3.64-3.54 (m, 2H, 
H7a,b), 3.34-3.21 (m, 2H, H8a,b) 3.00-2.87 (m, 2H, D4, D5), 2.29-2.14 (m, 2H, D3eq, D6eq), 2.09-
1.98 (m, 2H, D3ax, D6ax). 
13C NMR (100 MHz, CDCl3): 174.1, 174.0 (CO); 166.2, 165.9, 165.8, 165.7 (COBZ); 159.0, 
159.0 (C14); 133.8, 133.7, 133.4, 133.3 (CHBZ); 130.6, 130.4, 129.9, 129.0, 128.9 (CquatBZ, C11); 
130.1, 130.0, 129.9, 129.2, 129.1, 128.8, 128.6, 128.6, 128.4 (CHBZ, C12); 114.2, 114.1 (C13); 
97.1 (C1); 75.5 (CD1); 74.4 (CD2); 71.5 (C2); 70.2 (C3); 70.0 (C5); 68.6 (C7); 66.8 (C4); 63.0 (C6); 
55.4, 55.3 (C15); 50.8 (C8) 43.2, 43.0 (C10); 41.8, 41.0 (CD4, CD5); 28.7, 28.4 (CD3, CD6). 
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2.4.6.3 N1,N2-bis(3-methoxybenzyl)amide, 2.11b 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(3-methoxybenzyl)-4-(2-azidoethoxy)-5-[(2,3,4,6-
tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 3, starting from chloride 2.10b. 
 
10
11
12
13 O14
15
16
17
HN
R:
2.10b
 
Yield: 99% 
MS (FAB):  calculated for [C60H59N5O15]+: 1090; found: 1090 
  calculated for [C60H59N5O15Na]+: 1112; found: 1112 
1H NMR (400 MHz, CDCl3): δ = 8.06 – 7.90 (m, 6H, HBz), 7.71 – 7.65 (m, 2H, HBz), 7.60 – 7.46 
(m, 3H, HBz), 7.43–7.32 (m, 7H, HBz), 7.25 – 7.13 (m, 4H, HBz, H15), 6.88 - 6.67 (m, 7H, H12, 
H14, H16, HNH), 6.25 – 6.16 (brs, 1H, HNH), 6.11 (t, 1H, H4, J4-3 = J4-5= 10.0 Hz), 5.86 (dd, 1H, 
H3, J3-4 = 10.0 Hz, J3-2= 3.3), 5.65 (brs, 1H, H2), 5.24 (brs, 1H, H1), 4.70 – 4.62 (m, 1H, H6a), 
4.55 – 4.30 (m, 4H, H6b, H10a, H5), 4.30-4.19 (m, 2H, H10b), 4.06 (brs, 1H, D2), 3.86 – 3.65 (m, 
7H, H17, H7a), 3.67 – 3.55 (m, 3H, D1, H7b), 3.36 - 3.17 (m, 2H, H8), 3.01 – 2.87 (m, 2H, D4, D5), 
2.26 - 2.11 (m, 2H, D3eq, D6eq), 2.10 - 1.95 (m, 2H, D3ax, D6ax),  
2.4.6.4 N1,N2-bis(4-carbomethoxy)amide, 2.11c 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-carbomethoxy)-4-(2-azidoethoxy)-5-[(2,3,4,6-
tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S) 
  
Prepared according to general procedure 3, starting from chloride 2.10c. 
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10
11
12
13
14
HN
R:
OO 15
16
2.11c  
 
Yield: 78% 
MS (ESI): calculated for [C62H59N5O17Na]+: 1168.1; found: 1168.5 
1H NMR (400 MHz, CDCl3): δ = 8.06 – 8.03 (m, 2H, HBz), 7.99 – 7.86 (m, 8H, HBz, H13), 7.72 – 
7.64 (m, 2H, HBz), 7.59 – 7.51 (m, 2H, HBz), 7.50–7.45 (m, 1H, HBz), 7.41 – 7.17 (m, 13H, HBz, 
H12), 7.01 (t, 1H, HNH, JNH-10 = 5.62 Hz), 6.34 (t, 1H, HNH, JNH-10 = 5.8 Hz), 6.12 (t, 1H, H4, J4-3 = 
J4-5= 10.0 Hz), 5.87 (dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.3), 5.66 (dd, 1H, H2, J2-1 = 1.7 Hz, J2-3= 
3.3 Hz), 5.24 (d, 1H, H1, J1-2= 1.7 Hz), 4.74 – 4.62 (m, 1H, H6a), 4.51 – 4.30 (m, 6H, H6b, H10a,b, 
H5), 4.12 - 4.04 (m, 1H, D2), 4.87 (s, 3H, H16), 3.84 (s, 3H, H16), 3.79 – 3.74 (m, 1H, D1), 3.71 - 
3.51 (m, 2H, H7a,b), 3.40 - 3.16 (m, 2H, H8), 3.16 – 2.89 (m, 2H, D4, D5), 2.28 - 2.11 (m, 2H, 
D3eq, D6eq), 2.11 - 1.98 (m, 2H, D3ax, D6ax),  
13C NMR (100 MHz, CDCl3): δ = 174.5, 174.5 (C9); 167.0, 167.0 (C15); 166.3, 166.1, 166.0, 
165.7 (COBZ); 143.8, 143.7 (C11); 133.9, 133.7, 133.6, 133.4 (CHBZ); 130.1, 130.1, 130.0, 129.9, 
129.9  (CHBZ); 129.3, 129.3, 129.1, 128.9, 128.9  (CquatBZ, C14); 128.8, 128.6, 128.5 (CHBZ); 
127.6, 127.5 (C12, C13); 97.2 (C1); 75.6 (CD1); 74.2 (CD2); 73.1 (C2); 71.5 (C3); 70.1 (C5); 68.7 
(C7); 66.7 (C4); 63.0 (C6); 52.3, 52.2 (C16); 50.9 (C8); 43.3, 43.2, (C10); 41.7, 41.0 (CD4, CD5); 
28.9, 28.8  (CD3 , CD6).  
2.4.6.5 N1,N2-bis(4-nitrobenzyl)amide, 2.11d 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-nitrobenzyl)-4-(2-azidoethoxy)-5-[(2,3,4,6-tetra-O-
benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 3, starting from chloride 2.10d. 
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10
11
12
13
14
HN
R:
O2N
2.11d  
Yield: 65% 
MS (FAB):  calculated for [C58H53N7O17]+: 1120; found: 1120 
  calculated for [C58H53N7O17Na]+: 1143; found: 1142 
1H NMR (400 MHz, CDCl3): δ = 8.14 – 7.90 (m, 10H, HBz, H13), 7.68 – 7.64 (m, 2H, HBz), 7.61 
– 7.47 (m, 3H, HBz), 7.45 – 7.33 (m, 10H, H13, HBz), 7.26–7.11 (m, 3H, HNH, HBz), 6.36  (brs, 1H 
HNH), 6.14 (t, 1H, H4, J4-3 = J4-5= 10.0 Hz), 5.84 (dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.3), 5.68 (dd, 
1H, H2, J2-1 = 1.7 Hz, J2-3= 3.3 Hz), 5.24 (d, 1H, H1, J1-2= 1.7 Hz), 4.77 – 4.64 (m, 1H, H6a), 
4.62– 4.35 (m, 6H, H6b, H10a,b, H5), 4.10 - 4.04(brs, D2), 3.79 – 3.74 (m, 1H, D1), 3.71 - 3.51 (m, 
2H, H7a,b), 3.40 - 3.16 (m, 2H, H8), 3.15 – 2.90 (m, 2H, D4, D5), 2.28 - 2.10 (m, 2H, D3eq, D6eq), 
2.11 – 2.20 (m, 2H, D3ax, D6ax). 
2.4.6.6 N1,N2-bis(4-(methoxymethyl)benzyl)amide, 2.11e 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-methoxybenzyl)-4-(2-azidoethoxy)-5-[(2,3,4,6-
tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 3, starting from chloride 2.10e. 
 
10
11
12
13
14
HN
R:
O 15
16
2.11e  
Yield: 66% 
MS (ESI): calculated for [C62H63N5O15Na]+: 1141.2; found: 1140.6 
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1H NMR (400 MHz, CDCl3): δ = 8.06 – 7.92 (m, 6H, HBz), 7.72 – 7.68 (m, 2H, HBz), 7.60 – 7.47 
(m, 3H, HBz), 7.42 – 7.32 (m, 7H, H13, HBz), 7.29 – 7.19 (m, 10H, H13, HBz), 6.79 (t, 1H, HNH, 
JNH-10 = 5.7 Hz), 6.17 (t, 1H, HNH, JNH-10 = 5.7 Hz), 6.11 (t, 1H, H4, J4-3 = J4-5= 10.0 Hz), 5.86 
(dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.3), 5.64 (dd, 1H, H2, J2-1 = 1.7 Hz, J2-3= 3.3 Hz), 5.24 (d, 1H, 
H1, J1-2= 1.7 Hz), 4.70 – 4.63 (m, 1H, H6a), 4.51 – 4.20 (m, 10H, H15, H6b, H10a,b, H5), 4.08 - 4.04 
(m, 1H, D2), 3.78 – 3.74 (m, 1H, D1), 3.62 - 3.50 (m, 2H, H7a,b), 3.34 (s, 3H, H16), 3.32 - 3.17 (m, 
2H, H8), 3.29 (s, 3H, H16), 3.01 – 2.86 (m, 2H, D4, D5), 2.26 - 2.10 (m, 2H, D3eq, D6eq), 2.07 - 
1.95 (m, 2H, D3ax, D6ax),  
13C NMR (100 MHz, CDCl3): δ = 174.2, 174.2 (C9); 166.3, 165.9, 165.9, 165.8 (COBZ); 138.0, 
137.9, 137.5, 137.4 (C11, C14); 133.9, 133.7, 133.5, 133.4 (CHBZ); 130.2, 130.0, 130.0, 129.9 
(CHBZ); 129.2, 129.0 (CquatBZ); 128.8, 128.7, 128.7, 128.5, 128.2, 128.2, (CHBZ); 127.9, 127.9 
(C12, C13); 97.3 (C1); 75.6 (CD1); 74.6, 74.5 (C15); 74.4 (CD2); 71.5 (C2); 70.3 (C3); 70.1 (C5); 
68.7 (C7); 66.8 (C4); 63.1 (C6); 58.3, 58.2 (C16); 52.3, 52.2 (C16); 50.9 (C8); 43.4, 43.4 (C10); 
41.8, 41.1 (CD4, CD5); 28.8, 28.6 (CD6, CD3).  
 
2.4.6.7 N1,N2-bis(4-(hydroxymethylene)benzyl)amide, 2.11f 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-(hydroxymethylene)benzyl)-4-(2-azidoethoxy)-5-
[(2,3,4,6-tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 3, starting from chloride 2.10f. 
 
10
11
12
13
14
HN
R:
OH15
2.11f  
Yield: 98% 
MS (ESI): calculated for [C60H59N5O15Na]+: 1113.1; found: 1112.5 
1H NMR (400 MHz, CD3OD): δ = 8.15 – 7.89 (m, 6H, HBz), 7.77 – 7.71 (m, 2H, HBz), 7.68 – 
7.60 (m, 2H, HBz), 7.55 – 7.40 (m, 6H, H13, HBz), 7.38 – 7.20 (m, 12H, H12, HBz); 6.09 (t, 1H, H4, 
J4-3 = J4-5= 10.0 Hz), 6.00 (dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.3), 5.85 (dd, 1H, H2, J2-1 = 1.7 Hz, 
J2-3= 3.3 Hz), 5.38 (brs, 1H, H1), 4.79 – 4.74 (m, 1H, H6a), 4.66 – 4.51 (m, 6H, H15, H6b, H5), 
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4.42 - 4.28 (m, 4H, H10a,b), 4.23 – 4.16 (m, 1H, D2), 3.92 – 3.87 (m, 1H, D1), 3.80 - 3.53 (m, 2H, 
H7a,b), 3.40 - 3.23 (m, 2H, H8), 3.17 – 2.94 (m, 2H, D4, D5), 2.22 - 1.99 (m, 2H, D3, D6).  
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.8 (C9); 167.6, 167.2, 166.9, 166.9 (COBZ); 139.2, 
139.2, 139.1 (C11, C14); 134.9, 134.9, 134.7, 134.6 (CHBZ); 131.3 (CquatBZ); 130.9, 130.9, 130.9  
(CHBZ); 130.8 (CquatBZ); 130.7 (CHBZ); 130.4, 130.4 (CquatBZ); 130.0, 129.9, 129.7, 129.6 
(CHBZ); 128.6, 128.5, 128.3 (C12, C13); 98.1 (C1); 76.6 (CD1); 74.2 (CD2); 72.2 (C2); 72.0 (C3); 
71.0 (C5); 70.8 (C7); 68.5 (C4); 65.1, 65.1 (C15); 64.2 (C6); 52.1 (C8); 43.9 (C10); 42.0, 41.9 (CD4, 
CD5); 29.9, 29.1 (CD3 ,CD6)  
2.4.6.8 N1,N2-bis(4-(hydroxyl(α,α-dimethyl)methylene)benzyl)amide, 2.11g 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-(hydroxyl(α,α-dimethyl)methylene)benzyl)-4-(2-
azidoethoxy)-5-[(2,3,4,6-tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 3, starting from chloride 2.10g. 
 
10
11
12
13
14
HN
R:
HO 15 16
2.11g  
Yield: 82% 
MS (ESI): calculated for [C64H67N5O15Na]+: 1169.2; found: 1168.9 
1H NMR (400 MHz, CD3OD): δ = 8.12 – 7.89 (m, 6H, HBz), 7.78 – 7.70 (m, 2H, HBz), 7.68 – 
7.59 (m, 2H, HBz), 7.54 – 7.36 (m, 10H, HBz ,H13), 7.36 – 7.30 (m, 2H, HBz), 7.30 – 7.17 (m, 6H, 
H12, HBz),  6.08 (t, 1H, H4, J4-3 = J4-5= 10.0 Hz), 5.97 (dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.1), 5.83 
(dd, 1H, H2, J2-1 = 1.7 Hz, J2-3= 3.1 Hz), 5.36 (d, 1H, H1, J1-2= 1.7 Hz), 4.74 – 4.70 (m, 1H, H6a), 
4.65 – 4.48 (m, 2H, H6b, H5), 4.35 - 4.26 (m, 2H, H10a), 4.37 - 4.26 (m, 4H, H10a,b), 4.21 – 4.16 
(m, 1H, D2), 3.91 – 3.84 (m, 1H, D1), 3.75 - 3.67 (m, 1H, H7a), 3.61 - 3.52 (m, 1H, H7b), 3.38 - 
3.23 (m, 2H, H8), 3.15 – 2.94 (m, 2H, D4, D5), 2.22 - 1.99 (m, 2H, D3, D6), 1.48, 1.45 (s, 12H, 
H16).   
13C NMR (100 MHz, CD3OD): δ = 177.0, 176.7 (C9); 167.6, 167.2, 166.9, 166.9 (COBZ); 149.9 
(C14); 138.2, 138.1 (C11); 134.9, 134.9, 134.7, 134.6 (CHBZ); 131.3 (CquatBZ); 130.9, 130.9  
(CHBZ); 130.8 (CquatBZ); 130.7 (CHBZ); 130.4 (CquatBZ); 130.0, 129.9, 129.7, 129.6 (CHBZ); 
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128.3, 128.53 (C12, C13); 98.2 (C1); 76.5 (CD1); 74.4 (CD2); 73.0 (C2); 72.2 (C2); 72.0 (C3); 71.0 
(C5); 69.3 (C7); 68.5 (C4); 64.2 (C6); 52.1 (C8); 43.8 (C10); 42.1, 42.0 (CD4, CD5); 32.1, 32.1, 32.1 
(C16), 29.8, 29.1 (CD3 ,CD6)  
 
2.4.6.9 N1,N2-bis(4-(2-methyl-1,3-dioxolan-2-yl)benzyl)amide, 2.11h 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-(2-methyl-1,3-dioxolan-2-yl)-4-(2-azidoethoxy)-5-
[(2,3,4,6-tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 3, starting from chloride 2.10h. 
 
10
11
12
13
14
HN
R:
1516
O
O
17
18
2.11h
 
Yield: 62% 
MS (ESI) calculated for [C66H67N5O17Na]+: 1225.2; found: 1224.9. 
1H NMR (400 MHz, CDCl3): δ = 8.06 – 8.02 (m, 2H, HBz), 8.01 – 7.96 (m, 4H, HBz,), 7.75 – 
7.70 (m, 2H, HBz), 7.60 – 7.46 (m, 3H, HBz), 7.43–7.32 (m, 11H, HBz, H12), 7.26 – 7.19 (m, 6H, 
HBz, H13), 6.81 (t, 1H, HNH, JNH-10 = 5.8 Hz), 6.21 (t, 1H, HNH, JNH-10 = 5.8 Hz), 6.10 (t, 1H, H4, 
J4-3 = J4-5= 10.0 Hz), 5.86 (dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.3), 5.66 (dd, 1H, H2, J2-1 = 1.7 Hz, 
J2-3= 3.3 Hz), 5.24 (d, 1H, H1, J1-2= 1.7 Hz), 4.70 – 4.64 (m, 1H, H6a), 4.53 – 4.20 (m, 6H, H6b, 
H10a,b, H5), 4.09 - 4.04 (m, 1H, D2), 4.03 - 3.91 (m, 4H, H18a, 17a), 3.78 – 3.74 (m, 1H, D1), 3.74 - 
3.63 (m, 4H, H18b, 17b), 3.61 – 3.52 (m, 2H, H7), 3.34 - 3.17 (m, 2H, H8), 3.03 – 2.87 (m, 2H, D4, 
D5), 2.30 - 2.10 (m, 2H, D3eq, D6eq), 2.10 - 2.95 (m, 2H, D3ax, D6ax), 1.60 (s, 3H, H16), 1.55 (s, 
3H, H16). 
 13C NMR (100 MHz, CDCl3): δ = 174.2, 172.2 (C9); 166.3, 165.9, 165.9, 165.8 (COBZ); 142.7, 
142.6 (C11); 138.1 (C14); 133.9, 133.8, 133.6, 133.4 (CHBZ); 130.1, 130.0, 129.9 (CHBZ); 129.2, 
129.0, 129.0 (CquatBZ); 128.8, 128.7, 128.7, 128.5 (CHBZ); 127.7 (C13); 125.8, 125.8 (C12); 108,9 
(C15); 97.3 (C1); 75.5 (CD1); 74.2 (CD2); 71.5 (C2); 70.3 (C3); 70.1 (C5); 68.7 (C7); 66.8 (C4); 
64.6, 64.6 (C16, C17); 63.1 (C6); 50.9 (C8); 43.3 (C10);  41.8, 41.1 (CD4, CD5); 28.8 (CD3); 28.6 
(CD6); 27.8, 27.8 (C16);  
Chapter 2   Monovalent glycomimetic DC-SIGN ligands  
     116
2.4.6.10 N1,N2-bis(4-acetobenzyl)amide, 2.11i 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-acetylbenzyl)-4-(2-azidoethoxy)-5-[(2,3,4,6-tetra-
O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 3, starting from chloride 2.10i. 
 
NH
10
11
12
13
14
1516
O
2.11i  
 
 
Yield: 98% 
MS (ESI) calculated for [C62H59N5O15Na]+: 1137.1; found: 1136.3. 
1H NMR (400 MHz, CDCl3): δ = 8.04 (d, 2H, HBz, J = 8.3 Hz), 7.98 (d, 2H, HBz, J = 8.3 Hz), 
7.93 (d, 2H, HBz, J = 8.3 Hz), 7.85 (d, 2H, H13, J13-12 = 8.1 Hz), 7.80 (d, 2H, H13, J13-12 = 8.1 Hz), 
7.65 (d, 2H, HBz, J = 8.3 Hz), 7.90 – 7.45 (m, 3H, HBz), 7.41 – 7.28 (m, 11H, H12, HBz), 7.22 – 
7.16 (m, 2H, HBz), 7.00 (t, 1H, HNH, JNH-10 = 5.8 Hz), 6.32 (t, 1H, HNH, JNH-10 = 5.8 Hz), 6.12 (t, 
1H, H4, J4-3 = J4-5= 10.0 Hz), 5.86 (dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.2), 5.66 (m, 1H, H2), 5.24 
(br s, 1H, H1), 4.73 – 4.63 (m, 1H, H6a), 4.53 – 4.32 (m, 6H, H6b, H10a,b, H5), 4.13 - 4.06 (m, 1H, 
D2),  3.79 – 3.74 (m, 1H, D1), 3.66 – 3.54 (m, 2H, H7), 3.34 - 3.17 (m, 2H, H8), 3.09 – 2.88 (m, 
2H, D4, D5), 2.53 (s, 3H, H16), 2.45 (s, 3H, H16), 2.26 - 2.03 (m, 4H, D3, D6).  
13C NMR (100 MHz, CDCl3): δ = 197.8, 197.8 (C15); 174.5, 174.5 (C9); 166.3, 166.1, 166.1, 
165.7 (COBZ); 144.0, 144.9 (C11); 136.4, 136.3 (C14); 134.0, 133.8, 133.6, 133.4 (CHBZ); 130.1, 
130.0, 129.9, 129.9 (CHBZ); 129.1, 128.9, 129.0 (CquatBZ); 128.9, 128.9, 128.7, 128.5 (CHBZ, 
C13); 127.7, 127,6 (C12); 97.2 (C1); 75.3 (CD1); 74.3 (CD2); 71.5 (C2); 70.4 (C3); 70.2 (C5); 68.8 
(C7); 66.7 (C4); 63.0 (C6); 50.9 (C8); 43.3, 43.2 (C10);  41.7, 41.0 (CD4,CD5); 29.0 (CD3); 28.9 
(CD6); 26.8, 26.7 (C16).  
2.4.6.11 N1,N2-bis(2-(α-D-mannopyranosyloxy)ehyl)amide, 2.11j 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(2-(α-D-mannopyranosyloxy)ehyl)-4-(2-
azidoethoxy)-5-[(2,3,4,6-tetra-O-benzoyl-α-D-mannopyranosyl)oxy]- (1S,2S,4S,5S)  
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Prepared according to general procedure 3, starting from chloride 2.10i. 
 
O
OH
HO
HO
OH
O
N
H2.11j
 
 
Yield = 50 %;  
[α]D20  = + 14.5 (c = 0.22 in methanol) 
MS (FAB): calculated for: [C60H71N5O25Na]+: 1285; found: 1285 
 
 
2.11j 1H NMR  
(400 MHz, CD3OD) 
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2.4.7 Synthesis and characterization of final DC-SIGN ligands 1,2-
Cyclohexanedicarboxamide, 4-(2-azidoethoxy)-5-(α-D-
mannopyranosyloxy),- (1S,2S,4S,5S), 2.2a-j 
2.4.7.1 General procedure 4 
Compound 2.11 was dissolved in dry methanol (c = 0.1 M), under nitrogen at room temperature, 
and 1M solution of sodium methoxide in MeOH (2 eq) was added. After reaction completion (1 
h; TLC, DCM:MeOH = 9:1 or 8:2) the reaction mixture was diluted with methanol and 
neutralized with prewashed Amberlite IRA 120-H+. The resin was filtered off and the filtrate was 
concentrated under reduced pressure. The crude was purified by flash chromatography (CHCl3 
with gradient of methanol from 0 to 20%).  
O
O
N3
O
O
O
OH
HO
OH
HO
D1
D2
D3
D4
D5
D6
123
4 5
6
7
8
9
NH
H
N
R
R
  
2.11j 13C NMR  
(100 MHz, CD3OD) 
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General structure and numbering of pseudobimannoside bis-amides 2.2a-j in the NMR 
characterizations   
2.4.7.2 N1,N2-bis(4-methoxybenzyl)amide, 2.2a 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-methoxybenzyl)-4-(2-azidoethoxy)-5-[α-D-
mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 4, starting from 2.11a. 
 
 
10
11
12
13
14
15
HN
R:
O
2.2a  
 
 
Yield = 73 %;  
[α]D20  = + 1.81 (c = 0.15 in ethanol) 
MS (HRMS): calculated for: [C32H43N5O11Na]+: 696.28568; found: 696.28465 
1H NMR (400 MHz, CD3OD): δ = 7.20 (d, 4H, H12, J12-13 = 8 Hz), 6.88 (d, 4H, H13, J13-12 = 8 
Hz), 4.99 (d, 1H, H1,), 4.26 (d, 4H, H10a,b, J10a-10b = 2.4 Hz), 4.10 - 4.06 (m, 1H, D2), 3.95 (dd, 
1H, H2, J2-1 = 1.6 Hz, J2-3 = 3.2 Hz), 3.93 – 3.87 (m, 1H, H6a), 3.86 – 3.69 (m, 11H, D1, H6b, H7a,b, 
H3, H15 ), 3.51 - 3.7 (m, 2H, H4, H5), 3.49 – 3.35 (m, 2H, H8a,b), 3.01 - 2.86 (m, 2H, D4,D5), 2.08 - 
1.90 (m, 4H, D3, D6).  
13C NMR (100 MHz, CD3OD): δ = 177.0, 176.8 (C9); 160.4 (C14); 132.2 (C11); 129.9, 129.8 
(C12); 115.0 (C13); 100.4 (C1); 76.6 (C3); 75.6 (C5); 72.2 (CD1); 72.5 (C2); 72.5 (D2); 69.3 (C7); 
68.9 (C4); 63.2 (C6); 55.8 (C15); 52.2 (C8); 43.6 (C10); 42.1, 42.0 (CD4, CD5); 29.8, 29.0 (CD3, 
CD6).  
2.4.7.3 N1,N2-bis(3-methoxybenzyl)amide, 2.2b 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(3-methoxybenzyl)-4-(2-azidoethoxy)-5-[α-D-
mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 4, starting from 2.11b. 
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10
11
12
13 O14
15
16
17
HN
R:
2.2b
 
Yield = 67 %; 
[α]D20  = + 16.2 (c = 0.78 in methanol) 
MS (HRMS): calculated for [C32H43N5O11Na]+: 696.28568; found: 696.28599 
1H NMR (400 MHz, CD3OD): δ = 7.20 (t, 2H, H15, J = 8.0 Hz), 6.85 – 6.75 (m, 6H, H12, H14, 
H16), 4.96 (br s, 1H, H1), 4.28 (s, 4H, H10a,b), 4.09 - 4.03 (m, 1H, D2), 3.94 - 3.90 (m, 1H, H2), 
3.90 – 3.84 (m, 1H, H6a), 3.83 – 3.65 (m, 11H, D1, H17, H6b, H7a,b, H3), 3.64 - 3.54 (m, 2H, H4, 
H5), 3.47 – 3.31 (m, 2H, H8), 3.03 - 2.85 (m, 2H, D4, D5), 2.08 - 1.90 (m, 4H, D3, D6). 
 13C NMR (100 MHz, CD3OD): δ = 177.2, 177.0 (C9); 161.5 (C13); 141.8 (C11); 130.6 (C15); 
120.7, 120.7 (C16); 114.0, 113.9, 113.7, 113,7 (C14, C12); 100.4 (C1); 76.6 (C3); 75.7 (C5); 72.7 
(CD1); 72.5 (C2); 72.4 (D2); 69.3 (C7); 68.9 (C4); 63.2 (C6); 55.8 (C17); 52.1 (C8); 44.0 (C10); 42.1, 
41.9 (CD4, CD5); 29.9, 29.0 (CD3, CD6).  
2.4.7.4 N1,N2-bis(4-carbomethoxybenzyl)amide, 2.2c 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-carbomethoxy)-4-(2-azidoethoxy)-5-[α-D-
mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 4, starting from 2.11c. 
 
 
10
11
12
13
14
HN
R:
OO 15
16
2.2c  
 
Yield = 60 % 
[α]D20  = +54.3 (c = 0.55 in methanol) 
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MS (HRMS) calculated for: [C34H43N5O13Na]+:  752.27551; found: 752.27418 
1H NMR (400 MHz, CD3OD): 7.81 (d, 4H, H13, J13-12 = 8 Hz), 7.28 (d, 4H, H12, J12-13 = 8 Hz), 
4.96 (s, 1H, H1), 4.51 - 4.21 (m, 4H, H10a,b), 4.08 - 4.03 (m, 1H, D2), 3.92 - 3.89 (m, 1H, H2), 
3.88 – 3.83 (m, 7H, H6a, H16), 3.83 – 3.64 (m, 5H, D1, H6b, H7a,b, H3, ), 3.62 - 3.52 (m, 2H, H4, 
H5), 3.45 – 3.33 (m, 2H, H8a,b), 3.05 - 2.90 (m, 2H, D4,D5), 2.52 (s, 3H, H16), 2.06 - 1.91 (m, 4H, 
D3, D6). 
 13C NMR (100 MHz, CD3OD): 177.5, 177.3 (C9); 168.5 (C15); 145.9 (C11); 130.8 (C13); 130.0 
(C14); 128.2, 128.1 (C12); 100.5 (C1); 76.6 (C3); 75.7 (C5); 72.7 (CD1); 72.6 (C2); 72.5 (D2); 69.3 
(C7); 68.9 (C4); 63.2 (C6); 52.7 (C16); 52.2 (C8); 43.6 (C10); 42.0, 41.9 (CD4, CD5); 30.0, 29.2 
(CD3, CD6). 
 
2.4.7.5 N1,N2-bis(4-nitrobenzyl)amide, 2.2d 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-nitrobenzyl)-4-(2-azidoethoxy)-5-[α-D-
mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 4, starting from 2.11d. 
 
10
11
12
13
14
HN
R:
O2N
2.2d  
 
Yield = 72 %;  
[α]D20  = - 21.5 (c = 0.21 in methanol) 
MS (HRMS) calculated for: [C30H37N7O13Na]+: 726.23470; found: 726.23526 
1H NMR (400 MHz, CD3OD): δ = 7.99 (d, 4H, H13, J13-12 = 7.4 Hz), 7.40 (d, 4H, H12, J12-13 = 7.4 
Hz), 4.99 (s, 1H, H1), 4.60 (d, 2H, H10a, J10a-10b = 16.4 Hz), 4.30 (d, 2H, H10b, J10b-10a = 16.4 Hz), 
4.10 - 4.06 (m, 1H, D2), 3.94 - 3.91 (m, 1H, H2), 3.89 – 3.84 (m, 1H, H6a), 3.84 – 3.66 (m, 5H, 
D1, H6b, H7a,b, H3, ), 3.65 - 3.56 (m, 2H, H4, H5), 3.49 - 3.35 (m, 2H, H8a,b), 3.10 - 2.95 (m, 2H, 
D4,D5), 2.10 - 1.92 (m, 4H, D3, D6).  
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13C NMR (100 MHz, CD3OD): δ = 177.8, 177.6 (C9); 148.3 (C14); 148.1 (C11); 128.8 (C12); 
124.5 (C13); 100.6 (C1); 76.6 (C3); 75.7 (C5); 72.8 (CD1); 72.6 (C2); 72.6 (CD2); 69.4 (C7); 68.9 
(C4); 63.2 (C6); 52.2 (C8); 43.3 (C10); 41.9, 41.8 (CD4, CD5); 30.1, 29.3 (CD3, CD6).  
 
2.4.7.6 N1,N2-bis(4-(methoxymethylene)benzyll)amide, 2.2e 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-methoxybenzyl)-4-(2-azidoethoxy)-5-[α-D-
mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 4, starting from 2.11e. 
10
11
12
13
14
HN
R:
O 15
16
2.2e  
Yield = 78 %;  
[α]D20  = + 5.2 (c = 0.22 in methanol) 
MS (HRMS) calculated for: [C34H47N5O11Na]+: 724.31698; found: 724.31565 
1H NMR (400 MHz, CD3OD): δ = 7.28 – 7.18  (m, 8H, H12, H13),  4.94 (br s, 1H, H1), 4.40 (s, 
4H, H15), 4.25 (br s, 4H, H10), 4.06-4.01 (m, 1H, D2), 3.91 - 3.87 (m, 1H, H2), 3.87 – 3.82 (m, 
1H, H6a), 3.80 – 3.64 (m, 5H, D1, H6b, H7a,b, H3, ), 3.61 - 3.54 (m, 2H, H4, H5), 3.44 – 3.32 (m, 
8H, H8a,b, H16), 3.98 - 2.83 (m, 2H, D4,D5), 2.02 - 1.87 (m, 4H, D3, D6).  
13C NMR (100 MHz, CD3OD): δ = 177.2, 177.0 (C9); 139.8 (C14); 138.4, 138.3 (C11); 129.3 
(C13); 128.6, 128.5 (C12); 100.4 (C1); 76.6 (C3); 75.7 (C5); 75.5 (C15); 72.7 (CD1); 72.5 (C2); 72.4 
(D2); 69.3 (C7); 68.9 (C4); 63.2 (C6); 58.4 (C16); 52.1 (C8); 43.8 (C10); 42.1, 41.9 (CD4, CD5); 
29.9, 29.0 (CD3, CD6).  
 
2.4.7.7 N1,N2-bis(4-(hydroxymethylene)benzyl)amide, 2.2f 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-hydroxymethylenebenzyl)-4-(2-azidoethoxy)-5-[α-
D-mannopyranosyloxy]- (1S,2S,4S,5S)  
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Prepared according to general procedure 4, starting from 2.11f. 
 
Yield = 82 %; 
[α]D20  = + 12.1 (c = 0.81 in methanol) 
MS (HRMS) calculated for: [C32H43N5O11Na]+: 696.28568; found: 696.28423. 
 1H NMR (400 MHz, CD3OD): δ = 7.29 (d, 4H, H12, J12-13 = 8 Hz), 7.23 (d, 4H, H13, J13-12 = 8 
Hz), 4.96 (d, 1H, H1, J1-2 = 1,6 Hz), 4,58 (s, 4H, H15a,b),  4.31 (s, 4H, H10a,b), 4.08 - 4.03 (m, 1H, 
D2), 3.93 - 3.89 (m, 1H, H2), 3.89 – 3.84 (m, 1H, H6a), 3.84 – 3.65 (m, 5H, D1, H6b, H7a,b, H3, ), 
3.64 - 3.54 (m, 2H, H4, H5), 3.47 – 3.35 (m, 2H, H8a,b), 3.02 - 2.85 (m, 2H, D4,D5), 2.06 - 1.86 
(m, 4H, D3, D6).  
13C NMR (100 MHz, CD3OD): δ = 177.2, 177.0 (C9); 141.7 (C14); 139.2 (C11); 128.6, 128.7 
(C12); 128.3 (C13); 100.4 (C1); 76.6 (C3); 75.7 (C5); 72.7 (CD1); 72.5 (C2); 72.4 (D2); 69.3 (C7); 
68.9 (C4); 65.1 (C15); 63.2 (C6); 52.1 (C8); 43.8 (C10); 42.1, 41.9 (CD4, CD5); 29.9, 29.0 (CD3, 
CD6).  
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2.4.7.8 N1,N2-bis(4-(hydroxy(α,α-dimethyl)methylen)benzyl)amide, 2.2g 
 
2.2f 1H NMR  
(400 MHz, CD3OD) 
2.2f 13C NMR  
(100 MHz, CD3OD) 
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1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-(hydroxy(α,α-dimethyl)methylen)benzyl)-4-(2-
azidoethoxy)-5-[α-D-mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 4, starting from 2.11g. 
10
11
12
13
14
HN
R:
HO 15 16
2.2g  
Yield = 65 %; 
[α]D20  = + 5.3 (c = 0.48 in methanol) 
MS (HRMS) calculated for: [C36H51N5O11Na]+: 752.34828; found: 752. 34702. 
1H NMR (400 MHz, CD3OD): δ = 7.40 (d, 4H, H12, J12-13 = 8.1 Hz), 7.18 (d, 4H, H13, J13-12 = 8.1 
Hz), 4.93 (br s, 1H, H1), 4.26 (s, 4H, H10a,b), 4.04 - 3.00 (m, 1H, D2), 3.88 - 3.86 (m, 1H, H2), 
3.86 – 3.79 (m, 1H, H6a), 3.78 – 3.61 (m, 5H, D1, H6b, H7a,b, H3, ), 3.59 - 3.50 (m, 2H, H5, H4,), 
3.43 – 3.32 (m, 2H, H8a,b), 2.98 - 2.82 (m, 2H, D4,D5), 2.00 - 1.84 (m, 4H, D3, D6), 1.47 (s, 12H, 
H16).  
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.9 (C9); 149.9 (C14); 138.2 (C11); 128.3, 128.2 
(C12); 125.9 (C13); 100.4 (C1); 76.6 (C3); 75.7 (C5); 73.0 (C15); 72.7 (CD1); 72.5 (C2); 72.4 (D2); 
69.3 (C7); 68.9 (C4); 63.2 (C6); 52.1 (C8); 43.8 (C10); 42.1, 42.0 (CD4, CD5); 32.1 (C16); 29.9, 29.0 
(CD3, CD6).  
 
2.4.7.9 N1,N2-bis(4-(2-methyl-1,3-dioxolan-2-yl)benzyl)amide, 2.2h 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-(2-methyl-1,3-dioxolan-2-yl)-4-(2-azidoethoxy)-5-
[α-D-mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 4, starting from 2.11h. 
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Yield = 58 %;  
MS (ESI) calculated for: [C38H51N5O13Na]+: 808.8; found: 808.4 
1H NMR (400 MHz, CD3OD): δ = 7.38  (d, 4H, H13, J12-13 = 7.7 Hz), 7.21  (d, 4H, H12, J12-13 = 
7.7 Hz), 4.94  (d, 1H, H1, J1-2 = 1.4 Hz), 4.34 – 4.20 (m, 4H, H10), 4.06-4.01 (m, 4H, H17a, H18a), 
4.00 - 3.95 (m, 1H, D2), 3.91 - 3.87 (m, 1H, H2), 3.87 – 3.82 (m, 1H, H6a), 3.80 – 3.62 (m, 9H, 
D1, H6b, H7a,b, H3, H17b, H18b), 3.61 - 3.54 (m, 2H, H4, H5), 3.44 – 3.32 (m, 2H, H8a,b), 3.98 - 2.83 
(m, 2H, D4,D5), 2.02 - 1.87 (m, 4H, D3, D6), 1.54 (s, 6H, H16). 
13C NMR (100 MHz, CD3OD): δ = 177.2, 177.0 (C9); 143.7 (C11); 139.9 (C14); 128.5, 128.4 
(C12); 126.6, (C13); 100.4 (C1); 76.6 (C3); 75.7 (C5); 72.7, 72.6, 72.5 (C2, CD1, D2); 69.3 (C7); 
68.9 (C4); 65.6 (C17, C18); 63.2 (C6); 58.4 (C16); 52.2 (C8); 43.8 (C10); 42.1, 42.0 (CD4, CD5); 29.0, 
29.0 (CD3, CD6); 28.1 (C16).  
2.4.7.10  N1,N2-bis(4-acetylbenzyl)amide, 2.2i 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-acetylbenzyl)-4-(2-azidoethoxy)-5-[α-D-
mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 4, starting from 2.11i. 
 
10
11
12
13
14
HN
R:
O 15 16
2.2i  
Yield: 83% 
[α]D20  = - 42.8 (c = 0.1 in methanol) 
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MS (HRMS) calculated for: [C34H43N5O11Na]+: 720.28568; found: 720.28552 
1H NMR (400 MHz, CD3OD): δ = 7.82 (d, 4H, H13, J13-12 = 7.5 Hz), 7.33 (d, 4H, H12, J12-13 = 7.5 
Hz), 4.98 (d, 1H, H1, J1-2 = 1.6 Hz), 4.54 - 4.26 (m, 4H, H10a,b), 4.10 - 4.05 (m, 1H, D2), 3.94 - 
3.90 (m, 1H, H2), 3.90 – 3.84 (m, 1H, H6a), 3.84 – 3.66 (m, 5H, D1, H6b, H7a,b, H3), 3.64 - 3.57 
(m, 2H, H5, H4), 3.47 – 3.35 (m, 2H, H8a,b), 3.08 - 2.92 (m, 2H, D4,D5), 2.52 (s, 3H, H16), 2.52 (s, 
3H, H16), 2.08 - 1.92 (m, 4H, D3, D6). 
 13C NMR (100 MHz, CD3OD): δ = 200.2 (C15); 177.5, 177.3 (C9); 146.2 (C14); 137.1 (C11); 
129.8 (C13); 128.3 (C12); 100.5 (C1); 76.6 (C3); 75.7 (C5); 72.8 (CD1); 72.6 (C2); 72.6 (D2); 69.4 
(C7); 68.9 (C4); 63.2 (C6); 52.2 (C8); 43.6 (C10); 42.0, 41.9 (CD4, CD5); 30.0, 29.2 (CD3, CD6); 26.8 
(C16).  
 
2.4.7.11 N1,N2-bis(2-(α-D-mannopyranosyloxy)ehyl)amide, 2.2j 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(2-(α-D-mannopyranosyloxy)ethyl)-4-(2-
azidoethoxy)-5-[α-D-mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 4, starting from 2.11j. 
 
 
O
HO
HO
OH
O
HO
OC
O
COHN
N3
NH
O
O
O
HO HO
HO
HO
O
OH OH
HO
HO
D
A
B
C
123
4 5
6
7
8
123
4
5
6
1
2
34
56
1
2
3
4
56
2.2j
7
8
7 8 9
 
Yield = 85 %;  
[α]D20  = + 48.4 (c = 0.45 in H2O); 
MS (ESI): calculated for: [C32H55N5O21Na]+: 868.8; found: 868.4 
1H NMR (400 MHz, D2O): δ = 5.03 (d, 1H, A1, J1-2  = 1.6 Hz), 4.86 (s, 2H, B1, C1, J1-2  = 1.6 
Hz), 4.10 - 4.02 (m, 2H, A2, D2), 3.97 – 3.92 (m, 2H, B2, B2), 3.92 – 3.86 (m, 4H, A3, A6a, B6a, 
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C6a), 3.85 - 3.71 (m, 10H, D1, B3, C3, A6b, B6b, C6b, H7, B7a, C7a), 3.70 - 3.59 (m, 6H, A4, A5, B4, 
B5, C4, C5), 3.59 - 3.52 (m, 2H, , B7b, C7b), 3.50 (t, 2H, H8, J7-8 = 4.76 Hz), 3.47 - 3.41 (m, 2H, 
B8a, C8a), 3.40 - 3.30 (m, 2H, B8b, C8b), 2.92 - 2.78 (m, 2H, D4, D5), 2.07 - 1.81 (m, 4H, D3, D6).  
13C NMR (100 MHz, D2O): δ = 176.8, 176.6 (C9); 99.8, 99.8 (CB1, CC1); 98.8 (CA1); 74.5 (CD1); 
73.5 (CA5); 72.8 (CB5, CC5); 71.2 (CD2); 70.5 (CA2, CA3, CB3, CC3); 70.0 (CB2, CC2); 67.5 (C7); 
66.8 (CA4); 66.7 (CC4, CD4); 65.9 (CB7, CC7); 61.0 (CA6); 60.9 (CB6, CC6); 50.5 (C8); 40.3, 40.3 
(CD4, CD5); 38.9 (CB8, CC8);; 28.0, 27.5 (CD3, CD6).  
 
2.2j 1H NMR  
(400 MHz, D2O) 
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2.4.8 Synthesis and characterization of final DC-SIGN ligands 1,2-
Cyclohexanedicarboxamide, 4-(2-azidoethoxy)-5-(α-D-
mannopyranosyloxy),- (1S,2S,4S,5S), 2.2k-s 
2.4.8.1 General procedure 5   
The amine 2.12 (3 eq) was added to a 0.1 M PNP-scaffold 2.31 (1 eq) in dry MeCN under 
stirring and under nitrogen atmosphere at room temperature. After completion (TLC, hex : 
EtOAc) the solvent was evaporated under reduced pressure. The crude product was dissolved in 
dry methanol (c = 0.1 M), under nitrogen at room temperature, and a 1M solution of sodium 
methoxide in MeOH (2 eq) was added. After reaction completion the reaction mixture was 
diluted with methanol and neutralized with prewashed Amberlite IRA 120-H+. The resin was 
filtered off and the filtrate was concentrated under reduced pressure. The crude was purified by 
flash chromatography (CHCl3 with gradient of methanol from 0 to 20%). 
2.2j 13C NMR  
(100 MHz, D2O) 
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General structure and numbering of pseudobimannoside bis-amides 2.10a-j in the NMR 
characterizations of   
 
2.4.8.2 N1,N2-bis((L)phenylalaninol)amide, 2.2k 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis((L)phenylalaninol)-4-(2-azidoethoxy)-5-[α-D-
mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 5 using amine 2.12k. 
 
 
 
 
Yield = 75 %;  
[α]D20  = + 17.8 (c = 0.5 in methanol); 
MS (HRMS): calculated for: [C34H47N5O11Na]+: 724.31698; found: 724.31698 
1H NMR (400 MHz, CD3OD): δ = 7.31 - 7.10 (m, 10H, H14, H15, H16), 4.96 (br s, 1H, H1), 4.12 - 
4.00 (m, 2H, H10), 3.88 (dd, 1H, H2, J2-1  = 1.6 Hz, J2-3  = 3.1 Hz), 3.90 – 3.80 (m, 2H, H5, H6b), 
3.72. - 3.63 (m, 4H, D2, H6a, H7), 3.63 - 3.59 (m, 2H, H4, D1), 3.58 - 3.54 (m, 1H, H3), 3.47 (d, 
4H, H11, J11-10= 5.4), 3.39 - 3.33 (m, 2H, H8), 3.00 - 2.88 (m, 2H, H12), 2.71 - 2.57 (m, 4H, H11, 
D4, D5), 1.63 - 1.40 (m, 4H, D3, D6).  
13C NMR (100 MHz, CD3OD): δ = 177.2, 177.1 (C9); 140.1 (C13); 130.6, 129.5, 129.4, 127.4 
(C14, C15, C16); 100.2 (C1); 76.5 (C3); 75.6 (CD1); 72.8 (CD2); 72.6 (C5); 72.1 (C2); 69.3 (C7); 68.8 
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(C4); 64.8 (C11); 63.2 (C6); 53.9 (C10); 52.1 (C8); 41.9, 41.7 (CD4, CD5); 38.1 (C12); 29.9.5, 28.7 
(CD3, CD6).  
 
2.4.8.3 N1,N2-bis((1S,2S)-2-amino-1-phenylpropan-1-ol)amide, 2.2l 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis((1S,2S)-2-amino-1-phenylpropan-1-ol)-4-(2-
azidoethoxy)-5-[α-D-mannopyranosyloxy]- (1S,2S,4S,5S)  
 
 
Prepared according to general procedure 5 using amine 2.12l. 
 
 
Yield:  75 % 
[α]D20  = + 17.8 (c = 0.5 in methanol) 
MS (HRMS): calculated for: [C34H47N5O11Na]+: 724.31698; found: 724.31698 
1H NMR (400 MHz, CD3OD): δ = 7.36 (d, 4H, H14, J14-15  = 7.2 Hz), 7.27 (t, 4H, H15, J14-15  = 7.2 
Hz), 7.18 (t, 2H, H16, J14-15  = 7.2 Hz), 4.96 (br s, 1H, H1), 4.80 (d, 2H, H12, J12-10  = 1.7 Hz), 4.12 
- 4.00 (m, 3H, HD2, H10), 3.94 (dd, 1H, H2, J2-1  = 1.6 Hz, J2-3  = 3.1 Hz), 3.90 – 3.80 (m, 2H, H5, 
H6b), 3.82 - 3.63 (m, 5H, D2, H3, H6a, H7a,b), 3.63 - 3.59 (m, 2H, H4, D1), 3.49 – 3.36 (m, 2H, 
H8a,b), 2.97 – 2.822 (m, 2H, D4,D5), 1.96 - 1.84 (m, 4H, D3, D6), 0.95 (t, 6H, H11, J11-10  = 6.4 Hz), 
13C NMR (100 MHz, CD3OD): δ = 177.2, 177.1 (C9); 143.4, 143.3 (C14, C15); 129.2 (C15), 125.2 
(C16), 127.4 (C14); 100.5 (C1); 76.7 (C3); 76.1, 76.0 (C12, CD1); 75.7 (C5); 72.8 (CD1); 72.5, 72.5 
(C2, D2);  69.4 (C7); 68.9 (C4); 63.2 (C6); 52.5 (C8); 52.2 (C10); 42.1, 41.9 (CD4, CD5); 30.1, 29.1 
(CD3, CD6); 13.4, 13.3 (C11). 
 
2.4.8.4 N1,N2-bis(2-(1H-indol-3-yl)ethyl)amide, 2.2m 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(2-(1H-indol-3-yl)ethanamine)-4-(2-azidoethoxy)-5-
[α-D-mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 5 using amine 2.12m. 
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Yield = 47 %;  
[α]D20  = + 38.6 (c = 0.575 in methanol) 
1H NMR (400 MHz, CD3OD): δ = 2.54 (d, 2H, H16, J16-15 = 7.9 Hz), 7.3 (dd, 2H, H13, J13-14 = 8.1 
Hz, J13-15 = 0.8 Hz), 7.10 – 7.03 (m, 4H, H14, H12), 7.00 – 6.95 (m, 2H, H15), 4.92 (d, 1H, H1, J1-2 
= 1,6 Hz), 4.01 - 3.96 (m, 1H, D2), 3.90 – 3.83 (m, 2H, H2, H6a), 3.75 – 3.52 (m, 9H, D1, H6b, 
H7a,b, H3, H10), 3.51 – 3.32 (m, 4H, H8a,b, H4, H5), 2.96 - 2.81 (m, 4H, H10), 2.80 – 2.66 (m, 2H, 
D4,D5), 1.94 - 1.70 (m, 4H, D3, D6).  
 
2.4.8.5 N1,N2-bis(3-(hydroxymethylene)benzyl)amide, 2.2n 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(3-(hydroxymethylene)benzyl)-4-(2-azidoethoxy)-5-
[α-D-mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 5 using amine 2.12n. 
 
10
11
12
13
14
HN
R:
16
HO 15
17
2.2n
 
Yield = 65 %;  
[α]D20  = + 21.5 (c = 0.33 in methanol);  
MS (HRMS) calculated for: [C32H43N5O11Na]+: 696.28568; found: 696.28578 
1H NMR (400 MHz, CD3OD): δ = 7.35 – 7.18 (m, 8H, H12, H13, H14, H16), 5.01 (d, 1H, H1, J1-2 = 
1,6 Hz), 4,61 (s, 4H, H17a,b)  4.41 – 4.31 (m, 4H, H10a,b), 4.13 - 4.08 (m, 1H, D2), 3.96 (dd, 1H, 
H2, J2-1 = 1.6 Hz, J2-3 = 3.2 Hz), 3.94 – 3.89 (m, 1H, H6a), 3.88 – 3.71 (m, 5H, D1, H6b, H7a,b, H3, ), 
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3.71 - 3.59 (m, 2H, H4, H5), 3.51 – 3.38 (m, 2H, H8a,b), 3.06 – 2.92 (m, 2H, D4,D5), 2.09 - 1.95 
(m, 4H, D3, D6).  
13C NMR (100 MHz, CD3OD): δ = 177.2, 177.0 (C9); 143.1 (C15); 140.3 (C11); 129.7 (C16); 
127.7, 127.1, 126.8 (C12, C13, C14); 100.5 (C1); 76.7 (C3); 75.7 (C5); 72.8 (CD1); 72.6 (C2, D2);  
69.3 (C7); 69.0 (C4); 65.3 (C17); 63.2 (C6); 52.2 (C8); 44.0 (C10); 42.1, 41.9 (CD4, CD5); 29.9, 29.1 
(CD3, CD6).  
2.4.8.6 N1,N2-bis(2-fluoro-4-(hydroxymethylene)benzyl)amide, 2.2o 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(2-fluoro-4-(hydroxymethylene)benzyl)-4-(2-
azidoethoxy)-5-[α-D-mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 5 using amine 2.12o. 
 
 
Yield = 76 % 
[α]D20  = + 9.3 (c = 0.44 in methanol) 
MS (HRMS) calculated for: [C32H41F2N5O11Na]+: 732.26683; found: 732.26691. 
1H NMR (400 MHz, CD3OD): δ = 7.22 (t, 2H, H16, J16-15 = 7.7 Hz, J16-F = 7.7 Hz), 7.05 (d, 2H, 
H13, J13-F = 11.5 Hz), 7.04 (d, 2H, H15, J15-16 = 7.7 Hz), 4.94 (br s, 1H, H1), 4,55 (s, 4H, H17a,b),  
4.37 – 4.26 (m, 4H, H10a,b), 4.04 - 4.00 (m, 1H, D2), 3.89 (dd, 1H, H2, J2-1 = 1.6 Hz, J2-3 = 3.1 Hz 
), 3.87 – 3.81 (m, 1H, H6a), 3.81 – 3.63 (m, 5H, D1, H6b, H7a,b, H3, ), 3.62 - 3.51 (m, 2H, H4, H5), 
3.44 – 3.31 (m, 2H, H8a,b), 2.99 - 2.83 (m, 2H, D4,D5), 2.01 - 1.86 (m, 4H, D3, D6).  
13C NMR (100 MHz, CD3OD): δ = 177.3, 177.1 (C9); 162.1 (d, C12, J12-F = 250 Hz); 144.8, 
144.7 (d, C14, J14-F = 4.3 Hz); 130.6, 130.5 (d, C16, J16-F = 4.5 Hz); 125.5 (d, C11, J11-F = 13.8 Hz); 
123.5 (d, C15, J15-F = 3.1 Hz); 114.3 (d, C13, J13-F = 22.1 Hz); 100.4 (C1); 76.6 (C3); 75.7 (C5); 
72.7 (CD1); 72.5 (C2); 72.5 (D2); 69.3 (C7); 68.9 (C4); 64.3 (C17); 63.1 (C6); 52.1 (C8); 42.0, 41.8 
(CD4, CD5); 37.7 (d, C10, J10-F = 4.6 Hz); 29.8, 29.0 (CD3, CD6).  
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2.4.8.7 N1,N2-bis(3-fluoro-4-(hydroxymethylene)benzyl)amide, 2.2p 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(3-fluoro-4-(hydroxymethylene)benzyl)-4-(2-
azidoethoxy)-5-[α-D-mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 5 using amine 2.12p. 
 
10
11
12
1314
HN
R:
HO
15
16
17
F
2.2p  
Yield = 64 %  
[α]D20  = + 6.9 (c = 0.33 in methanol)  
MS (HRMS) calculated for: [C32H41F2N5O11Na]+: 732.26683; found: 732.26529. 
1H NMR (400 MHz, CD3OD): δ = 77.22 (t, 2H, H15, J15-16 = 7.7 Hz, J15-F = 7.7 Hz), 7.12 (d, 2H, 
H16, J16-15 = 7.7 Hz), 7.04 (d, 2H, H12, J12-F = 11.5 Hz), 5.04 (d, 1H, H1, J1-2 = 1.6 Hz), 4.69 (s, 
4H, H17a,b)  4.44 – 4.33 (m, 4H, H10a,b), 4.15 - 4.11 (m, 1H, D2), 3.99 (dd, 1H, H2, J2-1 = 1.6 Hz, 
J2-3 = 3.1 Hz ), 3.96 – 3.91 (m, 1H, H6a), 3.90 - 3.73 (m, 5H, D1, H6b, H7a,b, H3, ), 3.73 - 3.62 (m, 
2H, H4, H5), 3.53 – 3.41 (m, 2H, H8a,b), 3.08 - 2.93 (m, 2H, D4,D5), 2.13 - 1.96 (m, 4H, D3, D6). 
 13C NMR (100 MHz, CD3OD): δ = 177.3, 177.1 (C9); 162.0 (d, C13, J13-F = 245.0 Hz); 142.1 (d, 
C11, J11-F = 7.3 Hz); 130.6 (d, C15, J15-F = 5.0 Hz); 128.4, 128.3 (d, C14, J14-F = 15.2 Hz); 124.2, 
124.1 (d, C16, J16-F = 4.7 Hz); 115.1, 115.0 (d, C12, J13-F = 22.5 Hz); 100.5 (C1); 76.6 (C3); 75.7 
(C5); 72.8 (CD1); 72.6 (C2); 72.5 (D2); 69.3 (C7); 69.0 (C4); 63.2 (C6); 58.8 (d, C17, J17-F = 4.3 
Hz); 52.2 (C8); 43.4 (C10); 42.1, 42.0 (CD4, CD5); 29.9, 29.0 (CD3, CD6).  
2.4.8.8 N1,N2-bis(4,5-di-(hydroxymethylene)benzyl)amide, 2.2q 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4,5-(dhydroxymethylene)benzyl)-4-(2-azidoethoxy)-
5-[α-D-mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 5, using amine 2.12q. 
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Yield = 63 %; 
[α]D20  = + 9.4 (c = 0.2 in methanol) 
MS (HRMS) calculated for: [C34H47N5O13Na]+: 756.30681; found: 756.30576. 
1H NMR (400 MHz, CD3OD): δ = 7.20 (s, 2H, H14), 7.13 (s, 2H, H12), 4.95 (br s, 1H, H1), 4.67 - 
4.46 (m, 8H, H15), 4.36 - 4.24 (m, 4H, H10),  4.01 (d, 1H, H5, J  = 2.7 Hz), 3.90 (dd, 1H, H2, J2-1  = 
1.7 Hz, J2-3  = 3.2 Hz), 3.88 (d, 1H, H6b,  J6-6  = 11.3 Hz), 3.83 - 3.76(m, 1H, H3), 3.76 - 3.63 (m, 
4H, D2, H6a, H7), 3.62 - 3.52 (m, 2H, H4, D1), 3.45 - 3.33 (m, 2H, H8), 3.04 - 2.84 (m, 2H, D4, 
D5), 2.07 - 1.90 (m, 4H, D3, D6).  
13C NMR (100 MHz, CD3OD): δ = 177.9, 177,7 (C9); 143.8, (C13); 140.9 (C11); 126.4, 126.3 
(C12); 125.8 (C14); 100.0 (C1); 77.2 (C3); 76.2 (CD1); 73.2 (CD2); 73.1 (C5); 72.9 (C2); 69.8 (C7); 
69.4 (C4); 65.2(C15); 63.6 (C6); 52.2 (C8); 44.4 (C10); 42.5, 42.3 (CD4, CD5); 30.5, 29.6 (CD3, CD6).  
2.4.8.9 N1,N2-bis(3-methoxy-4-(hydroxymethylene)benzyl)amide, 2.2r 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(3-methoxy-4-(hydroxymethylene)benzyl)-4-(2-
azidoethoxy)-5-[α-D-mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 5, using amine 2.12r. 
 
Yield = 80 % 
[α]D20  = - 24.3 (c = 0.15 in methanol) 
MS (HRMS) calculated for: [C34H47N5O13Na]+: 756.30681; found: 756.30567 
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1H NMR (400 MHz, CD3OD): δ = 7.23 (d, 2H, H15, J15-16  = 7.6 Hz), 6.81 (s, 2H, H12), 6.80 (d, 
2H, H16, J15-16  = 7.6 Hz), 4.94 (br s, 1H, H1), 4.55 (s, 4H, H18), 4.27 (m, 4H, H10), 4.04 (d, 1H, 
H5, J6-5 = 2.7 Hz), 3.91 (dd, 1H, H2, J2-1  = 1.7 Hz, J2-3  = 3.2 Hz), 3.87 - 3.81 (m, 1H, H6b), 3.79 - 
3.76 (m, 6H, H17), 3.76 - 3.72 (m, 2H, H3, D2), 3.72. - 3.64 (m, 3H, H6a, H7), 3.59 - 3.54 (m, 2H, 
H4, D1), 3.44 - 3.33 (m, 2H, H8), 3.08 - 2.77 (m, 4H, D4, D5), 2.05 - 1.82 (m, 4H, D3, D6). 
13C NMR (100 MHz, CD3OD): δ = 177.3, 177.0 (C9); 158.6 (C13); 140.9, 140.8 (C11); 129.5 
(C14); 129.1 (C15);  120.2, 120.1 (C16); 110.4, 110.3 (C12); 100.4 (C1); 76.7 (C3); 75.7 (CD1); 72.7 
(CD2); 72.5 (C5); 72.4 (C2); 69.3 (C7); 68.9 (C4); 63.2 (C6); 60.4 (C18); 56.0 (C17); 52.1 (C8); 43.9 
(C10); 42.0, 41.9 (CD4, CD5);  30.0, 29.1 (CD3, CD6).  
 
2.4.8.10 N1,N2-bis(2,6-dimethoxy-4-(hydroxymethylene)benzyl)amide, 2.2s 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(2,6-dimethoxy-4-(hydroxymethylene)benzyl)-4-(2-
azidoethoxy)-5-[α-D-mannopyranosyloxy]- (1S,2S,4S,5S)  
 
Prepared according to general procedure 5, using amine 2.12s. 
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Yield = 28 % 
[α]D20  = + 36.5 (c = 0.1 in methanol)  
MS (HRMS) calculated for: [C36H51N5O15Na]+: 816.32794; found: 816.32600 
1H NMR (400 MHz, CD3OD): δ = 6.63 (s, 4H, H13), 4.97 (s, 1H, H1), 4.63 (s, 4H, H16), 4.46 (dd, 
2H, H10a,  J10a-NH = 7.6 Hz, J10a-10b = 13.4 Hz), 4.17 (dd, 2H, H10b, J10b-10a = 5.8 Hz), 3.97 (d, 1H, 
H5, J6-5 = 2.6 Hz), 3.90 - 3.76 (m, 14H, H15’, H2, H6b), 3.74 - 3.59 (m, 5H, H7, H6a, H3, D2), 3.59 - 
3.48 (m, 2H, H4, D1), 3.35 - 3.32 (m, 4H, H8), 2.81 - 2.62 (m, 2H, D4, D5), 1.98 - 1.72 (m, 4H, 
D3, D6). 13C NMR (100 MHz, CD3OD): δ = 176.4, 176.1 (C9); 160.2, 160.1 (C12); 144.7 (C11); 
129.1 (C14); 103.3 (C13); 100.4 (C1); 76.8 (C3); 75.6 (CD1); 72.7 (CD2); 72.5 (C5); 72.2 (C2); 69.3 
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(C7); 68.9 (C4); 65.4 (C16); 63.2 (C6); 56.4 (C15); 52.1 (C8); 42.1, 42.0 (CD4, CD5); 33.5, 33.3 
(C10); 29.5, 28.6 (CD3, CD6).  
2.4.8.11 1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-
hydroxymethylenebenzyl)-4-(2-azidoethoxy)-5-[α-D-
mannopyranosyloxy]- (1R,2R,4R,5R), 2.2t (diastereoisomer of 2.2f) 
 
1,2-Cyclohexanedicarboxamides-N1,N2-bis(4-hydroxymethylenebenzyl)-4-(2-azidoethoxy)-5-[α-
D-mannopyranosyloxy]- (1R,2R,4R,5R)  
 
Starting from a 4:1 mixture of diastereoisomers 2.31 and 2.43, and amine 2.12f  Prepared 
according to general procedure 5. The separation of the isomers were obtained after the first step, 
before the deprotection, (silica, Et2O with gradient of EA from 50% to 100%, TLC (Et2O/EA = 
1:1): Rf (1S, 2S, 3S, 4S) = 0.16, Rf (1R, 2R, 3R, 4R) = 0.2) 
 
[α]D20  = + 36.9 (c = 0.23 in methanol) 
MS (HRMS) calculated for: [C32H43N5O11Na]+ =  696.8568, found: 696.8560 
1H NMR (400 MHz, CD3OD): 7.27 (d, 4H, H12, J12-13 = 8.0 Hz), 7.22 (d, 4H, H13, J13-12 = 8.0 
Hz), 4.91 (d, 1H, H1, J1-2 = 1,5 Hz), 4.56 (s, 4H, H15a,b)  4.30 – 4.27 (m, 4H, H10a,b), 4.01 – 3.97 
(m, 1H, D2), 3.88 – 3.82 (m, 1H, H6a), 3.82 – 3.74 (m, 3H, H2, H7a,b, ), 3.74 - 3.69 (m, 1H, H3), 
3.69 - 3.61 (m, 3H,  D1, H5, H6b), .3.60 – 3.54 (m, 1H, H4), 3.45 – 3.33 (m, 2H, H8a,b), 3.01 - 2.84 
(m, 2H, D4,D5), 2.07 - 1.88 (m, 4H, D3, D6).  
13C NMR (100 MHz, CD3OD): 177.2, 177.0 (C9); 141.7, 141.6 (C14); 139.3, 139.2 (C11); 128.5 
128.5 (C12); 128.3, 128.3 (C13); 101.9 (C1); 75.8, 75.7 (C3, C5); 74.4 (CD2); 72.7 (C2); 72.4 (D1); 
69.2 (C7); 69.0 (C4); 65.1, 65.1 (C15); 63.3 (C6); 52.2 (C8); 43.8, 43.7 (C10); 42.5, 41.8 (CD4, 
CD5); 31.1, 29.5 (CD3, CD6).  
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2.2t 1H NMR  
(400 MHz, CD3OD) 
2.2t 13C NMR  
(100 MHz, CD3OD) 
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2.4.8.12 Macrocycle, 2.47  
To the flask charged with scaffold 2.31 (60 mg, 0.055 mmoli, 1 eq) a solution of p-
xylilbenzylamine 2.45a (3.81 mg, 0.028 mmol, 0.5 eq) in 0.55 mL of MeCN was added under 
nitrogen. The reaction was stirred for 5 h. TLC (silica, DCM:MeOH = 9:1, DCM:MeOH = 
9:1+1% TEA, Hex:AcOEt = 6:4) indicated no presence of amine 2.45a but scaffold 2.31 was 
still present, therefore another portion of amine 2.45a (0.5 eq) was added and the reaction 
mixture was stirred for additional 16 h. TLC indicated again no presence of amine 2.45a but still 
presence of scaffold 2.12, therefore another portion of amine 2.45a (0.3 eq) was added and the 
reaction mixture was stirred for additional 16 h. The solvent was removed under reduced 
pressure and the crude was purified by flash chromatography (silica, hexane with gradient of EA 
from 30 % to 70 %) to afford 18.6 mg of intermediate with macrocyclic structure. MS (ESI) 
calculated for [C104H98N10O26Na]+: 1926,9; found: 1926.6. To the solution of the product 
obtained in the previous reaction (18.6 mg, 0.0097 mmol, 0.18 eq) in dry methanol (0.7 ml), a 
solution of  sodium methoxide in MeOH (1M, 100 μL, 0.037 mmoli, 4 eq) was added. After 45 
min the reaction mixture was diluted with methanol and neutralized with prewashed Amberlite 
IRA 120-H+. The resin was filtered off and the filtrate was concentrated under reduced pressure. 
The crude was purified by flash chromatography (CHCl3 with gradient of methanol from 0 to 
20% with 10% water in methanol) to afford 8.7 mg of product.  
 
 
 
 
Yield = 15 %,  Note: The macrocyle was isolated as a 1:1 mixture of diastereoisomers, as shown 
by the 13C spectrum. 
MS (HRMS) calculated for: [C48H66N10O18Na]+: 1093,44543; found: 1093.44341. 
Chapter 2   Monovalent glycomimetic DC-SIGN ligands  
     140
1H NMR (400 MHz, CD3OD): δ = 7.11 (s, 8H, H12), 4.96 (d, 2H, H1, J2-1  = 1.7 Hz), 4.72 – 4.65 
(m, 4H, H10a), 4.05 – 4.02 (m, 2H, D2), 3.91 (dd, 2H, H2, J2-1  = 1.7 Hz, J2-3  = 3.2 Hz), 3.88 - 3.81 
(m, 2H, H6b), 3.80 - 3.62 (m, 14H, H10b, H3, H7, D1, H6b), 3.61 - 3.52 (m, 2H, H4, H5), 3.45 - 3.33 
(m, 2H, H8), 2.98 - 2.81 (m, 2H, D4, D5), 2.00 - 1.86 (m, 4H, D3, D6).  
13C NMR (100 MHz, CD3OD): δ = 177.1, 177.0, 176.8, 176.7 (C9); 138.9, 138.9 (C11); 128.9 
(C12); 100.3 (C1); 76.7 (CD1); 75.7 (C5); 72.7 (C3); 72.6 (C2); 72.5 (CD2); 69.3 (C7); 68.9 (C4); 
63.2 (C6); 52.2 (C8); 43.8 (C10); 41.9, 41.8 (CD4, CD5);  30.0, 29.1 (CD3, CD6).  
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2.4.9 Synthesis and characterization of 48a-e, 49b, 53-61 
2.4.9.1 6-azido-D-6-deoxymannopyranose, 2.53 
 
6-(p-toluensulfonyl)-D-6-deoxymannopyranose 
To the suspension of mannose 2.52 (0.5 g, 2.77 mmol, 1 eq) in 7 ml of pyridine a solution of 
TsCl (1g, 5.55 mmol, 2 eq) in 3 ml of pyridine was added at room temperature. The reaction was 
stirred at room temperature for 3 h but the TLC (DCM:MeOH = 8:2) indicated still some starting 
material so, and additional portion of TsCl (0.5 g, 2.75 mmol, 1 eq) was added and the reaction 
was stirred overnight. The pyridine was removed under reduced pressure and the crude residue 
was dissolved in a mixture of DCM:MeOH (9:1) and filtered through a pad of sodium carbonate 
in order to remove the excess of TsCl, TsOH and scavenge the HCl. The filtrate was 
2.47 13C NMR  
(100 MHz, CD3OD) 
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concentrated under reduced pressure and the crude residue was purified by silica (CHCl3 with 
gradient of MeOH from 0 to 15%) to obtain 2.6 g of 6-(p-toluensulfonyl)-D-6-
deoxymannopyranose as mixture of α and β anomers in 4:1 ratio.  
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Yield: 50%. 
MS (ESI) calculated for [C13H18O8SNa]+: 357.3; found: 357.2 
1H NMR (400 MHz, CD3OD):  
α anomer : 7.80 (d, 2H, H8, J8-9 =8.3 Hz), 7.43 (d, 2H, H9, J8-9 =8.3 Hz), 5.00 (d, 1H, H1, J1-2 = 
1.4 Hz), 4.39 - 4.23 (m, 1H, H6A), 4.19 – 4.07 (m, 1H, H6B), 3.93 - 3.82 (m, 1H, H5), 3.75 (dd, 
1H, H2, J1-2 =1.4 Hz, J3-2 =3.3 Hz), 3.70 (dd, 1H, H3, J3-4 = 9.3 Hz, J3-2 =3.3 Hz), 3.51 (t, 1H, H4, 
J3-4 = 9.3), 2.45 (s, 1H, H11). 
β anomer : 7.80 (d, 2H, H8, J8-9 =8.3 Hz), 7.43 (d, 2H, H9, J8-9 =8.3 Hz), 4.69 (d, 1H, H1, J1-2 = 
0.8 Hz), 4.39 - 4.23 (m, 1H, H6A), 4.19 – 4.07 (m, 1H, H6B), 3.93 - 3.82 (m, 1H, H5), 3.78 – 3.76 
(m, 1H, H2), 3.70 (dd, 1H, H3, J3-4 = 9.3 Hz, J3-2 =3.3 Hz), 3.51 (t, 1H, H4, J3-4 = 9.3), 2.45 (s, 1H, 
H11). 
 
13C NMR (100 MHz, CD3OD, the assignment of the NMR shifts for the α and β anomers was 
obtained using the HSQC spectrum):  
α anomer : 146.5 (C7); 134.7 (C10); 131.1 (C9); 129.3 (C8); 96.0 (C1); 72.9 (C2); 72.3 (C3); 71.8 
(C5); 71.5 (C6); 68.5 (C4); 21.7 (C11). 
β anomer : 146.5 (C7); 134.7 (C10); 131.2 (C9); 129.3 (C8); 95.8 (C1); 75.6 (C2); 75.3 (C3); 73.1 
(C5); 71.3 (C6); 68.2 (C4); 21.7 (C11). 
 
The 6-tosylate obtained in the previous reaction (2.5 g, 7.4 mmol, 1 eq) was dissolved in DMF 
(15 ml) and to this solution TBAI (catalytic amount) and NaN3 (1.5 g, 22 mmol, 3eq) were 
added. The solution was stirred at 60°C for 3 days. Then the solvent was removed under reduced 
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pressure and the crude was purified by a short pad of silica (EA with gradient of MeOH from 0 
to 20%) to obtain 1.35 g of product as a mixture of α and β anomers in 3.7:1 ratio.  
 
 
 
Yield: 89%. 
MS (ESI) calculated for [C6H11N3O5Na]+: 228.2; found: 228.1 
1H NMR (400 MHz, CD3OD):  
α anomer : 5.24 (br s, 1H, H1), 4.42 (dd, 1H, H5, J5-6 =0.9 Hz, J5-4 = 5.8 Hz), 4.08 (dd, 1H, H6A, 
J6A-6B = 7.1 Hz, J6A-5 = 0.9 Hz), 3.83 (dd, 1H, H2, J1-2 =1.5 Hz, J3-2 = 5.4 Hz), 3.77 (br s, 1H, H3), 
3.65 (t, 1H, H4, J3-4 = 6.4), 3.67 - 3.61 (m, 1H, H6B). 
β anomer : 5.08 (d, 1H, H1, J1-2 = 0.8 Hz), 4.42 (dd, 1H, H5, J5-6 =0.9 Hz, J5-4 = 5.8 Hz), 4.08 (dd, 
1H, H6A, J6A-6B = 7.1 Hz, J6A-5 = 0.9 Hz), 3.79 (dd, 1H, H2, J1-2 = 0.8 Hz, J3-2 = 7.1 Hz), 3.77 (br s, 
1H, H3), 3.67 - 3.61 (m, 1H, H6B), 3.58 (t, 1H, H4, J3-4 = 6.4). 
 
13C NMR (100 MHz, CD3OD, the assignment of the NMR shifts for the α and β anomers was 
obtained using the HSQC spectrum):  
α anomer : 103.5 (C1); 77.5 (C5); 73.3 (C3); 72.5 (C2); 67.8 (C4); 65.9 (C6). 
β anomer : 96.0 (C1); 77.5 (C5); 73.0 (C3); 72.2 (C2); 69.8 (C4); 65.9 (C6). 
2.4.9.2 (1,2,3,4-O-tetrabenzoyl)-6-azido-D-6-deoxymannopyranose, 2.54 
To the solution of 6-azido-mannose 2.53 (1.3 g, 6.34 mmol, 1 eq) in pyridine (30 ml) BzCl  (5.9 
ml, 5.72 mmol, 6 eq) was added at 0°C. The reaction was stirred at room temperature for 1 h 
then heated up to 70°C for 3h. The reaction was let to cool to room temperature then the solvent 
was removed under reduced pressure. The crude was taken up in ether and washed with 1M HCl 
and water. The organic layer was dried over sodium sulphate and concentrated under reduced 
pressure. The crude product was purified by flash chromatography (silica, hexane with gradient 
of EA from 5 % to 20 %) to afford 1.97 g of product as a mixture of α and β anomers in 4:1 ratio. 
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Yield: 50% 
MS (ESI) calculated for [C34H27N3O9Na]+: 644.6; found: 644.3. 
1H NMR (400 MHz, CDCl3):  
α anomer: δ = 8.20 – 7.20 (m, 20H, HBz), 6.36 (d, 1H, H1, J1-2 = 1.1 Hz), 6.07 (dd, 1H, H2, J1-2 = 
1.1 Hz, J3-2 = 3.2 Hz), 5.94 (t, 1H, H4, J4-3 = J4-5= 9.8 Hz), 5.75 (dd, 1H, H3, J3-4 = 9.8 Hz, J3-2= 
3.2), 4.20 – 4.13 (m, 1H, H5), 3.61 (dd, 1H, H6a, J5-6a = 2.8 Hz, J6a-6b= 13.5 Hz), 3.53 (dd, 1H, 
H6b, J5-6a = 5.5 Hz, J6a-6b= 13.5 Hz). 
β anomer: δ = 8.20 – 7.20 (m, 20H, HBz), 6.60 (d, 1H, H1, J1-2 = 2.0 Hz), 6.05 – 6.00 (m, 1H, H4), 
), 5.88 – 5.85 (m, 1H, H2), ), 5.74 – 5.63 (m, 1H, H3), 4.41 – 4.34 (m, 1H, H5), ), 3.55 – 3.41 (m, 
2H, H6a, H6b),  
 
13C NMR (100 MHz, CDCl3, the assignments of the NMR shifts for the α and β anomers were 
obtained using the HSQC spectrum):  
α anomer: δ = 165.9, 165.6, 165.6, 164.3 (COBZ); 134.0, 133.9, 133.8, 133.7 (CHBZ); 130.4, 
130.3, 130.0 (CHBZ); 129.5 (CquatBZ); 128.9, 128.8 (CHBZ); 128.8 (CquatBZ); 128.7, 128.6 
(CHBZ); 91.3 (C1); 74.9 (C5); 71.5 (C3); 69.5 (C2); 67.3 (C4); 51.1 (C6). 
β anomer: δ = 165.9, 165.6, 165.6, 164.3 (COBZ); 134.3, 133.9, 133.8, (CHBZ); 130.8, 130.4, 
130.3, 130.0 (CHBZ); 129.5 (CquatBZ); 129.1, 129.0 (CHBZ); 128.8 (CquatBZ); 128.8, 128.6 
(CHBZ); 91.4 (C1); 74.9 (C5); 69.5 (C4); 68.6 (C3); 67.2 (C2); 51.1 (C6). 
2.4.9.3 (2,3,4-O-tribenzoyl)-6-azido-D-6-deoxymannopyranosyl 
trichloroacetoimidate, 2.49b 
To a solution of mannose derivative 2.54 (120 mg, 0.193 mmol, 1 eq) in dry THF (0.5 ml) a 
methylamine solution in ethanol (33%, 0.074 ml, 0.57 mmol, 3 eq) was added at 0°C under 
nitrogen. The reaction was stirred at 0°C for 1 h. The solvent was removed under reduced 
pressure and the crude was purified by flash chromatography (silica, hexane with gradient of EA 
from 5 % to 30 %) to afford 84 mg of product as mainly the α anomer. 
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Yield: 84% 
MS (ESI) calculated for [C27H23N3O8Na]+: 540.5; found: 540.0. 
1H NMR (400 MHz, CDCl3):  
α anomer: δ = 8.13 – 8.04 (m, 2H, HBz), 8.00 – 7.90 (m, 2H, HBz), 7.87 – 7.75 (m, 2H, HBz), 7.67 
– 7.56 (m, 1H, HBz), 7.55 – 7.45 (m, 3H, HBz), 7.43 – 7.32 (m, 3H, HBz), 7.29 – 7.18 (m, 2H, 
HBz), 5.96 (dd, 1H, H3, J3-4 = 10.0 Hz, J3-2= 3.3), 5.87 (t, 1H, H4, J4-3 = J4-5= 10.0 Hz), 5.71 (dd, 
1H, H2, J1-2 = 1.6 Hz, J3-2 = 3.3 Hz), 5.52 (d, 1H, H1, J1-2 = 1.6 Hz), 4.54 – 4.43 (m, 1H, H5), 3.51 
– 3.45 (m, 2H, H6a,b), 3.35 (br s, 1H, H7). 
13C NMR (100 MHz, CDCl3):  
α anomer: δ = 165.8, 165.8, 165.7 (COBZ); 133.8, 133.8, 133.4 (CHBZ); 130.2, 130.0, 130.0 
(CHBZ); 129.5, 129.3, 129.0 (CquatBZ); 128.9, 128.7, 128,5 (CHBZ); 92.5 (C1); 70.9 (C2); 70.4 
(C5); 69.6 (C3); 68.0 (C4); 51.6 (C6). 
 
To the solution of mannose derivative obtained in the previous reaction (72 mg, 0.139 mmol, 1 
eq) in dry DCM (0.5 ml) trichloroacetonitrile  (0.07 ml, 0.696 mmol, 5 eq) and a catalytic 
amount of DBU  (cca 0.01 ml) was added at room temperature under nitrogen. The reaction was 
stirred at room temperature for 1 h. The solvent was removed under reduced pressure and the 
crude was purified by flash chromatography (silica, hexane with gradient of EA from 5 % to 30 
%) to afford 73 mg of product as mainly the α anomer. 
 
 
Yield: 80% 
MS (ESI) calculated for [C29H23Cl3N4O8Na]+: 684.9; found: 685.1 
1H NMR (400 MHz, CDCl3):  
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α anomer: δ = 8.88 (s, 1H, H8), 8.13 – 8.08 (m, 2H, HBz), 7.97 – 7.93 (m, 2H, HBz), 7.83 – 7.78 
(m, 2H, HBz), 7.65 – 7.59 (m, 1H, HBz), 7.55 – 7.46 (m, 3H, HBz), 7.45 – 7.33 (m, 3H, HBz), 7.29 
– 7.22 (m, 2H, HBz), 5.56 (d, 1H, H1, J1-2 = 1.8 Hz), 5.99 (t, 1H, H4, J4-3 = J4-5= 9.8 Hz), 5.95 – 
5.86 (m, 2H, H2, H3), 4.48 – 4.41 (m, 1H, H5), 3.54 (dd, 1H, H6a, J5-6a = 2.8 Hz, J6a-6b= 13.6 Hz), 
3.49 (dd, 1H, H6b, J5-6a = 5.4 Hz, J6a-6b= 13.6 Hz). 
13C NMR (100 MHz, CDCl3):  
α anomer: δ = 165.4, 165.2 (COBZ); 159.8 (C7); 133.8, 133.7 133.4 (CHBZ); 130.0, 129.9, 129.7 
(CHBZ); 129.9, 128.8 (CquatBZ); 128.7 (CHBZ); 128.6 (CquatBZ); 128.6, 128.4 (CHBZ); 100.0 
(C9); 94.5 (C1); 72.9 (C5); 69.5, 68.7 (C2, C3); 66.9 (C4); 50.9 (C6). 
2.4.9.4 1,2-Cyclohexanedicarboxylic acid, 4-(2-chloroethoxy)-5-((2,3,4-O-
tribenzoyl)-6-azido-α-D-6-deoxymannopyranosyloxy)-, 1,2-dimethyl 
ester, (1S,2S,4S,5S) 2.51b 
A mixture of the acceptor 2.508 (25.5 mg, 0.086 mmol, 1 eq.) and the donor 2.49b (70 mg, 0.105 
mmol, 1.22 eq.) was coevaporated with toluene three times. Powdered and activated acid washed 
4Å molecular sieves were added; the mixture was kept under vacuum for a few h and then 
dissolved with dry CH2Cl2 (1 mL) under nitrogen. After cooling at −30°C, TMSOTf (4 μL, 0.017 
mmol, 0.2 eq.) was added to the reaction mixture under stirring. The reaction was stirred at -
20°C for 1 h. The reaction was quenched with Et3N and the mixture warmed to room 
temperature and filtered over a celite pad. The filtrate was evaporated at reduced pressure and 
the crude product purified by flash chromatography (hexane with gradient of ethyl acetate from 5 
% to 40 %) to yield 61 % of pure product. 
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Yield: 80 % 
MS (ESI) calculated for [C39H40ClN3NaO13]+: 817.2; found 816.5 
1HNMR (400 MHz, CDCl3): 8.1 – 8.05 (m, 2H, HBz), 7.99 – 7.89 (m, 2H, HBz), 7.83 – 7.74 (m, 
2H, HBz), 7.65 – 7.56 (m, 1H, HBz), 7.55 – 7.46 (m, 3H, HBz), 7.45 – 7.33 (m, 3H, HBz), 7.29 – 
7.17 (m, 2H, HBz), 5.84 – 5.76 (m, 2H, H3, H4), 5.66 (dd, 1H, H2, J2-1 = 1.9 Hz, J2-3 = 2.7 Hz), 
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5.24 (d, 1H, H1, J1-2 = 1.6 Hz), 4.29 (t, 1H, H5, J6a-5 = J5-4 = 7.2 Hz), 4.06 (dd, 1H, D2, JD1-D2 = 4.0 
Hz, JD2-3 or 6 = 7.8 Hz), 3.93 – 3.83 (m, 1H, H7a), 3.81 – 3.67 (m, 8H, H7b, H2, H10), 3.63 (t, 2H, 
H8, J8-7 = 5.77 Hz), 3.57 (dd, 1H, H6a, J6b-5 = 7.2 Hz, J6a-6b = 13.3 Hz),  3.40 (dd, 1H, H6a, J6b-5 = 
2.3 Hz, J6a-6b = 13.3 Hz),  3.13 - 3.00 (m, 2H, D4, D5), 2.17 – 1.97 (m, 4H, D3, D6). 
13C NMR (100 MHz, CDCl3): δ = 174.9, 174.8 (C9); 165.9, 165.7, 165.6 (COBZ); 133.9, 133.5, 
133.6, 133.5 (CHBZ); 130.1, 130.1, 129.9, (CHBZ); 129.4, 129.1 (CquatBZ); 128.9 (CHBZ); 128.8 
(CquatBZ); 128.7, 128.5 (CHBZ); 96.3 (C1); 75.5 (CD1); 73.3 (CD2); 71.3 (C5); 70.9 (C2); 69.7 
(C7); 69.7 (C3); 68.0 (C4); 52.3, 52.3 (C10); 51.6 (C6); 43.3 (C8); 39.4, 39.3 (CD4,CD5); 28.2 (CD3); 
27.5 (CD6).  
 
2.4.9.5 1,2-Cyclohexanedicarboxylic acid, 4-(2-chloroethoxy)-5-(6-azido-α-D-
6-deoxymannopyranosyloxy)-, 1,2-dimethyl ester, (1S,2S,4S,5S) 2.55 
Compound 2.51b (435 mg, 0.548 mmol, 1 eq) was dissolved in dry methanol (5 ml), under 
nitrogen at room temperature, and a solution of sodium methoxide in MeOH (1 M, 1 ml, 1 mmol, 
2 eq) was added. After reaction completion (1 h, TLC: DCM:MeOH = 9:1) the reaction mixture 
was diluted with methanol and neutralized with prewashed Amberlite IRA 120-H+. The resin 
was filtered off and the filtrate was concentrated under reduced pressure. The crude was purified 
by flash chromatography (silica, CHCl3 with gradient of methanol from 3% to 20%) to afford 
248 mg of product. 
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Yield = 94 % 
MS (ESI) calculated for: [C18H28ClN3O10Na]+: 504.9; found: 504.3 
1H NMR (400 MHz, CD3OD): δ = 4.95 (d, 1H, H1, J1-2 = 1.6 Hz), 4.03 – 3.99 (m, 1H, D2), 3.94 
– 3.89 (m, 1H, H6a), 3.88 – 3.76 (m, 4H, H2, H3, H7), 3.75 – 3.71 (m, 1H, D1), 3.71 - 3.64 (m, 9H, 
H8, H5, H10), 3.61 – 3.54 (m, 1H, H4), 3.51 (dd, 1H, H6a, J6a-6b = 13.0 Hz, J6a-5 = 2.1 Hz), 3.43 
(dd, 1H, H6a, J6a-6b = 13.0 Hz, J6a-5 = 8.1 Hz),  3.00 – 2.81 (m, 2H, D4,D5), 2.21 - 1.94 (m, 2H, 
D3ax, D6ax), 1.94 – 1.72 (m, 2H, D3eq, D6eq)  
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13C NMR (100 MHz, CD3OD): δ = 177.2, 176.9 (C9); 100.8 (C1); 76.2 (CD1); 74.9 (C5); 72.9 
(D2);  72.5, 72.4 (C2, C3); 70.9 (C7); 69.6 (C4); 53.3 (C6); 52.6 (C10); 44.4 (C8); 40.5, 40.4 (CD4, 
CD5); 29.4, 28.5 (CD3, CD6).  
 
 
2.55 1H NMR  
(400 MHz, CD3OD) 
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2.4.9.6 1,2-Cyclohexanedicarboxylic acid, 4-(2-chloroethoxy)-5-(6-N-carbo-
tbutoxy-α-D-6-deoxymannopyranosyloxy)-, 1,2-dimethyl ester, 
(1S,2S,4S,5S) 2.56 
To a solution of 2.55 (50 mg, 0.103 mmol, 1 eq) and Boc2O (33 mg, 0.154 mmol, 1.5 eq) in 
methanol (10 ml) 10 % Pd/C was added in catalytic amount. The reaction was stirred under H2 (1 
atm) at room temperature for 2 h. The catalyst was filtered off through a celite pad. The filtrate 
was concentrated under reduced pressure to yield 53 mg of pure product. 
 
 
Yield = 94 % 
2.55 13C NMR  
(100 MHz, CD3OD) 
Chapter 2   Monovalent glycomimetic DC-SIGN ligands  
     150
MS (ESI) calculated for: [C23H38ClNO12Na]+: 579.0; found: 578.3  
1H NMR (400 MHz, CD3OD): δ = 4.90 (d, 1H, H1, J1-2 = 1.6 Hz), 4.98 – 3.93 (m, 1H, D2), 3.85 
– 3.74 (m, 3H, H2, H7), 3.72 – 3.62 (m, 10H, H10, D1, H8, H3), 3.62 – 3.45 (m, 3H, H4, H5, H6a), 
3.19 (dd, 1H, H6b, J6a-6b = 13.3 Hz, J6a-5 = 5.1 Hz), 2.97 – 2.78 (m, 2H, D4, D5), 2.14 - 1.98 (m, 
2H, D3ax, D6ax), 1.86 – 1.71 (m, 2H, D3eq, D6eq).  
13C NMR (100 MHz, CD3OD): δ = 177.1, 177.0 (C9); 158.7 (C11); 101.1 (C1); 80.4 (C12); 76.1 
(CD1); 74.3 (C5); 73.2 (D2); 72.6 (C2); 72.4 (C3); 70.9 (C7); 69.9 (C4); 52.5 (C10); 44.5 (C8); 42.9 
(C6); 40.5, 40.3 (CD4, CD5); 29.4 (CD3 or CD6); 29.0 (C13); 28.5 (CD3 or CD6).  
2.4.9.7 1,2-Cyclohexanedicarboxylic acid, 4-(2-azidoethoxy)-5-(6-amino-α-D-
6-deoxymannopyranosyloxy)-, 1,2-dimethyl ester, (1S,2S,4S,5S), 2.48a 
To a solution of 2.56 (50 mg, 0.0899 mmol, 1 eq.) in DMF (1 mL) sodium azide (35 mg, 0.539 
mmol, 5 eq.) was added. The reaction was stirred at 50°C for 4 days. The solvent was removed at 
reduced pressure and the crude residue was purified by flash chromatography (silica, chloroform 
with gradient of methanol from 3% to 20%) to afford 48 mg of product. 
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Yield = 94 % 
MS (ESI) calculated for: [C23H38N4O12Na]+: 585.6; found: 585.3 
1H NMR (400 MHz, CD3OD): δ = 4.84 (d, 1H, H1, J1-2 = 1.6 Hz), 3.93 – 3.89 (m, 1H, D2), 3.78 
– 3.77 (m, 1H, H2), 3.74 – 3.64 (m, 2H, H7), 3.65 – 3.55 (m, 8H, H10, D1, H3), 3.51 – 3.36 (m, 
3H, H4, H5, H6a), 3.31 (t, 2H, H8, J7-8 = 4.7 Hz), 3.12 (dd, 1H, H6b, J6a-6b = 13.5 Hz, J6a-5 = 5.4 
Hz), 2.90 – 2.72 (m, 2H, D4, D5), 2.08 - 1.92 (m, 2H, D3ax, D6ax), 1.80 – 1.63 (m, 2H, D3eq, D6eq)  
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.9 (C9); 158.7 (C11); 101.1 (C1); 80.4 (C12); 76.2 
(CD1); 74.4 (C5); 73.1 (D2); 72.6 (C2); 72.4 (C3); 69.9 (C4); 69.7 (C7); 52.5 (C10); 52.2 (C8); 42.8 
(C6); 40.5, 40.2 (CD4, CD5); 29.2 (CD3 or CD6); 29.0 (C13); 28.6 (CD3 or CD6).  
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The product obtained in previous reaction  (45 mg, 0.080 mmol, 1 eq.) was dissolved in TFA (1 
ml). The resulting solution was stirred at 35°C for 3 h. The solvent was removed under reduced 
pressure and the crude residue was washed twice with a small amount diethyl ether. The product 
was dried under reduced pressure to afford 32 mg of product. 
 
 
Yield = 87 %;  
[α]D20  = + 19.2 (c = 0.2 in methanol) 
MS (HRMS) calculated for: [C18H30N4O10Na]+: 485.18596; found: 485.18621 
          [C18H31N4O10]+: 463.20347; found: 463.20399 
1H NMR (400 MHz, CD3OD): δ = 4.98 (d, 1H, H1, J1-2 = 1.6 Hz), 4.04 – 3.89 (m, 1H, D2), 3.87 
(dd, 1H, H2, J1-2 = 1.6 Hz, J3-2 = 3.0 Hz), 3.82 – 3.76 (m, 1H, H7a), 3.74 – 3.63 (m, 9H, H10, D1, 
H3, H7b), 3.63 – 3.50 (m, 2H, H4, H5), 3.42 – 3.34 (m, 2H, H8), 3.19 (dd, 1H, H6a, J6a-6b = 13.2 
Hz, J6a-5 = 2.6 Hz), 3.04  – 2.79 (m, 3H, H6b, D4, D5), 2.20 – 2.00 (m, 2H, D3ax, D6ax), 1.88 – 1.70 
(m, 2H, D3eq, D6eq)  
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.8 (C9); 100.1 (C1); 76.3 (CD1); 72.9 (C5); 72.5 
(C2); 72.4 (D2); 72.2 (C3); 69.7 (C4); 69.4 (C7); 52.6, 52.6 (C10); 52.2 (C8); 42.8 (C6); 40.5, 40.2 
(CD4, CD5); 28.8 , 28.9(CD3, CD6).  
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2.4.9.8 1,2-Cyclohexanedicarboxylic acid, 4-(2-azidoethoxy)-5-(6-N-
methansulfonyl-α-D-6-deoxymannopyranosyloxy)-1,2-dimethyl ester, 
(1S,2S,4S,5S), 2.48b 
To a solution of 2.48a (15 mg, 0.0324 mmol, 1 eq.) in acetonitrile (0.5 mL) MsCl (3.2 µl, 0.042 
mmol, 1.3 eq.) and DIPEA (8.3 µl, 0.0648 mmol, 2 eq) were added under nitrogen. The reaction 
2.48a 1H NMR  
(400 MHz, CD3OD) 
2.48a 13C NMR  
(100 MHz, CD3OD) 
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was stirred at room temperature for 1 h. The solvent was removed at reduced pressure and the 
crude residue was purified by flash chromatography (silica, chloroform with gradient of 
methanol from 2% to 20%) to afford 5.5 mg of product. 
 
 
Yield = 45 %;  
[α]D20  = + 28.2 (c = 0.11 in methanol) 
MS (HRMS) calculated for: [C19H32N4O12SNa]+: 563,16351; found: 563.16366 
1H NMR (400 MHz, CD3OD): δ = 4.93 (s, 1H, H1), 4.09 – 4.02 (m, 1H, D2), 3.87 – 3.82 (m, 1H, 
H2), 3.81 – 3.73 (m, 3H, D1, H7), 3.71 – 3.62 (m, 7H, H10, H3), 3.62 – 3.45 (m, 3H, H4, H5, H6a), 
3.38 – 3.33 (m, 2H, H8), 3.14 (dd, 1H, H6b, J6a-6b = 13.5 Hz, J6a-5 = 5.8 Hz), 3.03 – 2.77 (m, 5H, 
H11, D4, D5), 2.20 – 2.02 (m, 2H, D3ax, D6ax), 1.87 – 1.69 (m, 2H, D3eq, D6eq)  
13C NMR (100 MHz, CD3OD): δ = 177.2, 176.9 (C9); 100.6 (C1); 76.0 (CD1); 74.6 (C5); 72.6 
(C2); 72.4 (C3); 72.3 (D2); 69.8 (C4); 69.8 (C7); 52.6 (C10); 52.3 (C8); 45.5 (C6); 40.5, 40.2, 40.1 
(C11, CD4, CD5); 29.3, 28.3 (CD3, CD6) 
2.4.9.9 1,2-Cyclohexanedicarboxylic acid, 4-(2-chloroethoxy)-5-(6-amino-α-D-
6-deoxymannopiranosyloxy)-1,2-dimethyl ester, (1S,2S,4S,5S), 2.57 
To a solution of 2.55 (17 mg, 0.0353 mmol, 1 eq) in methanol (7 ml) 10 % Pd/C was added in 
catalytic amount. The reaction was stirred under H2 (1 atm) at room temperature for 2 h. The 
catalyst was filtered off through a celite pad. The filtrate was concentrated under reduced 
pressure to yield 17 mg of product with some impurities, no further purification was performed.  
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Yield = (96%)  
MS (ESI) calculated for: [C18H30ClNO10Na]+: 455.9; found: 456.3 
1H NMR (400 MHz, CD3OD): δ = 4.99 (s, 1H, H1), 4.05 – 3.94 (m, 1H, D2,), 3.91 – 3.85 (m, 
12H, , H2, H10, D1, H3, H7, H5), 3.59 – 3.42 (m, 2H, H4, H8), 3.35 – 3.23 (m, 1H, H6a), 3.10 (dd, 
1H, H6b, J6a-6b = 13.1 Hz, J6a-5 = 7.7 Hz), 3.14  – 3.06 (m, 2H,, D4, D5), 2.15 – 1.96 (m, 2H, D3ax, 
D6ax), 1.88 – 1.70 (m, 2H, D3eq, D6eq).  
13C NMR (100 MHz, CD3OD): δ = 177.0, 176.7 (C9); 100.0 (C1); 76.1 (CD1); 72.7, 72.5, 72.0, 
71.2 (D2, C2, C3, C5); 70.7 (C7); 69.6 (C4); 52.6 (C10); 44.6 (C8); 42.2 (C6); 40.4, 40.3 (CD4, CD5); 
29.0, 28.0 (CD3, CD6).  
2.4.9.10 1,2-Cyclohexanedicarboxylic acid, 4-(2-azidoethoxy)-5-(6-N-
acetyl-α-D-6-deoxymannopyranosyloxy)-1,2-dimethyl ester, 
(1S,2S,4S,5S), 2.48c 
To a solution of 2.57 (10 mg, 0.02 mmol, 1 eq) in MeCN (1 ml) AcCl (5 µl, 0.06 mmol, 3 eq) 
and DIPEA (10 µl, 0.06 mmol, 3 eq) was added at room temperature under nitrogen. The 
reaction was stirred at room temperature for 3 h. TLC (DCM:MeOH = 9:1 and 8:1) indicated no 
starting material but several products. Probably the free hydroxyl groups got acetylated. The 
solvent was removed under reduced pressure and the crude residue was dissolved in dry MeOH 
(1 ml) under nitrogen. In order to deprotect the acetylated hydroxyl groups, sodium methoxide 
(0.5 M, 0.18 ml, 0.06 mol, 3 eq) was added. The reaction was stirred overnight. The reaction 
mixture was diluted with methanol and neutralized with prewashed Amberlite IRA 120-H+. The 
resin was filtered off and the filtrate was concentrated under reduced pressure. The crude was 
purified by flash chromatography (silica, CHCl3 with gradient of methanol from 3% to 20%) to 
afford 5.9 mg of product. 
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Yield = 60 % 
MS (ESI) calculated for: [C20H32ClNO11Na]+: 520.9; found: 520.5 
1H NMR (400 MHz, CD3OD): δ = 4.92 (d, 1H, H1, J1-2 = 1.4 Hz), 3.98 – 3.93 (m, 1H, D2), 3.87 
– 3.83 (m, 1H, H2), 3.83 – 3.78 (m, 1H, H7a), 3.78 – 3.71 (m, 1H, H7b), 3.71 – 3.61 (m, 11H, H10, 
D1, H8, H3, H6a), 3.60 – 3.41 (m, 2H, H4, H5), 3.36 – 3.31 (m, 1H, H6b), 2.99 – 2.79 (m, 2H, D4, 
D5), 2.13 – 2.01 (m, 2H, D3ax, D6ax), 1.97 (s, 3H, H12), 1.88 – 1.71 (m, 2H, D3eq, D6eq)  
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.9 (C9); 173.7 (C11); 100.3 (C1); 76.2 (CD1); 73.6 
(C5); 72.6 (C2); 72.3, 72.3 (C3, D2); 70.8 (C7); 69.8 (C4); 52.6 (C10); 44.5 (C8); 41.8 (C6); 40.5, 
40.3 (CD4, CD5); 29.2, 28.2 (CD3, CD6); 22.8 (C12).  
 
 
To a solution of the compound obtained in the previous reaction (5 mg, 0.01 mmol, 1 eq) in 
DMF (0.1 ml) sodium azide (3.5 mg, 0.05 mmol, 5 eq.) was added. The reaction was stirred at 
50°C for 4 days. The solvent was removed at reduced pressure and the crude residue was 
purified by flash chromatography (silica, chloroform with gradient of methanol from 3% to 20%) 
to afford 5 mg of product. 
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Yield = quant.   
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[α]D20  = + 34.4 (c = 0.125 in methanol) 
MS (HRMS) calculated for: [C20H32N4O11Na]+: 527.19653; found: 527.19650 
1H NMR (400 MHz, CD3OD): δ = 4.93 (d, 1H, H1, J1-2 = 1.6 Hz), 4.02 – 3.94 (m, 1H, D2), 3.85 
(dd, 1H, H2, J1-2 = 1.6 Hz, J3-2 = 3.3 Hz), 3.80 – 3.73 (m, 1H, H7a), 3.71 – 3.61 (m, 10H, H10, D1, 
H7b, H3, H6a), 3.60 – 3.45 (m, 2H, H4, H5), 3.42 – 3.34 (m, 3H, H8, H6b), 3.04 – 2.75 (m, 2H, D4, 
D5), 2.18 – 2.03 (m, 2H, D3ax, D6ax), 1.97 (s, 3H, H12), 1.87 – 1.67 (m, 2H, D3eq, D6eq).  
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.9 (C9); 173.7 (C11); 100.4 (C1); 76.4 (CD1); 73.5 
(C5); 72.6 (C2); 72.3, 72.3 (C3, D2); 69.8 (C4); 69.6 (C7); 52.6 (C10); 52.2 (C8); 41.8 (C6); 40.5, 
40.2 (CD4, CD5); 28.9, 28.1 (CD3, CD6); 22.7 (C12).  
2.4.9.11 1,2-Cyclohexanedicarboxylic acid, 4-(2-chloroethoxy)-5-(6-((4-
hydroxymethylene)triazol-1-yl)-α-D-6-deoxymannopyranosyloxy)-1,2-
dimethyl ester, (1S,2S,4S,5S), 2.58 
To a solution of propargyl alcohol  (4.7 mg, 0.083 mmol, 2 eq) in THF (0.5 ml) and water (0.5 
ml) TBTA  (8.8 mg, 0.0166 mmol, 0.4 eq.), copper(II) sulphate (0.5 mg, 0.002 mmol, 0.05 eq.) 
and sodium ascorbate (3.3 mg, 0.0166 mmol, 0.4 eq.) were added. The reaction was stirred at 
room temperature for 10 minutes then 2.55 was added (20 mg, 0.0415 mmol, 1 eq.). The reaction 
was stirred overnight at room temperature under nitrogen. The solvent was removed at reduced 
pressure and the crude residue was purified by flash chromatography (silica, chloroform with 
gradient of methanol from 3% to 30%) to afford 13.7 mg of product. 
 
 
 
Yield = 61 % 
MS (HRMS) calculated for: [C21H32ClN3O11Na]+: 560.9; found: 560.4 
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1H NMR (400 MHz, CD3OD): δ = 7.92 (s, 1H, H11), 4.91 – 4.81 (m, 2H, H1, H6a), 4.67 (s, 2H, 
H13), 4.44 (dd, 1H, H6b, J6a-6b = 14.2 Hz, J6b-5 = 9.3 Hz), 3.87 (dd, 1H, H2, J1-2 = 1.8 Hz, J2-3 = 9.5 
Hz), 3.83 (dd, 1H, H5, J5-4 = 3.0 Hz, J5-6a = 1.8 Hz), 3.71 (dd, 1H, H3, J3-4= 3.0 Hz, J5-3 = 9.4 Hz), 
3.67 – 3.50 (m, 11H, H10, D2, H7a, H4, H8), 3.50 – 3.42 (m, 1H, H7b), 3.16 – 3.11 (m, 1H, D1), 
2.89 – 2.72 (m, 2H, D4, D5), 1.98 – 1.88 (m, 2H, D3ax, D6ax), 1.75 – 1.55 (m, 2H, D3eq, D6eq).  
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.8 (C9); 149.0 (C12); 125.8 (C11); 100.9 (C1); 75.8 
(CD1); 74.2 (C2); 73.0 (C3); 72.5 (C5); 72.3 (C4); 70.8 (C7); 70.0 (D2); 56.7 (C13); 52.9 (C6); 52.6 
(C10); 44.6 (C8); 40.4, 40.2 (CD4, CD5); 29.3, 28.4 (CD3, CD6).  
2.4.9.12 1,2-Cyclohexanedicarboxylic acid, 4-(2-azidoethoxy)-5-(6-(4-
hydroxymethylenetriazol-1-yl)-α-D-6-deoxymannopyranosyloxy)-, 1,2-
dimethyl ester, (1S,2S,4S,5S), 2.48d 
To a solution of 2.55 (13.7 mg, 0.025 mmol, 1 eq) in DMF (0.3 ml) sodium azide (8.2 mg, 0.127 
mmol, 5 eq.) was added. The reaction was stirred at 50°C for 4 days. The solvent was removed at 
reduced pressure and the crude residue was purified by flash chromatography (silica, chloroform 
with gradient of methanol from 3% to 30%) to afford 12.4 mg of product. 
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Yield = 90 %;  
1H NMR (400 MHz, CD3OD): δ = 7.95 (s, 1H, H11), 4.95 – 4.85 (m, 2H, H1, H6a), 4.68 (s, 2H, 
H13), 4.47 (dd, 1H, H6b, J6a-6b = 14.2 Hz, J6b-5 = 9.3 Hz), 3.89 (dd, 1H, H2, J1-2 = 1.9 Hz, J2-3 = 9.6 
Hz), 3.87 – 3.84 (m, 1H, H5), 3.73 (dd, 1H, H3, J3-4= 3.3 Hz, J2-3 = 9.4 Hz), 3.67 – 3.50 (m, 8H, 
H10, D2, H4), 3.54 – 3.47 (m, 1H, H7a), 3.46 – 3.38 (m, 1H, H7b), 3.37 – 3.30 (m, 2H, H8), 3.19 – 
3.13 (m, 1H, D1), 2.91 – 2.73 (m, 2H, D4, D5), 2.03 – 1.93 (m, 2H, D3ax, D6ax), 1.77 – 1.55 (m, 
2H, D3eq, D6eq).  
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13C NMR (100 MHz, CD3OD): δ = 177.1, 176.8 (C9); 149.0 (C12); 125.8 (C11); 100.9 (C1); 76.0 
(CD1); 74.2 (C2); 72.9 (C3); 72.5 (C5); 72.3 (C4); 70.0 (D2); 69.7 (C7); 56.7 (C13); 53.0 (C6); 52.6, 
52.5 (C10); 52.2 (C8); 40.4, 40.1 (CD4, CD5); 29.1, 28.3 (CD3, CD6).  
 
2.4.9.13 1,2-Cyclohexanedicarboxylic acid, 4-(2-chloroethoxy)-5-(6-(4-(N-
carbotertbutoxy)methylene)triazol-1-yl)-α-D-6-
deoxymannopyranosyloxy)-1,2-dimethyl ester, (1S,2S,4S,5S), 2.59 
To a solution of N-Boc propargyl amine  (7 mg, 0.124 mmol, 2 eq) in THF (0.5 ml) and water 
(0.5 ml) TBTA (6.4 mg, 0.025 mmol, 0.4 eq.), copper(II) sulphate (1.5 mg, 0.006 mmol, 0.1 eq.) 
and sodium ascorbate (5 mg, 0.025 mmol, 0.4 eq.) were added. The reaction was stirred at room 
temperature for 10 min then 2.55 was added (30 mg, 0.062 mmol, 1 eq.). The reaction was 
stirred for 4 h at room temperature under nitrogen. The solvent was removed at reduced pressure 
and the crude residue was purified by flash chromatography (silica, chloroform with gradient of 
methanol from 3% to 15%) to afford 36 mg of product. 
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Yield = 93 % 
MS (ESI) calculated for: [C26H41ClN4O12Na]+: 660.1; found: 559.3 
1H NMR (400 MHz, CD3OD): δ = 7.85 (s, 1H, H11), 4.95 – 4.80 (m, 2H, H1, H6a), 4.43 (dd, 1H, 
H6b, J6a-6b = 14.2 Hz, J6b-5 = 9.5 Hz), 4.30 (s, 2H, H13), 3.80 - 3.78 (m, 2H, H5, H2), 3.71 (dd, 1H, 
H3, J3.4 = 3.2 Hz, J3-2 = 9.4 Hz), 3.67 – 3.42 (m, 12H, H10, D2, H7, H4, H8), 3.18 – 3.11 (m, 1H, 
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D1), 2.89 – 2.72 (m, 2H, D4, D5), 2.05 – 1.87 (m, 2H, D3ax, D6ax), 1.76 – 1.55 (m, 2H, D3eq, D6eq), 
1.45 (s 9H, H16), 
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.8 (C9); 147.0 (C12); 125.9 (C11); 100.6 (C1); 80.6 
(C15); 75.8 (CD1); 74.1 (C2); 72.5 (C3); 72.4 (C5); 72.3 (C4); 70.8 (C7); 70.0 (D2); 52.9 (C6); 52.6 
(C10); 44.7 (C8); 40.4, 40.2 (CD4, CD5); 36.9 (C13); 29.2 (CD3 or CD6); 28.9 (C16); 28.3 (CD3 or 
CD6). 
2.4.9.14 1,2-Cyclohexanedicarboxylic acid, 4-(2-azidoethoxy)-5-(6-(4-(N-
carbotertbutoxy)methylene)triazol-1-yl)-α-D-6-
deoxymannopyranosyloxy)-1,2-dimethyl ester, (1S,2S,4S,5S), 2.60 
To a solution of 2.59 (35 mg, 0.0255 mmol, 1 eq) in DMF (0.5 ml) sodium azide (25 mg, 0.384 
mmol, 7 eq.) was added. The reaction was stirred at 50°C for 4 days. The solvent was removed at 
reduced pressure and the crude residue was purified by flash chromatography (silica, chloroform 
with gradient of methanol from 2% to 15%) to afford 30 mg of product. 
 
 
 
Yield = 85 % 
MS (ESI) calculated for: C26H41N7O12Na]+: 666.6; found: 666.3  
1H NMR (400 MHz, CD3OD): δ = 7.86 (s, 1H, H11), 4.92 – 4.79 (m, 2H, H1, H6a), 4.43 (dd, 1H, 
H6b, J6a-6b = 14.2 Hz, J6b-5 = 9.5 Hz), 4.29 (s, 2H, H13), 3.89 - 3.80 (m, 2H, H5, H2), 3.71 (dd, 1H, 
H3, J3.4 = 3.2 Hz, J3-2 = 9.4 Hz), 3.65 (s, 3H, H10), 3.63 (s, 3H, H10), 3.60 - 3.52 (m, 2H, D2, H4), 
3.51 – 3.43 (m, 1H, H7a), 3.47 – 3.33 (m, 3H, H7b, H8), 3.19 – 3.13 (m, 1H, D1), 2.94 – 2.72 (m, 
2H, D4, D5), 2.03 – 1.93 (m, 2H, D3ax, D6ax), 1.77 – 1.55 (m, 2H, D3eq, D6eq), 1.45 (s 9H, H16). 
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13C NMR (100 MHz, CD3OD): δ = 177.1, 176.7 (C9); 147.0 (C12); 125.9 (C11); 100.6 (C1); 80.6 
(C15); 75.8 (CD1); 74.1 (C2); 72.4 (C3, C5); 72.3 (C4); 70.0 (D2); 69.7 (C7); 52.9 (C6); 52.6, 52.5 
(C10); 52.2 (C8); 40.4, 40.1 (CD4, CD5); 36.9 (C13); 29.1 (CD3 or CD6); 28.9 (C16); 28.1 (CD3 or 
CD6). 
2.4.9.15 1,2-Cyclohexanedicarboxylic acid, 4-(2-azidoethoxy)-5-(6-((4-
aminomethylene)triazol-1-yl)-α-D-6-deoxymannopyranosyloxy)-, 1,2-
dimethyl ester, (1S,2S,4S,5S), 2.48e 
2.60 (30 mg, 0.046 mmol, 1 eq.) was dissolved in TFA (1 ml). The resulting solution was stirred 
at 35°C for 20 minutes. The solvent was removed under reduced pressure and the crude residue 
was washed twice with a small amount diethyl ether. The product was dried under reduced 
pressure to afford 25 mg of product. 
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Yield = 98 %;  
[α]D20  = + 14.4 (c = 0.22 in methanol);  
MS (HRMS) calculated for [C21H33N7O10Na]+: 566.21866; found: 566.22022 
1H NMR (400 MHz, CD3OD): δ = 8.08 (s, 1H, H11), 4.90 – 4.79 (m, 2H, H1, H6a), 4.56 (dd, 1H, 
H6b, J6a-6b = 14.2 Hz, J6b-5 = 8.5 Hz), 4.25 (s, 2H, H13), 3.97 - 3.87 (m, 1H, H5), 3.85 (dd, 1H, H2, 
J1-2 = 1.7 Hz, J2-3 = 3.2 Hz), 3.75 - 3.69 (m, 1H, H3), 3.68 - 3.57 (m, 8H, H10, D2, H7a), 3.56 – 
3.45 (m, 2H, H4, H7b), 3.43 – 3.33 (m, 3H, H8), 3.32 – 3.26 (m, 1H, D1), 2.92 – 2.76 (m, 2H, D4, 
D5), 2.05 – 1.93 (m, 2H, D3ax, D6ax), 1.77 – 1.58 (m, 2H, D3eq, D6eq). 
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13C NMR (100 MHz, CD3OD): δ = 177.0, 176.7 (C9); 141.0 (C12); 127.4 (C11); 100.4 (C1); 76.1 
(CD1); 73.6 (C5); 72.4 (D2); 72.4 (C2), 72.2 (C3); 69.7 (C4); 69.6 (C7); 52.9 (C6); 52.6, 52.6 (C10); 
52.2 (C8); 40.4, 40.2 (CD4, CD5); 35.6 (C13); 28.9 (CD3, CD6). 
2.4.9.16  Compound 2.61 
To a solution of N-Boc-(L-)propargyl glycine  (13.3 mg, 0.062 mmol, 1.5 eq) in THF (0.5 ml) 
and water (0.5 ml) TBTA (4.4 mg, 0.0083 mmol, 0.2 eq.), (0.5 mg, 0.002 mmol, 0.05 eq) and 
sodium ascorbate (3.3 mg, 0.0166 mmol, 0.4 eq.) were added. The reaction was stirred at room 
temperature for 10 min then 2.55 was added (20 mg, 0.041 mmol, 1 eq.). The reaction was 
stirred for 2 h at room temperature under nitrogen. TLC (CHCl3:MeOH = 9:1 and 8:2) indicated 
only starting materials therefore another portions of  copper(II) sulphate (0.05 eq) and sodium 
ascorbate (0.4 eq) were added and the reaction was stirred for additional 2 h. The solvent was 
removed at reduced pressure and the crude residue was purified by flash chromatography (silica, 
chloroform with gradient of methanol from 3% to 30%) to afford ca 8.5 mg of product 
containing some insoluble impurities. 
 
 
O
O
Cl
O
O
O
O
OHO
OH
HO
D1
D2
D3
D4
D5
D6
123
4 5
6
7
8
9
10
N N
N11
12
13
OHO
N
H
O
O
14
16 17
18
15
2.61  
Yield = ca 30 % 
MS (ESI) calculated for: [C28H43ClN4O14]+: 695.1; found: 693.1  
1H NMR (400 MHz, D2O): δ = 7.90 (br s, 1H, H11), 4.96 – 4.79 (m, 2H, H1, H6a), 4.45 (dd, 1H, 
H6b, J6a-6b = 13.9 Hz, J6b-5 = 9.5 Hz), 4.12 – 4.23 (m, 1H, H14), 3.98 (dd, 1H, H2, J1-2 = 1.7 Hz, J2-
3 = 7.0 Hz), 3.91 - 3.81 (m, 2H, H5, H3), 3.73 – 3.59 (m, 9H, H10, H4, H8), 3.60 – 3.53 (m, 2H, 
H7a, D2), 3.52 – 3.41 (m, 1H, H7b), 3.27 – 3.17 (m, 1H, H13a), 3.13 – 3.08 (m, 1H, D1), 3.05 – 
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2.92 (m, 1H, H13b), 2.93 – 2.79 (m, 2H, D4, D5), 2.13 – 1.83 (m, 2H, D3ax, D6ax), 1.79 – 1.55 (m, 
2H, D3eq, D6eq), 1.36 (s, 9H, H18), 
13C NMR (100 MHz, D2O): δ = 179.2, 179.1 (C9); 159.0 (C16); 100.9 (C1); 76.0 (CD1); 74.2 (C5); 
72.5 (C3); 73.5 (D2); 72.2 (C2); 72.0 (C3); 70.8 (C7); 70.0 (C4); 54.5, 54.5 (C10); 53.2 (C6); 45.4 
(C8); 40.8 (CD4, CD5); 30.4 (C13); 29.5 (C18); 29.0, 28.6 (CD3, CD6).         
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3.1 Principles of multivalent structures in biological systems and drug design  
The ability of glycans to encode biochemical information has recently emerged and its 
unraveling has been acknowledged as one of the most critical challenges for the postgenomic 
era.1,2,3 The complexity of the problem has often been summarized: carbohydrates are the most 
abundant type of biomolecule in nature. They are widely expressed as glycolipids and 
glycoproteins, and glycosylation is the most widespread post-translational modification of 
proteins. Furthermore, glycans are more complex and difficult to analyze and synthesize than 
other macromolecules. Therefore, despite numerous efforts, the extent to which the sugar code 
has been deciphered is still limited. Nonetheless, it is clearly emerging that many fundamental 
biological processes are controlled by sugar-mediated information, among them: quality control 
of protein folding, intra- and extracellular trafficking of glycoconjugates, signalling, host defence 
pathways, modulation of cell–cell and cell–matrix adhesion, both in physiological situations (as 
egg-sperm interaction, embryogenesis, etc.) and in pathological conditions (inflammation, 
cancer, etc).4 Most of the sugar controlled processes identified so far involve polyvalent 
interactions of glycoconjugates with polyvalent (lectins) proteins. Polyvalent interactions are 
characterized by the simultaneous binding of multiple ligands on one biological entity (a 
molecule, a surface) to multiple receptors on another.5 These interactions occur throughout 
Nature, and have unique features that monovalent interactions do not share. In particular, 
polyvalent interactions can be collectively much stronger than the corresponding monovalent 
interactions: this is exactly the case for carbohydrates. Carbohydrates tend to bind only weakly to 
their complementary proteins6 and stronger binding or enhanced inhibition is often achieved by 
multiple interactions by multivalent carbohydrates compounds. 
There are mainly two different mechanisms of polyvalent binding that can be identified: 
Chelation 
If the protein receptor allows simultaneous binding of more than one ligand of a multivalent 
system to more than one binding site of the protein target, the binding of the second ligand 
should be enhanced, since translational and rotational entropic penalties were already paid for by 
the first binding event (Figure 3.1 A). Chelation can also occur by two non-identical ligands to 
two non-identical binding sites (Figure 3.1 B). Specially in this case, the nature of the spacer 
separating the ligands is of great importance: enhancements can be as high as 103–106 fold, for 
both carbohydrate based systems7 and non-carbohydrate systems.8 
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Statistical rebinding9 
When the tether between the ligands is too short to allow chelation or when the protein contains 
only a single binding site and multivalency enhancements are observed nonetheless, one of the 
active mechanisms can be named statistical rebinding. This effect, also called 
proximity/statistical effect, is caused by the slower off-rate of the multivalent carbohydrate in 
comparison with a monovalent ligand, due to the close proximity of additional ligands that can 
take the place of the first one after it is released, resulting in a net increased affinity (Figure 3.1 
C). In general, non-chelation effects are typically smaller than those observed where a chelation 
mechanism is operating. However, when the multivalent ligands are large and contain many 
ligand copies, the effects can be large as well. 
 
A
B
C
D
 
Figure 3.1 Schematic representation of the main polyvalent binding mechanisms 
 
Both these mechanisms can contribute to binding in the case of multimeric lectins (Figure 3.1D) 
depending on the ligand considered. This is the situation operating with DC-SIGN, which is 
generally presented as a tetramer (see introduction) and with other known lectins.  
In biological settings, the situation can be further complicated by the density of the multimeric 
receptor on the cell membrane. In case of a high density, a ligand which may be too small to 
reach two adjacent binding sites in the same protein, may be able to bridge across two different 
receptor molecules, adding a further layer of complexity to the system. 
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In the first chapter a brief review of some of the multivalent compounds which target DC-SIGN 
are described.10,11,12,13,14,15 From the reported results is clear that the principle of multivalency is 
used with great success in the development of antagonist of lectins such as DC-SIGN. Multi and 
polyvalent structures bearing sugars or sugar mimics were previously prepared also in our group 
(prof. Anna Bernardi, Scheme 3.1). 11,12 
 
 
Scheme 3.1 Boltorn type dendrimer 1.20 and dendron 1.21 decorated with mannose or mannose-
based DC-SIGN inhibitors10,11,12 
 
The two main polyvalent scaffolds used in the DC-SIGN project were a Boltorn type dendrimer 
1.20 able to conjugate 32 copies of a monovalent ligand, and a tetravalent dendron 1.21 also 
derived from 2,2-bishydroxymethylene propanoic acid, which could be loaded with four 
monovalent ligands. Both of them have a polyester backbone which possesses relatively good 
flexibility and water solubility, while the outer shelves are functionalized with carboxylic 
groups. The conjugation occurs via amide bond formation between the amines of the monovalent 
ligands and carboxylic acids of the corresponding scaffolds (Scheme 3.2).   
 
Scheme 3.2 Functionalisation of polyvalent scaffolds 1.20 and 1.21 with a corresponding 
monovalent ligand 
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Compounds such as (2-aminoethyl)-α-D-mannose 2.12j, or the mimics 1.7c16 and 1.917 were 
used as monovalent ligands during the preparation of polyvalent structures (Scheme 3.3). 
 
 
Scheme 3.3 Mannose based monovalent DC-SIGN ligands 2.2j, 1.7c and 1.9 
 
3.2 Goal of the study 
Structures 1.20 and 1.21 demonstrated that going from mono to multivalent presentation is a 
promising way to improve the affinity of our ligands. However, during the preparation of these 
structures some drawbacks, such as relatively long synthesis and chemical instability of the 
scaffolds, were observed. Therefore, to overcome this problem, a set of new multivalent 
structures were proposed (Scheme 3.4). The synthesis and development of these molecules was 
carried out in collaboration with the group of Dr. Javier Rojo (Seville, Spain)18. Several, 
structurally similar multivalent scaffolds have been proposed differing in the number of possible 
functionalization (valency).   
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Scheme 3.4 Multivalent structure developed in the laboratory of Dr. Javier Rojo 
 
The designed molecules have chemically solid backbone decorated with terminal triple bonds 
which allow functionalization with monovalent ligands having an azide function (Scheme 3.5). 
The corresponding reaction is a copper(I) catalyzed dipolar cycloaddition also known as click 
reaction (described more in details in the following section).   
 
n
N3 N N
N
n n
multivalent scaffold
DC-SIGN ligand
Cu(I)
 
 
Scheme 3.5 Functionalisation of polyvalent scaffolds via 1,3 dipolar cycloadition 
 
The three basic structures 3.1,19 3.220 and 3.3 can lead to a tri, tetra and hexavalent presentation 
of a corresponding monovalent ligand. Further, a trivalent scaffold 3.521 was proposed, which 
can be functionalized with three copies of a ligand and, after transformation of the chloride on 
the tail to an azide, to give molecule 3.6. Dendron 3.6 can be connected to scaffolds such as 3.1, 
3.2, 3.3 and 3.4 leading to compounds with higher valency and different shape (Scheme 3.6). For 
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instance, after the functionalization of molecule 3.422 with dendron 3.6 an elongated hexavalent 
system can be obtained. 
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Scheme 3.6 Synthesis of dendron 3.6 and its use in the preparation of multivalent ligands with 
higher valency. 
 
Mannose mimetics 1.7b, 2.2f and 1.9 (described in chapter 1 and 2) we selected as monovalent 
ligands for conjugation with the multivalent scaffolds mentioned above. The IC50 activities of 
these molecules measured by SPR competition are ranging from 0.1 Mm to 0.6 mM, which 
allows us to study the impact of the potency of a monovalent lingand on the multivalency effect.   
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Scheme 3.7 Monovalent mannose based DC-SIGN ligand 
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The general goal is to synthesize a small library of multivalent compounds using different 
scaffolds (Scheme 3.4 and 3.6) and ligands (Scheme 3.7) in order to investigate which 
multivalent structures have the best properties in terms of activity, stability and solubility.  
In order to learn the basic techniques required during the synthesis of multivalent compounds, I 
was seconded for 3 months in the group of Dr. Javier Rojo18 in Seville. Some of the multivalent 
compounds described below were prepared during this period, whereas others were prepared in 
the group of Anna Bernardi (Milano) after my return. 
 
In addition to the scaffolds discussed so far, a new approach of binding DC-SIGN in the 
multivalent fashion is discussed. Based on the fact that DC-SIGN is a homo tetramer with known 
distances between the binding sites (35 – 38 Å)23, a multivalent structure with proper size and 
shape could bind several binding sites simultaneously. The concept of inhibition of multiple 
binding sites by one molecule has been previously found as an efficient way to inhibit certain 
proteins.7,24 To achieve the same goal with DC-SIGN, multivalent structures must be designed 
for this purpose. We thought that elongated molecules functionalized with DC-SIGN ligands at 
the two terminals could reach two binding sites within one CRD (Figure 3.2). The spacer should 
be rigid to control the position of the ligands relative to one another, as well as the distance 
between them. Furthermore, in order to allow some flexibility in the system and to exploit also a 
statistical rebinding mechanism, the two ends of the spacer should be decorated with small, 
flexible dendrons.   
DC-SIGN CRD
multivalent
ligand
 
Figure 3.2 The concept of the inhibition of two binding sites within one DC-SIGN CRD one 
multivalent molecule  
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The rigidity of the spacer could be achieved using aromatic rings connected via triple bonds 
(Scheme 3.8). By preparing “molecular rods”,25 with different number of aromatic-alkyne unit, a 
set of rigid spacers with different lengths can be generated. However, to avoid solubility 
problems (first of all in water) the spacers have to be decorated with functional groups which 
would help to solubilize the final molecule. As already mentioned, the two terminals of the 
molecular rods are functionalized with triple bonds which allow conjugation with molecules 
such as 3.6, bearing previously tested monovalent ligands (Scheme 3.8). The final structures 
consist of a rigid spacer functionalized with two flexible dendrons. A molecule of this type has 
the potential of combining simultaneous binding of two DC-SIGN binding sites (chelation) with 
proximity effects generated at each binding site by the trivalent dendron (statistical rebinding). 
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Scheme 3.8 The strategy of preparation of molecular rods targeting DC-SIGN 
 
Since the final molecules are relatively rigid, the distances between the monovalent ligands of 
each dendrimer play a crucial role. By preparing a set of aromatic rods 3.7, 3.8 and 3.9 the 
overall length of the final molecule can be efficiently tuned. In order to know which molecule 
among the proposed ones is the most promising candidate to inhibit two binding sites 
simultaneously, molecular modeling and docking studies have been performed in collaboration 
with computational chemists within the group.26 
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3.3 Synthesis of multivalent glycoconjugates  
3.3.1 Synthesis of multivalent scaffolds 
The synthesis of structures 3.1 - 3.5 mentioned in the previous chapter was developed in the 
laboratory of Dr. Javier Rojo by a PhD student, Renato Ribeiro (collaboration within 
CARMUSYS)27. The synthesis of multivalent scaffolds used in this study is simple and much 
more efficient in comparison with the preparation of dendrimers 1.20 and 1.21. Compounds 
3.1,20 3.219 and 3.3 can be prepared in one step starting from commercially available starting 
materials. The general strategy is based on the treatment of polyalcohols 3.10 - 3.12 with a base 
in the presence of propargyl bromide (Scheme 3.9).   
 
 
Scheme 3.9 Synthesis of multivalent scaffolds 3.1 – 3.3 
 
Scaffold 3.422 was prepared from ditosylate derivative 3.13 which was treated with an excess of 
propargyl alcohol in the presence of potassium carbonate (Scheme 3.10) 
 
Scheme 3.10 Synthesis of multivalent scaffolds 3.4 
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The synthesis of 3.521 starts from pentaerytritol 3.11 in which three of the alcohols are 
functionalized with a propargyl group (3.14) and the remaining hydroxyl group is substituted 
with a linker in the second step (Scheme 3.11). 
 
Scheme 3.11 Synthesis of dendronic scaffold 3.5 
 
3.3.2 Functionalisation, purification 
The multivalent scaffolds were functionalised with monovalent ligands 1.7b, 2.2f and 1.9. The 
used reaction is a 1,3 dipolar cycloaddition which occurs between the triple bond of the scaffold 
and the azide of the ligand, resulting in a disubstituted triazol ring.  
The 1,3-dipolar cycloadition was described by Huisgen in 1968.28 The reaction required elevated 
temperature resulting in a mixture of 1,4 and 1,5 subtituted triazols (Scheme 3.12).  
 
 
Scheme 3.12 Thermally catalyzed 1,3-dipolar cycloadition 
 
In 2002 the groups of Sharpless29 and Medal30 independently reported a regioselective synthesis 
of 1,4 substituted triazols. The reaction between the alkyne and the azide was mediated by 
copper(I) salts, which provided regioselectivity and allowed to perform the reaction at room 
temperture in shorter times. The copper(I) salt creates a salt with the terminal alkyne and at this 
stage it can coordinate the first nitrogen of the azide group (Scheme 3.13). The proposed 
mechanism explains the importance of copper(I) in the 1,4 regioselectivity of the reaction as well 
as the fact that only terminal alkynes can undergo the  copper catalyzed transformation. 
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Scheme 3.13 Copper(I) catalyzed 1,3-dipolar cycloadition 
 
This copper catalyzed cycloaddition tolerates the presence of oxygen, water, and different 
temperatures or pH, which makes it highly suitable for use in biological systems.31,32,33 The 1,3 
dipolar cycloadition was included in the group of so called “click reactions”. The term “click 
chemistry” is used for those chemical transformations that generate substances quickly and 
reliably by joining small units together. 34,35,36 This is inspired by the fact that nature also 
generates substances by joining small modular units.    
In order to find the proper conditions to perform the 1,3 dipolar cycloaddition (later know as 
click reaction) between our substrates, a range of different conditions was screened in the group 
of Dr. Javier Rojo. The source of copper(I) plays an important role and therefore several salts 
were tested to perform the click reaction. Finally, a previously described37 approach using 
copper(II) sulphate (0.1 equivalent) in combination with sodium ascorbate (0.4 equivalent) was 
found to be an efficient source of Cu(I). In this system, the ascorbate reduces copper(II) to 
copper(I) and moreover its excess prevents the possible re-oxidation. In order to stabilize the 
Cu(I) cation and, once again, prevent its oxidation, tris[(1-benzyl-1H-1,2,3-triazol-4-
il)metyl]amine (TBTA) was used as a stabilizing ligand.38 It was found that 1.1 equivalent of 
azide for 1 equivalent of alkyne is sufficient to achieve full conversion within several hours at 
room temperature. A mixture of water and THF in 1:1 ratio was used as solvent which efficiently 
dissolves all the reagents and starting materials (Scheme 3.14). 
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triple bond
CuSO4 .5H20 (0.1eq)
Sodium ascorbate (0.4eq)
TBTA (0.2eq)
THF:H2O = 1:1
rt, 4-24h
multivalent scaffold
monovalent ligand  
Scheme 3.14 Reaction conditions used for the copper(I) catalyzed 1,3-dipolar cycloadition (click 
reaction) 
 
Using the established protocol, several multivalent compounds were synthesized by me and 
Renato Ribeiro during my stage in Seville (Spain). However, purity issues were observed during 
the 1H NMR and MASS analysis in some of the prepared compounds. One of the molecules with 
the most obvious impurity problem was 3.15 prepared from 3.2 and 2.2f using a click reaction 
(Scheme 3.15).     
 
Scheme 3.15 Synthesis of 3.15 
 
 
The 1H NMR spectra of compound 3.15 showed several peaks in the region 7.9 – 8.1 
ppm, which corresponds for the triazol signals (Figure 3.3). However, the structure of the 
molecule indicates only one singlet. 
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Figure 3.3 1H NMR spectra of the mixture 3.15 with byproducts, (400 MHz, MeOD) 
 
Compound 3.15 was submitted for LC-MASS analysis, which confirmed the presence of several 
molecules and also gave important information about the molecular weights of components of 
the mixture (Figure 3.4). The MASS spectrum indicated the presence of molecule 3.15 and of its 
degradation byproducts 3.15a and 3.15b (Scheme 3.16).  
 
 
Scheme 3.16 Structures and molecular weights with single, double and triple charges of product 
3.15 and byproducts 3.15a-b 
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Figure 3.4 LC-MASS analysis of the mixture of 3.15 with impurities 39 
 
In order to purify the mixture of compounds 3.15 and 3.15a-b, size exclusion chromatography 
was performed. Using Sephadex® LH20 matrix and methanol as eluent, after two attempts only 
partial separation was observed due to the relatively small difference between the molecular 
weight of 3.15 and 3.15a. As other possibility to purify the mixture, reverse phase 
chromatography was used. Using C18 coated TLC plates, water and methanol mixture in 1:1 
ratio was found to be an efficient eluent to separate product 3.15 from 3.15a. However, the 
reverse phase chromatography (Biotage®, C18 columns, water with gradient of methanol from 
0% to 50%) yielded partial separation only with very slow gradient (Figure 3.5).  
 
 
 
 
3.15 
3.15a 
3.15b 
(3.15+H)++
(3.15+H)+++
(3.15a+H)++ 
(3.15b+H)++
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Figure 3.5 Absorption spectra of the fractions coming from the purification of compound  3.15  
using C18 reverse phase column. (Collection - 240 nm, Monitor - 210 nm) 
     
Nevertheless, the partially separated products were submitted to 1H NMR and MALDI MASS 
analysis which confirmed the presence of two compounds 3.15 and 3.15a respectively (Figure 
3.6).  
 
Figure 3.6 1H NMR (MeOD, 400MHz) of fractions collected as 3.15mix and 3.15 during the 
purification showed in Figure 3.5 
 
Compounds 3.15 and 3.15a were not found to be unstable, to click reaction conditions, which 
suggests that the fragmentation happens with the multivalent scaffold before or during the 
reactions. It is known that propargyl groups can undergo rearrangements to reactive allenes. This 
rearrangement can be catalyzed by heat, light or base.40 Furthermore, it was reported that alkynes 
and allenes can undergo inter and intramolecular cyclyzations under different conditions.41 
Indeed, it was observed that most of the scaffolds 3.1 - 3.5 decompose in time even at low 
3.15 
3.15mix 
3.15 
3.15mix 
3.15 3.15a 
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temperatures (-20°C). This fact suggests that the scaffolds must be purified immediately before 
functionalization. With this modification, the synthesis of 3.15 proceeded smoothly and no 
byproducts were formed. Similarly all other dendrons could be prepared from freshly 
chromatographed scaffolds in very high purity. It was further observed that often an excess of 
sodium ascorbate was required to start the reaction or achieve complete conversion. Sodium 
ascorbate can be easily oxidized after which it can not perform the reduction of copper(II) to 
copper(I). To avoid this oxidation process, water was degassed in order to remove the dissolved 
oxygen and THF was freshly distilled to eliminate the presence of peroxides. The reaction was 
performed under nitrogen atmosphere and in the dark. The reaction mixtures were purified by 
size exclusion chromatography using Sephadex®-LH20 matrix and methanol as eluent. Since 
some of the multivalent ligands were studied in biological assays, the potential copper residues 
had to be removed from in tested compounds. In order to remove the residual copper, the 
products isolated via size exclusion chromatography were further purified by reverse phase 
chromatography (C18 columns and water in combination with MeOH or MeCN as eluent) or 
metal scavengers such as QuadrasilTM MP were used.42 
3.3.3 Prepared molecules 
Although 1.7b has only moderate activity with DC-SIGN, its relatively easy synthetical 
accessibility (Chapter 2) and very good water solubility make it a good candidate for the 
synthesis of a variety of multivalent compounds. Using different multivalent scaffolds with one 
monovalent ligand can give us important information about the influence of the type of 
multivalent backbone on the multivalency effect.  Therefore, following the general reaction setup 
(Scheme 3.14), 1.7b was conjugated with most of the scaffolds mentioned above (Scheme 3.17). 
In particular, we prepared a series of structures which present 4, 6 or 9 copies of 1.7b. 
Additionally, two different hexavalent presentations were generated to examine the efficiency of 
scaffolds with different lengths.  
The click reaction using 1.7b was initially performed with nuclei 3.2 and 3.3 which resulted in 
its tetra and hexavalent presentations, 3.16 and 3.17. Further, ligand 1.7b was conjugated with 
3.5 to afford compound 3.18, which after treatment with NaN3 in DMF gave the trivalent 
dendron 3.19. This allows the preparation of higher valency compounds by click reaction with 
alkyne containing scaffolds.   
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Scheme 3.17 Synthesis of dendrons and dendrimers bearing 1.7b via click reaction 
 
Compound 3.16 was prepared in 200 mg scale to investigate the scale up possibilities of the click 
reaction with our substrates. Moreover, 3.16 can be used in different assays and biological 
studies as a reference compound. 1H NMR and MALDI mass analysis showed good purity 
(Figure 3.7).  
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Figure 3.7 1H NMR (400MHz, CD3OD) and MALDI mass spectra (matrix: sinapinic acid, 
solvent H2O/MeOH) of 3.16 
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Dendron 3.19 was further conjugated with scaffolds 3.1 and 3.4 which resulted in a nonavalent 
dendrimer, 3.20, and a hexavalent structure, 3.21, with a flexible spacer between the two 
dendrons (Scheme 3.18).  
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Scheme 3.18 Synthesis of 3.20 and 3.21 using glycodendron 3.19 
 
Compounds 3.21 and 3.20 were obtained as mixtures of the desired product as the major 
component and other byproducts resulting from degradation of the multivalent scaffolds. Both 
molecules were repeatedly purified using size exclusion chromatography (Sephadex LH20, 
methanol) and reverse phase chromatography (silica-C18 matrix, methanol:water), however the 
products were obtained with only approximately 80% purity .    
Bisamide 2.2f, similarly to 1.7b, was conjugated with the tri, tetra and hexavalent scaffolds to 
afford the basic multivalent constructs 3.15, 3.23 and 3.24 (Scheme 3.19).  
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Scheme 3.19  Synthesis of dendrimers (3.15, 3.23) and dendrons (3.24, 3.25) bearing 2.2f via 
click reaction 
 
Initially significant purity issues were observed with the prepared molecules, but when the click 
reactions were repeated using the optimized protocol described above the desired compounds 
were obtained with good purity (Figure 3.8). 
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Figure 3.8 1H NMR (400Mhz, MeOD) and MALDI  mass  spectra (matrix: α-cyano-4-hydroxy-
cinnamic acid, solvent: MeOH) of 3.15 
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Dendron 3.25 was connected via click reaction to nucleus 3.1 in order to obtain multivalent 
ligand 3.26 with nine copies of 2.2f (Scheme 3.20). The product was obtained in relatively good 
purity but unfortunately significant solubility problems were observed. It was found that in the 
case of multivalent ligands bearing 2.2f solubility in water decreases with the growing valency. 
Probably the high number of aromatic residues (benzyls of 2.2f, triazols, and central benzene 
core) give a rather lipophylic profile to the molecule, moreover, π-π stacking interactions 
between the aromatic groups can have a negative effect on the solubility in general. No solubility 
problems were observed with tetravalent 3.15, but hexavalent construct 3.23 already showed 
signs of lower water solubility. In the case of 3.26 with nine 2.2f residues, the solubility was at 
the limit of approximately 2mg/ml, corresponding to a concentration of 0.27 µM. This can be a 
crucial problem during the determination of IC50 since the experiments are performed in water 
media, and leads to the conclusion that six copies of 2.2f within a multivalent structure is on the 
limit in terms of solubility for these constructs.   
 
Scheme 3.20 Synthesis of nonavalent dendrimer 3.26 using dendron 3.25 
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Finally, the most potent monovalent ligand prepared in our laboratory, the pseudotrisaccharide 
1.9, was conjugated with tetra and hexavalent structures to obtain multivalent ligands 3.27 and 
3.28 (Scheme 3.21).  
 
Scheme 3.21 Synthesis of dendrimers 3.27 and 3.28 bearing 1.9 via click reaction  
 
3.3.4 Molecular rods 
In the first part of this chapter a general goal to prepare multivalent structures containing a rigid 
rod-like core was described. The two terminals of the central rod would be decorated with 
flexible dendrons bearing DC-SIGN ligands. The aim of this kind of structures is to bind 
simultaneously two binding sites within one CRD (Figure 3.2 and Scheme 3.8). As it was stated 
in the previous section, with increasing valency the solubility of multivalent compounds starts to 
be a significant issue. Therefore, rather than preparing polyvalent compounds with high valency, 
the investigation focused on multivalent scaffolds that can control the position and orientation of 
the monovalent ligands and thus achieve efficient binding with lower valency.  
The first and simplest molecule 3.7a (Figure 3.9) which could act as a rod was previously 
described and prepared for different purpouses43.  
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Figure 3.9 Structure of rod 3.7a 
 
Although its length may not be sufficient to achieve the desired multiple binding, its structural 
simplicity can be useful to optimize the functionalization step with dendrons such as 3.25 and to 
give us information about the properties of multivalent rod-like structures. Further, ligands built 
on rod 3.7a can be a good comparison with molecules which are long enough to reach two 
binding sites.  
The synthesis of 3.7a is relatively simple: it can be prepared in three steps (Scheme 3.22). In the 
first reaction 1,4-dimethoxy benzene 3.29 is functionalized in positions 2 and 5 with two iodide 
moieties, which are substituted in the following step with triisopropylsilylacetylene (TIPS-
acetylene) via Sonogashira reaction, affording compound 3.31. The TIPS groups are cleaved 
with TBAF to obtain 3.7a in high yield.   
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Scheme 3.22 Synthesis of 3.7a 
 
In order to prepare the first multivalent DC-SIGN ligand with a rigid spacer, compound 3.7a was 
functionalized with dendron 3.25 bearing three copies of monovalent ligand 2.2f (Scheme 3.23). 
The click reaction was performed using the conditions described in the previous section and, 
after purification by size exclusion chromatography, the product was isolated in high yield (90%, 
Scheme 3.22). However after the subsequent purification by reverse phase chromatography the 
yield dropped to 55%. It was later found that 3.32 has solubility issues in water, which could 
explain the loss of product during the purification using reverse phase.   
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Scheme 3.23 Synthesis of 3.32 via click reaction between 3.7a and 3.25 
 
In order to improve the solubility of the final molecule compound 3.7a was modified. The 
methoxy groups were substituted with short polyethyleneglycol chain (PEG), which should 
increase the polarity of the molecule and enhance the solubility in water.  
 
Figure 3.10 Structure of 3.7b 
 
The synthesis of 3.7b starts form the previously obtained 3.30 (Scheme 3.22) which is treated 
with BBr3 at low temperature in order to cleave the methyl ethers and obtain the bis-phenol 3.33 
(Scheme 3.24). In the following step, short PEG chains are introduced by treatment of 3.33 with 
2-(2-chloroethoxy)ethanol in the presence of K2CO3. With product 3.34 Sonogashira coupling 
was performed using 1.5 eq. of TIPS-acetylene, which resulted in the mono and disubstituted 
products 3.35 and 3.36. 3.35 was deprotected using TBAF to obtain the final product 3.7b 
(Scheme 3.23), whereas the monosubstituted compound 3.36 was used during the synthesis of 
longer rods.   
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Scheme 3.24 Synthesis of 3.7b 
 
Another reaction path to obtain product 3.7b could be functionalization of 3.33 with an alkyne 
derivative 3.37 which would result in 3.38 that could be further elaborated to obtain the desired 
rod (Scheme 3.25). However, it was previously described that structures as 3.38 undergo 
intramolecular cyclisations to benzofuranes (3.39). This cyclization can be promoted by various 
reaction conditions, as mild bases,44 palladium/copper catalytic systems,45 TBAF46 and UV 
irradiation 47 Therefore this reaction route was not investigated.  
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Scheme 3.25 Alternative reaction route for the synthesis of 3.7b and the possible cyclysation of 
its intermediate 3.38 
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In order to obtain rods with longer structures, another two molecules have been proposed. The 
first one (3.8) contains two aromatic rings connected via a triple bond, whereas the second 
molecule (3.9) consists of three aromatic rings also connected with triple bonds (Scheme 3.26).  
 
Scheme 3.26 Structure of rod-like scaffolds 3.8 and 3.9 
 
The first attempt to prepare the desired molecules used a Sonogashira coupling between the 
previously prepared molecules 3.36 and 3.7b (Scheme 3.27). This reaction was performed 
several times using different conditions but in most cases a complex mixture of products was 
obtained. The purification of the products was demanding, however two compounds were 
isolated.  
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Scheme 3.27 Synthesis of the desired molecule 3.40 and 3.41 using Sonogashira reaction 
between 3.36 and 3.7b, and the subsequent homo-coupling of 3.40 (Glaser reaction) 
    
Product 3.41 is a precursor for the desired rod 3.9, however 3.42 is the result of dimerisation of 
the desired molecule 3.40 via copper(I) catalyzed Glaser reaction.48,49,31 In order to avoid the 
homo-coupling of 3.40, the monoprotected bis-alkyne 3.43 would be required (Scheme 3.28). 
This could be, in principle, obtained by monodeprotection of 3.35. 
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Scheme 3.28 structure of 3.43 and its possible precursor 3.35 
 
The attempts to deprotect only one of the triple bonds in 3.35 using one equivalent of TBAF 
resulted either in double deprotection (to 3.7b, Scheme 3.29) or in the migration of the TIPS 
group to the oxygen atom (3.44, Scheme 3.29). This suggested that the cleavage can be catalyzed 
by the basic nature of TBAF, therefore THF in combination with acetic acid was used as solvent 
to prevent the deprotection of the second TIPS group. 
 
Scheme 3.29 Attempts to selectively deprotect only one of the TIPS groups in 3.35 
 
 Interestingly, it was observed that in acidic media none of the silyl groups was cleaved using 
TBAF. To prevent the migration of the sylyl groups, the alcohols were protected with acetyl 
moieties (3.45), however the subsequent reaction resulted again in full deprotection even when 
only 0.3 equivalent of TBAF was used (Scheme 3.30).  
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Scheme 3.30 Protection of the free OH groups in 3.35 in order to prevent the migration of TIPS 
and the subsequent attempt to deprotect only one of the TIPS groups in 3.45 
 
The synthesis of 3.8 still remains a target of our study. One of the options to achieve our goal is 
to prepare molecule 3.47 in which the alkynes are protected with two different protecting groups. 
The diverse nature of silyl groups could facilitate the selective deprotection (Scheme 3.31).   
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Scheme 3.31 A possible reaction path to obtain the precursor of 3.8, compound 3.48 
 
Nevertheless, in order to obtain a DC-SIGN ligand with a rod-like structure our study focused on 
compound 3.9 and its precursor 3.41. The first functionalisation of 3.9 was performed with 
pseudodisacharide 1.7b used as a model system (Scheme 3.32). In the first step compound 3.41 
was deprotected with TBAF, and the product was not isolated from the reaction mixture; rather 
ligand 1.7b was added and the click reaction was performed in one pot.  
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Scheme 3.32 Synthesis of 3.49 
 
The product was isolated with good purity and yield and no chemoselectivity problems 
concerning the internal triple bonds were observed (Figure 3.11).   
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Figure 3.11 Structure and 1H NMR (CD3OD, 400MHz) of 3.49 with the assignement of 
aromatical protons 
 
The two final reactions, in order to obtain our target molecules, were performed between 
dendron 3.25 and rod–like structures 3.7b and 3.9 (Scheme 3.33 and 3.34). The synthesis of 3.50 
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was achieved by clicking 3.25 on 3.7b under the click conditions. The product was isolated using 
size exclusion chromatography followed by reverse phase chromatography (Scheme 3.33).  
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Scheme 3.33 Synthesis, 1H NMR (400MHz, CD3OD) and MALDI mass (matrix: sinapinic acid, 
solvent: MeOH) spectra of 3.50  
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Similarly to the reaction shown in Scheme 3.32, for the synthesis of 3.51 the TIPS groups of 3.41 
were cleaved in the first step using TBAF and subsequently the click reaction was performed 
(one pot). Compounds 3.50 and 3.51were obtained in good purity and moderate yields. 
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Scheme 3.34 Synthesis, 1H NMR (400MHz, CD3OD) and MALDI mass (matrix: sinapinic acid, 
solvent: MeOH) spectra of 3.51  
 
 
Although the solubility of 3.50. was improved in comparison with 3.32 it still remains a rather 
significant problem.  
3.4 Activity determination of multivalent structures with DC-SIGN  
3.4.1 SPR 
Similarly to monovalent ligands described in the second chapter, the multivalent 
glycodendrimers described above were tested initially using SPR. The measurements were 
performed in the group of professor Franck Fieschi50 by a PhD student, Ieva Sutkeviciute. Full 
IC50 curve was measured for each compound and the experimental setup was identical to the 
one used for the monovalent ligands showed in the previous chapter. A competition experiment 
was used, and the ligands were tested for their ability to inhibit binding of DC-SIGN to Man-
BSA which is immobilized on the surface of the chip. The multivalent compounds were tested in 
two different campaigns, but some of them were tested in both campaigns as standards in order 
to obtain more accurate comparison between the examined ligands.  
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In the following figure, the structures and activities of 1.7b and of the multivalent constructs 
derived are shown.  
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Figure 3.12 Schematic structures and IC50 values of 1.7b, glycodendron 1.21a  (Boltorn type) 
and glycodendrimers 3.16, 3.17, 3.21 and 3.20 (derived from erythritol) measured by SPR 
 
Comparing the monovalent 1.7b with its multivalent forms significant improvement of the IC50 
values are observed. The tetravalent presentation 3.16 with IC50 = 139 µM is more active by a 
factor of 6.5 in comparison with the monovalent ligand. The two hexavalent ligands 3.17 and 
3.21 showed approximately the same potency with IC50 = 37 µM and 33 µM, which suggests, 
that unlike the valency, the shape of the multivalent molecule has a minor influence on the 
activity if this SPR technique is used for determination. The most remarkable improvement was 
observed in the case of the nonavalent system 3.20, where the activity is higher by a factor of 
approximately 60. Besides the multivalent ligands 3.16, 3.17, 3.20 and 3.21 which are based on 
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the triazole containing scaffolds, also the tetravalent compound 1.21a (see first chapter) with the 
polyester backbone was tested. Its activity is similar to that of the new tetravalent construct 3.16. 
It was previously found that the polyester scaffold of compound 1.21a undergoes 30% 
hydrolysis after 3 hour at pH = 7.5.51 The SPR measurements are done in pH = 8 what may cause 
partial decomposition of the polyester backbone, therefore the sample of 1.21a was prepared 
immediately before the experiment to minimize the degradation.   
Positive affinity improvement was also observed for multivalent forms of the bisamide 
derivative 2.2f. The tetravalent and hexavalent constructs 3.15 and 3.23, both based on the 
triazol-containing scaffolds were tested in the SPR competition assays.  
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Graph 3.1 IC50 values of 2.2f and glycodendrimers 3.15 and 3.23 measured by SPR 
 
The affinity improvement was higher in comparison with 1.7b. The tetravalent presentation 3.15 
showed improvement by a factor of 33 with an IC50 = 6 µM. The hexavelent presentation 3.23 
was found to be the most active DC-SIGN ligand from this series of multivalent compounds with 
an IC50 = 2 µM (Graph 3.1).  
An interesting tendency was observed in the case of pseudotrisaccharide 1.9. Although 1.9 is the 
most potent monovalent mannose mimic among those tested by SPR, its multivalent forms 
showed no or minimum improvement (Graph 3.2). The Boltorn-based tetravalent dendron 1.21b 
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has an IC50 of 62 µM, over half the value of 149 µM observed for the monovalent ligand 1.9 in 
the same campaign. The tetravalent triazol-based construct 3.27 is close to activity to its 
monovalent counterpart (IC50 = 96 µM) and even the hexavalent dendron 3.28 is more active 
only by a factor of 3. 
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Graph 3.2 IC50 values of 1.9 and glycodendrimers 1.21b, 3.27 and 3.28 measured by SPR 
 
The puzzling behavior of multivalent constructs of the pseudotrisaccharide 1.9 was initially 
rationalized by the idea that this monovalent ligand is actually itself a divalent presentation of 
mannose units. If both end of the molecule can interact with the same DC-SIGN Ca2+ site, 
statiscal rebind can occur and this can explain the gain in affinity over the pseudodisaccharide 
1.7 (Scheme 3.13A). Furthermore, when the reducing end terminus is connected to a multivalent 
scaffold, steric hindrance may prevent its interaction with the metal, and thus explain the lack of 
multivalency effect (3.13B). This interpretation, however, was not supported by the X-ray 
structure of the DC-SIGN:1.9 complex, which showed a single binding mode, involving only the 
non-reducing end of the molecule, and fully superimposable with the structure of the 
DC:SIGN:1.7 complex.52 NMR data also showed that the X-ray structure explains at least 80% 
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of the STD interaction observed. A second binding mode may be present in solution, but it does 
not account for more than 20% of the data.53 This distribution cannot account for the one order 
of magnitude increase in affinity observed when going from 1.7 to 1.9. In an effort to understand 
the thermodynamics of the interaction, isothermal calorimetry (ITC) studies were performed in 
Grenoble, by Ieva Sutkeviciute. These titrations provided the surprising result that a 1:2 complex 
is formed in solution at the concentration used (Scheme 3.13C). Further exams, using analytical 
ultracentrifugation (AUC) of DC-SIGN tetramer in the presence of 1.9 confirmed the formation 
of a higher molecular weight species, consistent with a dimer of tetramers. These results led to 
the current working hypothesis: 1.9 apparently can bridge two DC-SIGN ECD using the non 
reducing end mannose for one ECD and the reducing end one for a second ECD (Figure 3.13C). 
Modeling studies did not find significant sterical clashes which would prevent the DC-SIGN 
ECD aggregation induced by 1.9. This hypothesis would explain the low potency of multivalent 
ligands functionalized with 1.9, since the reducing end of 1.9 is not available anymore for 
interaction (Scheme 3.13B). 
 
Figure 3.13 Schematic representation of A) binding of 1.9 to DC-SIGN B) binding of 
multivalent 1.9 to DC-SIGN C) aggregation of two DC-SIGN CRDs induced by monovalent 1.9;  
 
After the first SPR campaign the investigation focused on the preparation of multivalent forms of 
2.2f and on the use of rod-like structures as multivalent scaffolds. Once they were prepared, 
similarly to the majority of final compounds prepared during this thesis, the last series of 
multivalent DC-SIGN ligands 3.26, 3.32, 3.50, 3.51 were sent to Grenoble to perform SPR 
experiments and determine their activities (Graph 3.3). The experimental setup was the same as 
the setup used for both monovalent ligands (second chapter) and multivalent ligands described 
above. The absolute IC50 value of the tested compounds can vary from campaign to campaign 
depending on the SPR chips used, however, their relative inhibition potency should remain same 
(or at least in same range). In order to follow the relative improvements of the activities of the 
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new molecules, some of the previously tested mono and multivalent DC-SIGN ligands were also 
examined along the rod-like structures.   
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Graph 3.3 IC50 values of monovalent ligands 1.7b, 2.2f and glycodendrimers 3.15, 3.16, 3.23, 
3.26, 3.32, 3.50 and 3.51 measured by SPR. * ligand not fully soluble in the buffer used. ** 20% 
DMSO added to the buffer. 
 
 The IC50 values found for the already tested monovalent (1.7b, 2.2f) and multivalent (3.15, 
3.16, 3.23) ligands are in good accordance with the SPR data coming from previous experiments. 
Structure 3.26 with nine copies of 2.2f was tested for the first time in this campaign, however no 
improvement was found in comparison with the hexavalent 3.23 (IC50 = 3 µM) what can be 
attributed to the low solubility of 3.26. The two hexavalent molecules 3.32 and 3.50 built on the 
shortest rod-like unit had the same activity as 3.23 (IC50 = 3 µM). This is in agreement with the 
data from molecular modeling that predicted that 3.32 and 3.50 like 3.23 are not long enough to 
reach two binding sites within one DC-SIGN CRD. Furthermore, the data show that the short 
PEG chain on the central aromatic ring in 3.50 has no effect on the activity. For the most 
complex molecule 3.51 significant solubility issues were reported. Using the same conditions as 
for the other compounds the IC50 was found to be 10 µM but, as with 3.26, this number is likely 
to be incorrect. However adding 20% of DMSO to the buffer the compound was completely 
dissolved and the subsequent measurement showed IC50 = 1 µM.  
Chapter 3   Multivalent glycoconjugate systems 
     211
3.4.2 Relative potency of multivalent ligands (β factor) 
The relative potency, often called β factor, of multivalent ligands is an important value and can 
be considered as a measure of the multivalency effect.5 It can be calculated as the activity of 
monovalent ligand divided by the activity of the corresponding multivalent ligand multiplied by 
the valency (equation 3.1).  
valencyIC
IC
compmultiv
compmonov
⋅= ..
.
50
50β  
Equation 3.1 Calculation of the β factor of multivalent molecules 
 
The higher the β factor, the higher is the multivalency effect. The calculated β factor values of 
each tested multivalent compound are summarized in graph 3.4. 
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Scaffold 
Monovalent 
ligand 
Valency Compound 
 
1.7b 4 1.21a 
1.7b 4 3.16 
 
2.2f 4 3.15 
1.7b 6 3.17 
 2.2f 6 3.23 
 
2.2f 6 3.21 
1.7b 9 3.20 
 
2.2f 9 3.26 
3.32 
(OCH3) 
 
2.2f 6 
3.50 
(-OC2H4OC2H4OH) 
 
2.2f 6 3.51 
Table 3.1 Legend for graph 3.4 
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Graph 3.4 Relative potency (β factor) of multivalent DC-SIGN ligands tested by SPR. * ligand 
not fully soluble in the buffer used. ** 20% DMSO added to the buffer. 
 
 
With multivalent ligands decorated with 1.7b (1.21a, 3.16, 3.17, 3.20 and 3.21) a general trend 
of increasing β factor with growing valency has been observed and the highest relative potency 
was found for the nonavalent 3.20 (β factor = 6.7). On the other hand, among the erirthrytol 
derived scaffolds decorated with 2.2f (3.15, 3.23 and 3.26) the hexavalent 3.23 has the most 
efficient multivalency effect with a β factor of 13.6. Multivalent structures functionalized with 
pseudotrisaccharide 1.9 (not shown in Graph 3.4) have β factors below 1 which indicates that the 
multivalency does not improve the potency, on the contrary it has a significant negative effect. 
For the rod-like structures, the shorter ones 3.32 and 3.50 with six copies of 2.2f have the same β 
factor as 3.23, which is also hexavalent. However the hexavalent elongated rod-like dendrimer 
3.51 has a remarkable relative potency of 41.5 which may be a good indication that this molecule 
can achieve simultaneous binding of two binding site.   
In conclusion regarding the SPR data, multivalent structures bearing the previously optimized 
bis-amide 2.2f, were found to be the most promising among the tested molecules. The relatively 
easy access and  significant multivalency effect of the hexavalent 3.23 suggests that further 
biological or structural studies should focus on this molecule. On the other hand, multivalent 
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compounds with 1.7b gave us an important information about the influence of the scaffold on the 
overall activity of the molecule. Ligand 1.7b is relatively cheap in terms of synthesis, therefore it 
can be used for further screening of novel multivalent scaffolds. In the case of 1.9, it was found 
that going multivalent does not bring any additional improvement in the potency, therefore any 
further investigation of more complex structures with 1.9 should be abandoned.  
Regarding the rod-like multivalent structures it is useful to note that the kind of SPR experiments 
performed so far, for the reason that are fully described below, are not completelly appropriate 
for the determination of improvements which are coming from the simultaneous inhibition of 
two binding sites in one DC-SIGN tetramer. Nevertheless, the results from the last SPR 
campaigns are rather interesting and several suggestions can be proposed for further 
investigation. One of them is related with the bad solubility of some of the multivalent 
compounds bearing bis amide 2.2f. To avoid this problem the rod-like structures should be 
decorated with 1.7b which shows good water solubility in all of its multivalent presentations. 
The lower potency of 1.7b in comparison with 2.2f could result in higher IC50 values, however 
the goal in this case is to achieve the “prove of concept”. The second suggestion is more 
complex and is related with the SPR method used for the activity determination of ligands. The 
potency of our ligands were measured by SPR experiments in which both the DC-SIGN ECD 
and its potential inhibitor are flowing in the buffer media whereas the competitive inhibitor (1-α-
trimannoside) is immobilized on the surface of the chip (for more details see chapter 2). This 
suggests that the increase of activity in the case of  multivalent compounds can be a result of 
both proximity effect and aggregation of two or more DC-SIGN ECDs promoted by the 
multivalent ligand (Figure 3.14A).  
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Figure 3.14 Schematic representation of A) DC-SIGN ECD aggregation induced by a 
multivalent ligand B) DC-SIGN ECD aggregation induced by a multivalent rod-like ligand C) 
simultaneous inhibition of two binding sites in one DC-SIGN ECD by a multivalent rod-like 
ligand 
 
Based on this hypothesis, multivalent compounds containing rigid spacers can inhibit either two 
binding sites of two DC-SIGN tetramers (Figure 3.14B, similarly to 3.14A) or two binding sites 
of the same DC-SIGN tetramer (Figure 3.14C). It is difficult to predict which of these 
hypothetical binding forms has a bigger effect on the outcoming result, but most probably the 
impact is similar. Therefore it is difficult to recognize those compounds which are able to bind 
two binding sites within one CRD using this experimental setup. For this purpose the setup 
should be changed in a way where the DC-SIGN ECD is immobilized on the chip and the 
potential ligand is dissolved in the media. The DC-SIGN ECD immobilization leads to an 
oriented surface in which the density of the DC-SIGN can be controlled.54,55  
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Figure 3.15 Schematic representation of an oriented surface immobilized with DC-SIGN which 
are inhibited by a multivalent rod-like structure 
 
Having the appropriately low density of immobilized DC-SIGN ECD, multivalent compounds 
should be able to bind two binding sites only within one CRD. This should result in a much 
lower IC50 for those compounds which can perform the simultaneous binding.    
3.4.3 Cell studies 
Some of the synthesized compounds were tested for the ability to inhibit HIV transmission in an 
in vitro trans infection assay. Tests were performed by Angela Berzi in the lab of Prof. Clerici at 
the university of Milano.  
B-THP-1/DC-SIGN cells are derived from B-THP-1 human B cell line by transfection of 
DC-SIGN expression vector in order to express high levels of the DC-SIGN receptor at the 
surface of these cells. This cell line supports efficient DC-SIGN mediated HIV transmission and 
it is a widely-used model system to mimic HIV capture and transmission to T-lymphocytes by 
dendritic cells.56 In a first series of experiments, B-THP-1/DC-SIGN or BTHP1 cells pre-
incubated for 30 minutes in the presence or in the absence of the DC-SIGN inhibitors were 
subsequently exposed to HIV (the R5 tropic laboratory-adapted strain HIV-1 BaL) in the 
continued presence of inhibitors. Mannan is known to inhibit DC-SIGN mediated viral 
infection57,58,59 and was used as positive control. Non transfected B-THP-1 cells were used as a 
negative control and, as expected, did not transmit infection. 
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Figure 3.16 Schematic representation of the experimental setup of the HIV trans infection 
studies 
 
After washing, the B-THP-1/DC-SIGN cells were co-cultured with activated CD4+ T 
lymphocytes from healthy volunteer donors. Viral infection of CD4+ T lymphocytes was 
assessed by measuring the concentration of the HIV core protein p24 in the co-culture 
supernatants by ELISA. p24, immunologically distinct from the protein of most other retrovirus, 
is a major structural core component of HIV-1 and is estimated to be present at 2000-4000 
molecules in each virion. The measurement of p24 levels is therefore a commonly exploited 
method to verify the successful infection by the virus. Each point was obtained in triplicate using 
CD4+ T lymphocytes from three different healthy donors, and each compound was tested at 
different concentration (1 µM, 10 µM and 100 µM,). The HIV trans infection studies focused on 
those multivalent structures which were found to be the most active in the SPR experiment, 
namely compounds 3.15 and 3.23. Besides the structures containing bis-amide 2.2f and the 
selected standard 3.16, several other molecules which had been previously tested  were included 
into the campaign (Scheme 3.35).  
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Scheme 3.35 Glycodendrons and glycodendrimers tested by HIV trans infection studies 
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Graph 3.5 Level of HIV infection after the treatment with mono and multivalent DC-SIGN 
ligands in trans HIV infection studies 
 
Tetravalent 3.16 reduced the infection to 66% and 26% at 10 µM and 1 µM concentration, 
respectively. After treatment with compound 3.15, bearing four copies of 2.2f, 47 % of infection 
was determined at 10 µM and almost no infection took place at 100 µM concentration. The most 
impressive inhibition of the trans HIV infection was observed in the case of 3.23 (hexavalent 
2.2f). At 1 µM concentration the infection was reduced to 50 %, and at 10 µM and 100 µM the 
infection was completely suppressed. For comparison, previously prepared and reported 
multivalent ligands 1.21a and 1.21b were also tested. Pseudotrisaccharide 1.9 in its tetravalent 
form, 1.21b, showed similar activity to 3.16 at 1 µM and 10 µM but at 100 µM no infection was 
observed. For pseudodisacharide derivative 1.21a, connected to the same polyester based 
scaffold as 1.21b, very similar activity to compound 3.16 at 1 µM and 100 µM was found, but at 
10 µM higher activity was observed. The most complex multivalent ligand 1.20c with 
approximately 31 copies of 1.9 showed very strong inhibition potency. No infection was 
observed at 10 µM concentration and only 5.9 % of infection took place at 1 µM what is in a 
good agreement with previously reported data. 60  
Activities obtained in the trans infection studies for 3.16, 3.15 and 3.23 are in relatively good 
correlation with the data from the SPR measurements. Approximately 50% of inhibition was 
determined for the tetravalent presentation of 2.2f at 10 µM, leading to the conclusion that the 
IC50 of 3.15 is 10 µM. For the hexavalent presentation 3.23 the IC50 can be set to 1 µM. The 
most potent inhibitor is still the Boltorn type dendrimer 1.20c, however this compound is bearing 
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31 copies of structurally complex 1.9 and moreover, its synthesis is much more demanding in 
comparison with the multivalent structures based on click chemistry. On the other hand, 
compound 3.23, with only 6 copies of 2.2f, approaches the activity of 1.20c what makes 3.23 the 
most efficient multivalent ligand. 
DC-SIGN plays an important role also during the transmission of dengue virus.61 This disease  is 
primarily transmitted by mosquitoes and the symptoms are fever, muscle and joint pains and skin 
rash. In order to examine the potential activity of our compounds to inhibit dengue virus 
infection, compound 3.23 was sent to the group of Dr. Ali Amara62 (INSERM, Paris) to perform 
some initial studies. The experiments were carried out by a PhD, student Rasika Mohan 
Ramdasi. Raji DC-SIGN cells were infected with dengue virus serotype-2 in the presence of 3.23 
at different concentrations (Graph 3.6). 
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Graph 3.6 Level of dengue virus infection after the treatment with 3.23 at different 
concentration 
 
Ligand 3.23 showed concentration dependent antiviral activities. At 50 µM concentration the 
infection was almost completely blocked and the IC50 was found to be 5 µM proving that 
multivalent ligands functionalized with 2.2f can inhibit both HIV and dengue virus at low 
micromolar range.  
The citotoxicity of 3.23 was evaluated by cell labeling after the incubation period with a specific 
marker for death cells, 7-aminoactinomicin D (7-AAD). Percentage of 7-AAD positive cells 
(apoptotic cells) did not change significantly in the absence of the compound or in its presence 
up to 50 µM. 
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The infection studies confirmed that 3.23 is the most interesting ligand. Both the multivalent 
scaffold 3.3 and monovalent ligand 2.2f are synthetically achievable in gram scale in our 
laboratory and only one functionalization is needed to obtain DC-SIGN ligand 3.23. Moreover, 
the final structure 3.23 is chemically stabile unlike the multivalent compounds based on the 
polyester backbone.   
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3.5 Experimental part 
3.5.1 General 
Dichloromethane, methanol, N,N-diisopropylethylamine and triethylamine were dried over 
calcium hydride; THF was distilled over sodium, N,N-dimethylacetamide (DMA) was dried over 
activated molecular sieves (4Å). Reactions requiring anhydrous conditions were performed 
under nitrogen. 1H and 13C spectra were recorded at 400MHz on a Bruker AVANCE-400 and 
300MHz on Brucker  DPX-300 instrument. Chemical shifts (δ) for 1H and 13C spectra are 
expressed in ppm relative to internal standard (CDCl3: 7.24 for 1H and 77.23 for 13C; CD3OD: 
3.31 for 1H and 49.15 for 13C; D2O: 4.80 for 1H). Signals were abbreviated as s, singlet; br s, 
broad singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Mass spectra were obtained with a 
ThermoFisherLCQapparatus (ESI ionization), or iontrap ESI Esquire 6000 from Bruker, or a 
Microflex apparatus (MALDI ionization) from Bruker, or Apex II ICR FTMS (ESI ionization-
HRMS). Specific optical rotation values were measured using a Perkin-Elmer 241, at 589 nm, in 
a 1 dm cell. Thin layer chromatography (TLC) was carried out with pre-coated Merck F254 
silica gel plates. Flash chromatography (FC) was carried out with Macherey-Nagel silica gel 60 
(230–400 mesh).  
Numbering: The numbering used in the NMR characterizations is indicated in the structures 
showed after the procedures. Sugar signals were numbered as customary; cyclohexane protons 
are indicated with the letter D followed by numbers. The unusual numbering of the pseudo-
saccharide derivatives in the NMR characterizations was adopted to facilitate comparison with 
the native disaccharide. In the case of rod-like dendrimers 3.32, 3.49, 3.50 and 3.51 the aryl-
ethynyl units are indicated with the letter R followed by numbers, and the polyethyleneglycol 
chains with letter the G followed with numbers. In the names of the compounds the conventional 
numbering is used.  
Click reaction: In the optimized procedure of the copper(I) catalyzed 1,3-dipolar cycloadition 
the starting materials and reagents were added to the reaction mixtures as solutions in water or 
THF. Monovalent lignds (1.7b, 1.9 and 2.2f) and dendrons (3.19, 3.25) with azide groups were 
added as solids. The reagents were added to the reaction in the following order: multivalent 
scaffold (THF), TBTA (THF), copper(II) sulphate (water), sodium ascorbate (water) and finally 
the azide derivative. The water was degassed by bubbling with nitrogen and the THF was freshly 
distilled. The reactions were stirred under nitrogen atmosphere and protected form light. After 
reaction completion the mixtures were loaded directly on SEPHADEX LH-20 columns (55 cm x 
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3.5cm) to purify the products by size exclusion chromatography. In order to remove copper 
residues from the products reverse phase chromatography was performed (C18, eluent: H2O with 
gradient of methanol or acetonitrile) or to the solution of product in methanol a metal 
scavenger42 (such as QuadrasilTM MP) was added and stirred for 5 min. The scavenger was 
filtered off through a cotton pad and the filtrate was concentrated to obtain the product. 
Compounds 3.2, 3.4, 3.16 - 3.21 and 3.28 were prepared during my secondment in the group of 
Dr. Javier Rojo (Seville)18, whereas the rest of the molecules were synthesized in the group of 
professor Anna Bernardi (Milano). Scaffolds 3.1 and 3.3 were prepared by Renato Ribeiro 
(group of Dr. Javier Rojo) in Seville.  
 
3.5.2 Synthesis of multivalent scaffolds 3.1-3.5  
3.5.2.1 1,3,5-Tris(2-propynyloxy)benzene, 3.119 
To a solution of 1,3,5-trihydroxybenzene (0.265 g, 1.58 mmol, 1 eq.) in dry DMF (4 mL) 
potassium carbonate (anhydrous, 0.628 g, 6.35 mmol, 4.2 eq.) was added at room temperature. 
The solution was stirred at 50ºC for 1 h then propargyl bromide (0.680 mL, 6.35 mmol, 4.2 eq.) 
was slowly added. The mixture was stirred at 65ºC for 16 h. The reaction was quenched by slow 
addition of distilled water then extracted with diethyl ether (3 x 30 mL). The combined organic 
phases were dried over sodium sulphate and concentrated under reduced pressure. The crude was 
purified by flash chromatography (silica, hex:EA = 9:1) to afford 60 mg of pure product. 
O
OO
3.1  
Yield: 25 % 
MS (ESI) calculated for [C15H12O3Na]+: 263.2; found = 262.9. 
1H NMR (300 MHz, CDCl3): δ = 6.27 (s, 3H, Ar-H), 4.67 (d, 6H, OCH2, J2-1 = 2.4 Hz), 2.53 (t, 
3H, CCH, J2-1 = 2.4 Hz) 
3.5.2.2 Tetrakis(2-propynyloxymethyl)methane, 3.220  
To a solution of pentaeritritol (0.1 g, 0.74 mmol, 1 eq.) in dry DMF (20 mL) sodium hydride 
(0.176 g, 3.99 mmol, 5.4 eq.) was added under argon at -5ºC. The solution was stirred at -5ºC for 
1 h then propargyl bromide (0.42 mL, 4.41 mmol, 6 eq.) was added. The reaction mixture kept at 
Chapter 3   Multivalent glycoconjugate systems  
     224
-5ºC for 20 min then, was let to warm up to room temperature and stirred for 19 h. The reaction 
was quenched by slow addition of water then extracted with diethyl ether (3 x 30 mL). The 
combined organic phases were dried over sodium sulphate and concentrated under reduced 
pressure. The crude was purified by flash chromatography (slica, hex:EA = 8.5:1.5) to afford 130 
mg of pure product. 
O
O
O
O
1 2
3
3.2  
Yield: 66 % 
MS (ESI) calculated for [C17H20O4Na]+: 311.1; found = 311.1. 
1H NMR (300 MHz, CDCl3): δ = 4.12 (d, 8H, H2, J2-1 = 2.4 Hz), 3.53 (s, 8H, H3), 2.40 (t, 4H, 
H1, J2-1 = 2.4 Hz) 
3.5.2.3 Hexa(2-propynyloxymethyl) bispentaeritritol, 3.3 
To a solution of bispentaeritritol (0.3 g, 1.18 mmol, 1 eq.) in dry DMF (20 mL) sodium hydride 
(0.34 g, 14 mmol, 11.8 eq.) was added under argon at -5ºC. The solution was stirred at -5ºC for 1 
h then propargyl bromide (1.15 mL, 14 mmol, 11.8 eq.) was added and the mixture was kept at -
5ºC for additional 20 min. The reaction was let to warm up to room temperature and stirred for 
19 h. The reaction was cooled to 0ºC, quenched by slow addition of distilled water and extracted 
with diethyl ether (3 x 30 mL). The combined organic phases were dried over sodium sulphate 
and concentrated under reduced pressure. The crude was purified by flash chromatography 
(slica, hex:EA = 9:1 and 8.5:1.5) to afford 130 mg of pure product. 
 
O
O
O O
O
O
O
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3.3  
Yield: 65 % 
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MS (HRMS) calculated for [C28H34O7Na]+: 483.2383; found = 483.2379. 
1H NMR (300 MHz, CDCl3): δ = 4.12 (d, 12H, H3, J3-1 = 2.4 Hz), 3.52 (s, 12H, H4), 3.38 (s, 4H, 
H6), 2.53 (t, 6H, H1, J3-1 = 2.4 Hz). 
13C NMR (75 MHz, CDCl3): δ = δ 80.2 (C1); 74.3 (C2); 69.9 (C3); 69.3 (C4); 58.9 (C6); 45.2 
(C5). 
3.5.2.4 4,7,10,13,16-Pentaoxanonadeca-1,18-diyne, 3.422 
To a solution of ditosylate 3.14 (60 mg, 0.119 mmol, 1 eq.) in propargyl alcohol (0.5 mL) 
potassium carbonate (66 mg,, 0.477 mmol, 4 eq.) was added. The solution was stirred at 45ºC 
overnight. The reaction was diluted with ethyl acetate washed with water and brine. The organic 
phases was dried over sodium sulphate and concentrated under reduced pressure. The crude was 
purified by flash chromatography (silica, hexane with gradient of ethyl acetate from 20% to 
50%) to afford 30 mg of pure product. 
 
Yield: 93 % 
1H NMR (300 MHz, CDCl3): δ = 4.13 (d, 6H, H3, J3-1 = 2.4 Hz), 3.71 - 3.54 (m, 16H, HPEG), 
2.40 (t, 2H, H1, J3-1 = 2.4 Hz). 
3.5.2.5 Tris(2-propynyloxymethyl)hydroxymethyl methane, 3.1421  
To a solution of pentaeritritol (0.1 g, 0.74 mmol, 1 eq.) in dry DMF (20 mL) sodium hydride 
(0.092 g, 2.29 mmol, 3.1 eq.) was slowly added under argon at 0ºC. The solution was stirred at 
0ºC for 1 h then propargyl bromide (0.25 mL, 2.29 mmol, 3.1 eq.) was added. The reaction 
mixture was stirred at 0ºC for 20 min then, was let to warm up to room temperature and stirred 
for 19 h. The reaction was quenched by slow addition of distilled water then extracted with 
diethyl ether (3 x 30 mL). The combined organic phases were dried over sodium sulphate and 
concentrated under reduced pressure. The crude was purified by flash chromatography (silica, 
hex:EA = 8:2, 7:3) to afford 114 mg of pure product. 
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3.14  
Yield: 62 % 
MS (ESI) calculated for [C14H18O4Na]+: 273.3; found = 273.1. 
1H NMR (300 MHz, CDCl3): δ = 4.14 (d, 6H, H2, J3-1 = 2.3 Hz), 3.69 (s, 2H, H4), 3.57 (s, 6H, 
H3), 2.24 (t, 3H, H1, J3-1 = 2.3 Hz). 
3.5.2.6 2-(2-Cloroethoxy)ethoxymethyl tris(2-propynyloxymethyl)methan, 
3.521 
To a solution of 3.14 (50 mg, 0.2 mmol, 1 eq.) in bis(2-cloroethyl)eter (1 mL) (nBu)4N.HSO4 
(136 mg, 0.4 mmol, 3.1 eq.) and NaOH (aq. 50%, 1 mL) was slowly added at room temperature. 
The reaction mixture was virgously stirred at 40ºC for 18 h then DCM (6 mL) and water (6 mL) 
were added. The organic phase was separated and washed with distilled water (2 x 10 mL), dried 
over sodium sulphate and concentrated under reduced pressure. The crude was purified by flash 
chromatography (silica, hex:EA = 9:1, 8.5:1.5) to afford 60 mg of pure product. 
O
O
O
O O
Cl
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Yield: 80 % 
MS (ESI) calculated for [C18H25ClO5Na]+: 379.8; found = 379.2. 
1H NMR (300 MHz, CDCl3): δ = 4.05 (d, 6H, H2, J3-1 = 2.4 Hz), 3.70 (t, 2H, H8, J7-8 = 5.9 Hz), 
3.61 – 3.50 (m, 6H, H5, H6, H7), 3.46 (s, 6H, H3), 3.40 (s, 2H, H4), 2.33 (t, 3H, H1, J3-1 = 2.4 Hz). 
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3.5.3 Synthesis of rod-like scaffolds 3.7a-b, 3.41 and 3.42 
3.5.3.1 1,4-diiodo-2,5-dimethoxybenzene, 3.3043a 
To a solution of H5IO6 (10 g, 42 mmol, 0.6 eq.) in methanol (70 mL) iodine (11.5 g, 90 mmol, 
1.25 eq.) was added. The resulting solution was stirred at room temperature for 10 min then 1,4-
dimethoxybenzene (10 g, 72 mmol, 1 eq.) was added. The reaction was heated to reflux for 4 h 
then stirred at room temperature overnight. The mixture was poured into an aqueous solution of 
Na2S2O5 (20 g in 200 mL of water) and the resulting precipitates were filtered off, washed with a 
small amount of water (20 mL) and methanol (10 mL) and recrystallized from isopropanol (300 
mL) to afford 11 g of pure product.  
O
O
I
I
3.30  
Yield: 40 % 
1H NMR (400 MHz, CDCl3): δ = 7.18 (s, 2H, Ar-H), 3.81 (s, 6H, OCH3). 
3.5.3.2 1,4-dimethoxy-2,5-bis[2-[tris(1-methylethyl)silyl]ethynyl]benzene, 
3.3143a 
3.30 (200 mg, 0.51 mmol, 1 eq.), Pd(PPh3)4 (23 mg, 0.02 mmol, 0.04 eq.), CuI (4 mg, 0.02 
mmol, 0.04 eq.), and PPh3 (14 mg, 0.05 mmol, 0.1 eq.) were placed into the reaction flask and 
dried under vacuum. The reagents were dissolved by addition of toluene (3 mL) and finally 
ethynyltriisopropylsilane (TIPS-acetylene, 187 mg, 1.02 mmol, 2 eq.), and TEA (2 mL) were 
added under nitrogen. The reaction was heated to 120°C for 24 h. The solvent was removed 
under reduced pressure and the resulting crude was purified by flash chromatography (silica, 
hexane with gradient of ethyl acetate from 0 to 20%) to afford 200 mg of product. 
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Yield: 83 % 
1H NMR (400 MHz, CDCl3): δ = 6.86 (s, 2H, Ar-H), 3.79 (s, 6H, OCH3), 1.3 - 0.94 (m, 6H, Si-
CH), 1.11 – 1.13 (m, 36H, CH(CH3)2). 
3.5.3.3 1,4-Diethynyl-2,5-dimethoxybenzene, 3.7a 43a 
To a solution of 3.31 (100 mg, 0.2 mmol, 1 eq.), in THF (1 mL) a solution of TBAF in THF (1 
M, 1 mL, 1 mmol, 5 eq.) was added. The resulting solution was stirred for 2 h at room 
temperature. The solvent was removed under reduced pressure and the crude was purified by 
flash chromatography (silica, hexane with gradient of ethyl acetate from 0 to 50%) to afford 35 
mg of pure product.  
O
O
3.7a  
Yield: 95 % 
1H NMR (400 MHz, CDCl3): δ = 6.89 (s, 2H, Ar-H), 3.84 (s, 6H, OCH3), 3.38 (s, 2H, CCH). 
3.5.3.4 1,4-Dihydroxy-2,5-diiodobenzene, 3.33 63 
To a solution of 3.30 (7 g, 17.9 mmol, 1 eq.), in DCM (70 mL) a solution of BBr3 in DCM (1 M, 
71 mL, 71 mmol, 4 eq.), was added at -78°C under nitrogen. The reaction was let to warm up to 
room temperature and stirred overnight. The reaction was quenched by addition of water at 0°C 
then the mixture was diluted with ethyl acetate, washed with water and brine, dried over sodium 
sulphate and concentrated under reduced pressure to afford 5.6 g of pure product.  
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Yield: 86 % 
1H NMR (400 MHz, CDCl3): δ = 7.27 (s, 2H, Ar-H), 4.89 (br s, 2H, OH). 
3.5.3.5 1,4-bis[2-(2-hydroxyethoxy)ethoxy]-2,5-diidobenzene, 3.3464  
A solution of 3.33 (1.8 g, 4.97 mmol, 1 eq.), 2(2-Chloroethoxy)ethanol (3.1 g, 24.86 mmol, 5 
eq.) and K2CO3 (2.7 g, 19.88 mmol, 4 eq.) in DMF (10 mL) was stirred at 70°C overnight. The 
solvent was removed under reduced pressure, the crude residue was taken up with ethyl acetate 
and transferred to a separatory funnel, washed with aq. Na2S2O5 (10%), water and dried over 
sodium sulphate. The solvent was removed under reduced pressure and the crude was purified by 
flash chromatography (silica, chloroform with gradient of methanol from 0% to 10%) to afford 
1.5 g of pure product.   
O
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Yield: 57 % 
MS (ESI) calculated for [C14H20I2O6Na]+: 561.1; found = 561.3 
1H NMR (400 MHz, CDCl3): ): δ = 7.22 (s, 2H, H3), 4.11 – 4.07 (m, 4H, H4), 3.88 – 3.84 (m, 
4H, H5), 3.76 – 3.72 (m, 4H, H7), 3.71 – 3.76 (m, 4H, H6), 1.67 (s, 2H, H8). 
13C NMR (100 MHz, CDCl3): δ = 123.6 (C3); 86.7 (C2); 72.8 (C6); 70.3 (C4); 69.7 (C5); 62.1 
(C7). 
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3.5.3.6 1,4-bis[2-(2-hydroxyethoxy)ethoxy]-2-[tris(1-
methylethyl)silyl]ethynyl)-5-idobenzene, 3.36 and 1,4-bis[2-(2-
hydroxyethoxy)ethoxy]-2,5-bis[tris(1-
methylethyl)silyl]ethynyl)benzene, 3.35 
3.34 (50 mg, 0.093 mmol, 1 eq.), Pd(PPh3)4  (4 mg, 0.003 mmol, 0.04 eq.), CuI (6.5 mg, 0.003 
mmol, 0.04 eq.), and PPh3 (2.3 mg, 0.009 mmol, 0.1 eq.) were placed into the reaction flask and 
dried under vacuum, then the reagents were dissolved in toluene (0.6 mL) and finally 
ethynyltriisopropylsilane (TIPS-acetylene, 25.4 mg, 0.139 mmol, 1.5 eq.), and TEA (0.2 mL) 
were added under nitrogen. The reaction was heated to 50°C for 5h. The reaction was diluted 
with EA, filtered through a silica pad and the filtrate was concentrated under reduced pressure. 
The resulting crude was purified by flash chromatography (silica, hexane with gradient of ethyl 
acetate from 0 to 90%) to afford 30.3 mg of product 3.35 and 16.3 mg of product 3.36. 
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3.36 
Yield: 31 %  
MS (ESI) calculated for [C25H41IO6Si]+: 592.6; found = 593.0 
1H NMR (400 MHz, CDCl3): δ = 7.27 (s, 1H, H6), 6.87 (s, 1H, H3), 4.15 – 4.05 (m, 4H, H7, 
H11), 3.93 – 3.78 (m, 4H, H8, H12), 3.77 – 3.58 (m, 8H, H9, H10, H13, H14), 1.16 – 0.86 (m, 3H, 
H17), 1.10 - 1.12 (m, 18H, H18). 
13C NMR (100 MHz, CDCl3): δ = 155.0 (C1); 152.0 (C4); 124.3 (C6); 117.6 (C3); 114.4 (C2); 
102.4 (C15); 96.7 (C16); 87.8 (C5); 72.8, 72.8 (C13, C9); 70.1, 69.8, 69.7, 69.5 (C7, C8, C11, C12); 
62.1, 62.1 (C10, C14); 18.9 (C18); 11.5 (C17). 
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3.35 
Yield: 50 %  
MS (ESI) calculated for [C36H62O6Si2Na]+: 670.0; found = 669.8 
1H NMR (400 MHz, CDCl3): δ = 6.89 (s, 2H, H3), 4.15 – 4.09 (m, 4H, H4), 3.85 – 3.80 (m, 4H, 
H5), 3.74 – 3.67 (m, 4H, H7), 3.66 – 3.59 (m, 4H, H6), 1.29 – 0.91 (m, 6H, H10), 1.10 – 1.12 (m, 
38H, H11). 
13C NMR (100 MHz, CDCl3): δ = 154.1 (C1); 118.2 (C3); 114.7 (C2); 102.9 (C8); 97.1 (C9); 
72.7(C6); 69.9 (C5); 69.3 (C4); 62.1 (C7); 18.9 (C11); 11.6 (C10).  
3.5.3.7 1,4-bis[2-(2-hydroxyethoxy)ethoxy]-2,5-diethynylbenzene, 3.7b 
To a solution of 3.35 (200 mg, 0.31 mmol, 1 eq.), in THF (3 mL) TBAF (1 M, 0.93 mL, 0.93 
mmol, 3 eq.), was added. The resulting solution was stirred for 20 min at room temperature. The 
solvent was removed under reduced pressure and the crude was purified by flash 
chromatography (silica, chloroform with gradient of methanol from 0 to 15%) to afford 62 mg of 
pure product.  
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Yield: 60%  
MS (ESI) calculated for [C18H22NaO6]+: 357.4; found = 357.3 
1H NMR (400 MHz, CDCl3): δ = 6.98 (s, 2H, H3), 4.16 – 4.10 (m, 4H, H4), 3.90 – 3.82 (m, 4H, 
H5), 3.76 – 3.70 (m, 4H, H7), 3.68 – 3.62 (m, 4H, H6), 3.34 (s, 2H, H9). 
13C NMR (100 MHz, CDCl3): δ = 154.2 (C1); 118.4 (C3); 113.8 (C2); 83.2 (C9); 79.6 (C8); 72.7 
(C6); 69.6 (C5); 69.5 (C4); 62.0 (C7). 
3.5.3.8 Rod 3.41 and 3.42 
3.7b (50 mg, 0.151 mmol, 3 eq.), 3.36 (30 mg, 0.05 mmol, 1 eq.), Pd(PPh3)4  (5.8 mg, 0.005 
mmol, 0.1 eq.), CuI (1 mg, 0.005 mmol, 0.1 eq.), and PPh3 (2.6 mg, 0.01 mmol, 0.2 eq.) were 
placed into the reaction flask and dried under vacuum, then the reagents were dissolved by 
addition of toluene (0.6 mL) and TEA (0.2 mL) under nitrogen. The reaction was heated to 50°C 
overnight. The solvent was removed under reduced pressure and the resulting crude was purified 
by flash chromatography (chloroform with gradient of methanol from 0 to 15%) to afford 15.5 
mg of product 3.41 and 5 mg of product 3.42. 
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3.41 
Yield: 50 %  
MS (ESI) calculated for [C68H102NaO18Si2]+: 1286.7; found = 1286.0           
1H NMR (400 MHz, CD3OD): δ = 7.16 (s, 2H, H2), 7.12 (s, 2H, H5), 7.05 (s, 2H, H23), 4.31 – 
4.12 (m, 12H, H7, H11, H24), 3.97 – 3.80 (m, 12H, H8, H12, H25), 3.76 – 3.56 (m, 24H, H9, H10, 
H13, H14, H26, H27), 1.35 – 0.98 (m, 6H, H17), 1.16 – 1.18 (m, 36H, H18). 
13C NMR (100 MHz, CD3OD): δ = 155.9, 155.2, 154.9 (C4, C1, C22); 119.6, 119.1, 118.3 (C5, 
C2, C23); 116.1, 116.0, 115.7 (C3, C6, C21); 104.3 (C15); 97.7 (C16); 92.6, 92.6 (C19, C20); 74.3, 
74.2, 74.1 (C9, C13, C26); 71.2, 71.1, 71.0, 71.0, 70.5 (C7, C8, C11, C12, C24, C25); 65.5, 62.4 (C10, 
C14, C27); 19.3 (C18); 12.7 (C17). 
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3.42 
Yield: 12 %  
MS (ESI) calculated for [C86H122O24Si2Na]+: 1619.0; found = 1618.9 
1H NMR (400 MHz, CD3OD): δ = 7.17 (s, 2H, H2), 7.16 (s, 2H, H23), 7.12 (s, 2H, H5), 7.05 (s, 
2H, H26), 4.27 – 4.15 (m, 16H, H7, H11, H27, H31), 3.95 – 3.82 (m, 16H, H8, H12, H28, H32), 3.72 – 
3.59 (m, 32H, H9, H10, H13, H14, H29, H30, H33, H34), 1.36 – 0.96 (m, 6H, H17), 1.16 – 1.18 (m, 
36H, H18). 
13C NMR (100 MHz, CD3OD): δ = 156.7, 155.8, 154.9 (C1, C4, C22, C25); 119.7, 119.6, 118.4, 
118.4 (C2, C5, C23, C26); 117.1, 116.6, 115.9, 115.6 (C3, C6, C21, C24); 74.4, 74.2, 74.2, 74.1 (C9, 
C13, C29, C33); 71.2, 71.1, 71.0, 70.9, 70.8, 70.6 (C7, C8, C11, C12, C27, C28, C31, C32); 62.6, 62.5, 
62.4 (C10, C14, C30, C34); 19.3 (C18); 12.7 (C17). 
3.5.3.9 1-[2-(2-(tris(1-methylethyl)silyloxy)ethoxy)ethoxy]-4-[2-(2-
hydroxyethoxy)ethoxy]-2,5-diethynylbenzene, 3.44 
To a solution of 3.35 (32 mg, 0.049 mmol, 1 eq.) in THF (0.3 mL)  a solution of TBAF in 
THF (1 M, 0.05 mL, 0.049 mmol, 1 eq.) was added. The resulting solution was stirred for 2 h at 
room temperature. The solvent was removed under reduced pressure and the crude was purified 
by flash chromatography (silica, chloroform with gradient of methanol from 0 to 15 %) to afford 
11.3 mg of product.  
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Yield: 47 %  
1H NMR (400 MHz, CDCl3): δ = 6.98 (s, 1H, H3 or H6), 6.97 (s, 1H, H3 or H6), 4.17 – 4.05 (m, 
4H, H7, H11), 3.90 – 3.79 (m, 6H, H8, H12, H14), 3.77 – 3.70 (m, 2H, H10), 3.70 – 3.58 (m, 4H, H9, 
H13), 3.33 (s, 1H, H16 or H18), 3.30 (s, 1H, H16 or H18), 1.13 – 0.96 (m, 3H, H19), 1.03 – 0.05 (m, 
18H, H20). 
13C NMR (100 MHz, CDCl3): δ = 154.4, 154.0 (C1, C4); 118.6, 118.4 (C3 ,C6); 113.9, 113.8 (C2, 
C5); 83.0, 83.0 (C16, C18); 79.7 (C15, C17); 73.4, 72.7 (C9, C13); 70.0, 69.8, 69.6, 69.5 (C7, C8, C11, 
C12); 63.3(C14); 62.0 (C10); 12.8 (C20); 12.2 (C19). 
3.5.3.10 1,4-bis[2-(2-(acetoxy)ethoxy)ethoxy]-2,5-bis[tris(1-
methylethyl)silyl]ethynyl)benzene, 3.45 
To a solution of 3.35 (50 mg, 0.077 mmol, 1 eq.) in DCM (1 mL) Ac2O (30 µl, 0.31 mmol, 4 eq.) 
and Et3N (64 µl, 0.46 mmol, 6 eq.) were added under nitrogen atmosphere. The reaction was 
stirred at room temperature for 3 h. The solvent was removed under reduced pressure and the 
crude was purified by flash chromatography (silica, hexane with gradient of ethyl acetate from 0 
to 30 %) to afford 33.2 mg of product. 
 
Yield: 59 %  
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1H NMR (400 MHz, CDCl3): δ = 6.88 (s, 2H, H3), 4.23 – 4.16 (m, 4H, H7), 4.14 – 4.05 (m, 4H, 
H4), 3.86 – 3.79 (m, 4H, H5), 3.78 – 3.68 (m, 4H, H6), 2.05 (s, 6H, H13), 1.27 – 0.89 (m, 6H, 
H10), 1.10 – 1.12 (m, 36H, H11). 
3.5.3.11 1,4-bis[2-(2-(acetoxy)ethoxy)ethoxy]-2,5-diethynylbenzene, 3.46  
To a solution of 3.45 (33 mg, 0.045 mmol, 1 eq.) in THF (1 mL) a solution of TBAF in THF 
(0.03 M, 0.3 mL, 0.009 mmol, 0.2 eq.), was added. The resulting solution was stirred for 10 min 
at room temperature. The solvent was removed under reduced pressure and the crude was 
purified by flash chromatography (silica, hexane with gradient of ethyl acetate from 0% to 60%) 
to afford 20.1 mg of product. 
 
Yield: 97%   
1H NMR (400 MHz, CDCl3): δ = 6.97 (s, 2H, H3), 4.24 – 4.18 (m, 4H, H7), 4.16 – 4.08 (m, 4H, 
H4), 3.89 – 3.82 (m, 4H, H5), 3.81 – 3.75 (m, 4H, H6), 3.31 (s, 2H, H9), 2.06 (s, 6H, H11). 
3.5.4 Synthesis of glycodendrons and glycodendriners 3.15–3.21, 3.23-3.26 
and 3.28 
3.5.4.1 Tetravalent glycodendrimer 3.16 
Pseudodisaccharide 1.7b16 (10 mg, 0.02 mmol, 4.4 eq.), scaffold 3.2 (1.4 mg, 0.005 mmol, 1 
eq.), copper(II) sulphate pentahydrate (0.72 mg, 0.003 mmol, 0.1 eq.), sodium ascorbate (2.3 
mg , 0.012 mmol, 0.4 eq.) and TBTA (3 mg, 0.006 mmol, 0.2 eq.) were dissolved in 0.6 mL of 
THF/H2O (1:1). After 2.5 h, the solvent was removed under reduced pressure and the resulting 
crude was purified by size exclusion chromatography (Sephadex LH20, MeOH) to afford 8.6 mg 
of pure product. 
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Yield: 85 % 
[α]D 25 = + 26 (c = 0.2, MeOH) 
MS (ESI-HRMS) calculated for [C89H136N12O48Na]+: 2163.8468; found = 2163.8449 
MS (MALDI, matrix: sinapinic acid, solvent H2O/MeOH)  
calculated for [C89H136N12O48]+: 2142.1; found = 2142.8 
calculated for [C89H136N12O48Na]+: 2165.1; found = 2165.1 
1H NMR (400 MHz, D2O): δ = 8.00 (s, 4H, H11), 4.96 (br s, 4H, H1), 4.63 - 4.59 (m, 8H, H8), 
4.56 (m, 8H, H13), 3.98 - 3.94 (m, 12H, H2, H7), 3.89 - 3.85 (m, 8H, H6a, D2), 3.81 (m, 4H, H3), 
3.77 - 3.65 (m, 32H, H6b, D1,  H10), 3.65 - 3.58 (m, 8H, H4, H5), 3.42 (s, 8H, H14), 2.84 (td, 4H, 
D4 or D5, J = 12.3 Hz, 3.2 Hz), 2.42 (td, 4H, D4 or D5, J = 12 Hz, 2.8 Hz), (td, J = 12 Hz, 2.8 Hz, 
4 Hz), 2.03-1.94 (m, 8H, D3eq., D6eq.), 1.77 - 1.70 (m, 4H, D6ax), 1.48-1.41 (m, 4H, D3ax)     
13C NMR (100 MHz, D2O): δ = 177.2, 176.8 (C9); 144.4 (C12); 125.2 (C11); 98.6 (C1); 73.6 (D1); 
73.4 (C4); 70.8 (D2); 70.5, 70.4 (C2, C3); 68.1 (C14); 66.7 (C7); 66.5 (C5); 63.7 (C13); 60.9 (C6); 
52.5 (C10); 50.4 (C8); 44.8 (C15); 38.7 (D4, D5); 26.8, 26.5 (D3, D6). 
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3.5.4.2 Hexavalent glycodendrimer 3.17 
Pseudodisaccharide 1.7b16 (20 mg, 0.04 mmol, 6.6 eq.), scaffold 3.3 (2.3 mg, 0.005 mmol, 1 
eq.), copper(II) sulphate pentahydrate (0.48 mg, 0.002 mmol, 0.1 eq.), sodium ascorbate (1.6 
mg , 0.048 mmol, 0.4 eq.) and TBTA (1 mg, 0.002 mmol, 0.2 eq.) were dissolved in 1 mL of 
THF/H2O (1:1). After 4 h, the solvent was removed under reduced pressure and the resulting 
crude was purified by size exclusion chromatography (Sephadex LH20, MeOH) to afford 12 mg 
of pure product. 
 
3.16 MALDI MASS  
(matrix: sinapinic acid,  
solvent: H2O/MeOH) 
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Yield: 79 % 
[α]D 25 = + 30 (c = 0.4, MeOH) 
MS (ESI-HRMS) calculated for [C136H208N18O73Na]++: 1653.6450; found = 1653.6460 
MS (ESI) calculated for [C136H208N18O73Na]+: 3286.2; found = 3285.3 
1H NMR (400 MHz, D2O): δ = 8.01 (s, 6H, H11), 4.98 (br s, 6H, H1), 4.60 - 4.56 (m, 24H, H13, 
H8), 3.98 - 3.92 (m, 18H, H2, H7), 3.90 - 3.47 (m, 78H, H6ab, D2, H3, D1, H10, H4, H5), 3.42 (s, 
12H, H14), 3.19 (s, 4H, H16), 2.88 – 2.81 (m, 6H, D4), 2.47 – 2.41 (m, 6H, D5), 1.94 – 1.85 (m, 
12H, D3eq., D6eq.), 1.78 - 1.70 (m, 6H, D6ax), 1.49 - 1.41 (m, 6H, D3ax). 
13C NMR (100 MHz, D2O): δ = 177.1, 176.8 (C9); 144.3 (C12); 125.3 (C11); 98.6 (C1); 73.6 (D1); 
73.5 (C4); 70.8 (D2); 70.5, 70.4 (C2, C3); 68.1 (C14); 66.7 (C7); 66.6 (C5); 63.8 (C13); 60.9 (C6); 
52.4 (C10); 50.4 (C8); 45.1 (C15); 38.7 (D4, D5); 26.9, 26.6 (D3, D6). 
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3.5.4.3 Trivalent glycodendron 3.18 
Pseudodisaccharide 1.7b16 (210 mg, 0.453 mmol, 3.3 eq.), scaffold 3.5 (46.2 mg, 0.129 mmol, 1 
eq.), copper(II) sulphate pentahydrate (3.4 mg, 0.0136 mmol, 0.1 eq.), sodium ascorbate (10.8 
mg , 0.054 mmol, 0.4 eq.) and TBTA (14 mg, 0.026 mmol, 0.4 eq.) were dissolved in 10 mL of 
THF/H2O (1:1). After 1 h TLC (hex:EA = 8:0) indicated presence of scaffold 3.5, therefore 
another portion of sodium ascorbate (10.8 mg , 0.054 mmol, 0.4 eq.) was added, and the reaction 
was stirred another 4 h. The solvent was removed under reduced pressure and the resulting crude 
was purified by size exclusion chromatography (Sephadex LH20, MeOH) to afford 198 mg of 
pure product. 
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Yield: 88 % 
MS (ESI) calculated for [C72H112ClN9O38Na]+: 1768.7; found = 1768.7 
1H NMR (400 MHz, CD3OD): δ = 7.98 (s, 3H, H11), 4.90 (br s, 3H, H1), 4.60 (t, 6H, H8, J8-7 = 5 
Hz), 4.55 (s, 6H, H13), 4.00 - 3.79 (m, 15H, H2, H6a, D2, H7), 3.75 - 3.45 (m, 37H, H6b, D1, H3, 
H10, H4, H5, H17, H18, H19, H20), 3.48 (s, 6H, H14), 3.43 (s, 2H, H16), 2.83 – 2.63 (m, 6H, D4, D5), 
2.04 – 1.92 (m, 6H, D3eq., D6eq.), 1.78 - 1.51 (m, 6H, D3ax, D6ax). 
13C NMR (100 MHz, CD3OD): δ = 177.0, 176.8 (C9); 146.4 (C12); 125.9 (C11); 100.7 (C1); 75.8 
(C3); 75.8 (C5); 72.7 (CD1); 72.7 (C19); 72.6 (C2); 72.3 (D2); 72.2 (C17); 71.5 (C16); 70.8 (C14); 
70.2 (C18); 68.8 (C4); 68.5 (C7); 65.6 (C13); 63.2 (C6); 52.6 (C10); 51.7 (C8); 46.8 (C15); 44.2 
(C20); 40.4, 40.3 (CD4, CD5); 29.0, 28.5 (CD3, CD6).  
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3.5.4.4 Trivalent glycodendron 3.19 
To a solution of 3.18 (150 mg, 0.0855 mmol, 1 eq.) in DMF (1 mL) sodium azide (44.5 mg, 
0.684 mmol, 8 eq.) was added. The reaction was stirred at 60ºC for 4 days. The solvent was 
removed under reduced pressure and the resulting crude was purified by size exclusion 
chromatography (Sephadex LH20, MeOH) to afford 130 mg of pure product. 
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Yield: 87 % 
MS (ESI) calculated for [C72H112N12O38Na]+: 1775.5; found = 1775.5 
1H NMR (400 MHz, CD3OD): δ = 7.97 (s, 3H, H11), 4.90 (br s, 3H, H1), 4.60 (t, 6H, H8, J8-7 = 5 
Hz), 4.55 (s, 6H, H13), 4.01 - 3.80 (m, 15H, H2, H6a, D2, H7), 3.72 - 3.49 (m, 35H, H6b, D1, H3, 
H10, H4, H5, H17, H18, H19), 3.48 (s, 6H, H14), 3.44 (s, 2H, H16), 3.40 – 3.32 (m, 2H, H20), 2.84 – 
2.61 (m, 6H, D4, D5), 2.05 – 1.95 (m, 6H, D3eq., D6eq.), 1.77 - 1.46 (m, 6H, D3ax, D6ax). 
13C NMR (100 MHz, CD3OD): δ = 177.0, 176.8 (C9); 146.4 (C12); 125.9 (C11); 100.7 (C1); 75.8 
(C3); 75.7 (C5); 72.7 (CD1); 72.5 (C2); 72.3 (D2); 72.3 (C17); 71.6 (C16); 71.3 (C19); 70.9 (C14); 
70.2 (C18); 68.8 (C4); 68.5 (C7); 65.6 (C13); 63.2 (C6); 52.6 (C10); 52.0 (C20); 51.7 (C8); 46.8 
(C15); 40.4, 40.2 (CD4, CD5); 29.0, 28.5 (CD3, CD6).  
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3.5.4.5 Hexavalent glycodendrimer 3.21 
Glycodendron 3.19 (25 mg, 0.0142 mmol, 2.2 eq.), bis-alkyne 3.4 (1.7 mg, 0.00648 mmol, 1 
eq.), copper(II) sulphate pentahydrate (0.16 mg, 0.0006 mmol, 0.1 eq.), sodium ascorbate (0.51 
mg , 0.0025 mmol, 0.4 eq.) and TBTA (0.68 mg, 0.0013 mmol, 0.2 eq.) were dissolved in 1 mL 
of THF/H2O (1:1). After 2 h TLC (hex:EA = 8:2) indicated presence of bys-alkyne 3.4, therefore 
another portion of sodium ascorbate (0.51 mg , 0.0025 mmol, 0.4 eq.) was added, and the 
reaction was stirred overnight. The solvent was removed under reduced pressure and the 
resulting crude was purified twice by size exclusion chromatography (Sephadex LH20, MeOH) 
to afford 11.3 mg of product.  
 
 
Yield: 54 % 
[α]D 25 = 17 (c = 0.22, MeOH) 
MS (ESI) calculated for [C158H246N24O81Na]+: 3798.6; found = 3799.4 
1H NMR (400 MHz, D2O): δ = 8.04 (br s, 8H, H11, H18), 4.99 (br s, 6H, H1), 4.68 - 4.52 (m, 
24H, H13, H8), 3.98 - 3.92 (m, 18H, H2, H7), 4.04 - 3.93 (m, 18H, H6a, D2), 3.83 (dd, 6H, H3, J3-2 
= 3.2 Hz, J3-4 = 9.0), 3.80 - 3.47 (m, 96H, H10, H5, H4, H6b, D1, H17, H20, HPEG), 3.42 (s, 12H, 
H14), 3.35 (s, 4H, H16), 2.90 – 2.80 (m, 6H, D4), 2.50 – 2.41 (m, 6H, D5), 2.06 – 1.93 (m, 12H, 
D3eq., D6eq.), 1.81 - 1.70 (m, 6H, D6ax), 1.53 - 1.41 (m, 6H, D3ax). 
13C NMR (100 MHz, D2O): δ = 177.9, 177.6 (C9); 125.4 (C11); 99.3 (C1); 74.3 (D1); 73.5 (C5); 
71.5 (D2); 71.1, 71.1 (C2, C3); 70.3, 70.3, 70.2, 69.7, 69.4, 68.9 (C14, C16, CPEG); 67.4 (C4);  67.3 
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(C7); 64.4, 64.4 (C13, C20); 61.7 (C6); 53.2, 53.2 (C10); 51.1, 50.7 (C17, C8); 45.5 (C15); 39.5, 39.4 
(C4, C5); 27.5, 27.2 (D3, D6). 
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3.5.4.6 Nonavalent glycodendrimer 3.20 
Glycodendron 3.19 (20 mg, 0.0114 mmol, 3.3 eq.), tris-alkyne 3.1 (0.83 mg, 0.00345 mmol, 1 
eq.), copper(II) sulphate pentahydrate (0.086 mg, 0.0003 mmol, 0.1 eq.), sodium ascorbate (0.27 
mg , 0.0014 mmol, 0.4 eq.) and TBTA (0.36 mg, 0.0007 mmol, 0.2 eq.) were dissolved in 1 mL 
of THF/H2O (1:1). After 2 h TLC (C18, H2O:MeOH = 1:1) indicated presence of several 
products (probably intermediates), therefore another portion of sodium ascorbate (0.27 mg , 
0.0014 mmol, 0.4 eq.) was added, and the reaction was stirred overnight. The solvent was 
removed under reduced pressure and the resulting crude was purified by size exclusion 
chromatography (Sephadex LH20, MeOH) and reverse phase flash chromatography (C18, water 
with gradient of MeOH from 30 to 50%) to afford 13 mg of product.  
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Yield: 54 % 
[α]D 25 = 22 (c = 0.22, MeOH) 
MS (MALDI, matrix: 2,5-dihydroxybenzoic acid, solvent: MeOH)  
calculated for [C231H348N36O117]+: 5501.4; found = 5502.5 
calculated for [C231H348N36O117Na]+: 5524.4; found = 5525.7 
1H NMR (400 MHz, CD3OD): δ = 8.10 (s, 3H, H21), 7.94 (s, 9H, H11), 6.33 (s, 3H, H25), 5.11 (s, 
6H, H23), 4.90 (br s, 9H, H1), 4.62 – 4.49 (m, 42H, H8, H13, H20), 3.99 – 3.78 (m, 45H, H7, H2, 
H6a, D2), 3.71 - 3.46 (m, 117H, H6b, D1, H3, H10, H4, H5, H17, H18, H19), 3.44 (s, 18H, H14), 3.38 
(s, 6H, H16), 2.83 – 2.58 (m, 18H, D4, D5), 2.05 – 1.90 (m, 18H, D3eq., D6eq.), 1.77 - 1.49 (m, 
18H, D3ax, D6ax). 
13C NMR (100 MHz, CD3OD): δ = 177.0, 176.8 (C9); 146.3 (C12); 144.8 (C22); 126.4 (C21); 
125.9 (C11); 100.7 (C1); 96.6 (C24); 75.8, 75.8 (C5, C3); 72.7 (CD1); 72.6 (C2); 72.3 (D2); 72.2, 
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71.5, 70.8, 70.5, 70.2 (C14, C16, C17, C19, C18); 68.8 (C4); 68.5 (C7); 65.6 (C13); 63.2 (C23, C6); 
52.7 (C10); 51.7 (C8); 46.8 (C15); 40.4, 40.3 (CD4, CD5); 29.0, 28.5 (CD3, CD6).  
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3.5.4.7 Tetravalent glycodendrimer 3.15 
A flask was charged with the following reagents in the following order: tetra-alkyne 3.2 
(1.94 mg, 0.00674 mmol, 1 eq.), TBTA (3.6 mg, 0.0067 mmol, 1 eq.), copper(II) sulphate 
pentahydrate (0.084 mg, 0.0003 mmol, 0.1 eq.), sodium ascorbate (0.53 mg , 0.00269 mmol, 0.4 
eq.) and finally with bis-amide 2.2f (20 mg, 0.0296 mmol, 4.4 eq.) in 1 mL of THF/H2O (1:1, 
THF freshly distilled and water degassed). The reaction was stirred at room temperature under 
nitrogen atmosphere in dark. After 18 h TLC (silica, hex:EA = 8:2 and C18, H2O: MeOH = 1:1) 
indicated no presence of tetra-alkyne 3.2 and one major product. The reaction was charged to a 
column in order to purify by size exclusion chromatography (Sephadex LH20, MeOH). The 
isolated product was further purified by reverse phase flash chromatography (C18, water with 
gradient of MeOH from 30% to 60%) to afford 16 mg of product.  
 
3.20 MALDI MASS 
(matrix: 2,5-dihydroxybenzoic acid 
solvent: MeOH)
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Yield: 87 % 
[α]D 25 = - 4.7 (c = 0.21, MeOH) 
MS (MALDI, matrix: α-cyano-4-hydroxy-cinnamic acid, solvent: MeOH): calculated for 
[C145H192N20O48Na]+: 3006.2; found = 3005.4 
MS (ESI-HRMS): calculated for [C145H192N20O48]+: 2981.31979; found = 2981.32444 (after 
deconvolution, error: 1.6 ppm) 
1H NMR (400 MHz, CD3OD): δ = 7.96 (s, 4H, H16), 7.31 – 7.07 (m, 32H, H12, H13), 4.89 (br s, 
4H, H1), 4.54 (s, 16H, H15), 4.51 (t, 8H, H8, J8-7 = 5.4 Hz), 4.44 (s, 8H, H18), 4.27 (s, 8H, H10a), 
4.25 (s, 8H, H10b), 3.95 - 3.80 (m, 20H, H2, H6a, D2, H7), 3.72 - 3.60 (m, 12H, H6b, D1, H3), 3.59 - 
3.49 (m, 8H, H4, H5), 3.44 (br s, 8H, H19), 2.90 – 2.75 (m, 8H, D4, D5), 1.96 – 1.66 (m, 16H, D3, 
D6). 
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.9 (C9); 146.3 (C17); 141.7 (C14); 139.2 (C11); 
128.5, 128.3 (C13, C12); 126.2 (C16); 100.6 (C1); 76.3 (C3); 75.7 (CD1); 72.7 (D2); 72.5 (C2); 72.4 
(C5); 70.0 (C19); 69.0 (C4); 68.5 (C7); 65.5 (C18); 65.1 (C15); 63.3 (C6); 52.6 (C10); 51.7 (C8); 46.7 
(C20); 43.8 (C10); 41.9, 41.9 (CD4, CD5); 29.9, 29.2 (CD3, CD6).  
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3.15 1H NMR, 
(400 MHz, CD3OD) 
3.15 13C NMR, 
(100 MHz, CD3OD) 
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3.5.4.8 Hexavalent glycodendrimer 3.23 
A flask was charged with the following regents in the following order: hexa-alkyne 3.3 (2.04 mg, 
0.00424 mmol, 1 eq.), TBTA (2.24 mg, 0.00424 mmol, 1 eq.), copper(II) sulphate pentahydrate 
(0.05 mg, 0.0002 mmol, 0.05 eq.), sodium ascorbate (0.33 mg , 0.0017 mmol, 0.4 eq.) and finally 
with bis-amide 2.2f (20 mg, 0.0297 mmol, 7 eq.) in 1 mL of THF/H2O (1:1, THF freshly distilled 
and water degassed). The reaction was stirred at room temperature under nitrogen atmosphere in 
dark. After 3 h TLC (silica, hex:EA = 8:2 and C18, H2O: MeOH = 1:1) still indicated the 
presence of hexa-alkyne 3.3, therefore another portion of sodium ascorbate (0.33 mg , 
0.0017 mmol, 0.4 eq.) was added. The mixture was stirred overnight, then the reaction was 
charged to a column in order to purify by size exclusion chromatography (Sephadex LH20, 
MeOH). The isolated product was further purified by reverse phase flash chromatography (C18, 
water with gradient of MeOH from 30% to 80%) to afford 13 mg of product.  
 
3.15 MALDI MASS 
(matrix: α-cyano-4-hydroxy-cinnamic acid 
solvent: MeOH) 
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Yield: 70 % 
[α]D 25 = - 2.8 (c = 0.27, MeOH)  
MS (MALDI, matrix: 2,5-dihydroxybenzoic acid, solvent: MeOH) 
 calculated for [C220H292N30O73]+: 4524.8; found = 4524.7 
calculated for [C220H292N30O73Na]+: 4547.8; found = 4549.1 
MS (ESI-HRMS): calculated for [C220H292N30O73]+: 4522.00590; found = 4522.01473 (after 
deconvolution, error: 2.0 ppm) 
1H NMR (400 MHz, CD3OD): δ = 7.95 (s, 6H, H16), 7.28 – 7.07 (m, 48H, H12, H13), 4.89 ( br s, 
6H, H1), 4.54 (s, 24H, H15), 4.51 - 4.45 (m, 12H, H8), 4.44 (s, 12H, H18), 4.28 - 4.20 (m, 24H, 
H10), 3.95 - 3.80 (m, 30H, H2, H6a, D2, H7), 3.73 - 3.61 (m, 18H, H6b, D1, H3), 3.60 - 3.47 (m, 
12H, H4, H5), 3.38 (br s, 12H, H19), 3.26 (br s, 4H, H21), 2.89 – 2.78 (m, 12H, D4, D5), 1.93 – 
1.69 (m, 24H, D3, D6). 
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.9 (C9); 146.3 (C17); 141.7 (C14); 139.2 (C11); 
128.6, 128.3 (C13, C12); 126.1 (C16); 100.7 (C1); 76.3 (C3); 75.7 (CD1); 72.7 (D2); 72.5 (C2, C5); 
71.1 (C21); 70.3 (C19); 69.0 (C4); 68.5 (C7); 65.5 (C18); 65.1 (C15); 63.3 (C6); 52.6 (C10); 51.7 
(C8); 43.8 (C10); 41.9, 41.9 (CD4, CD5); 29.9, 29.3 (CD3, CD6).  
 
Chapter 3   Multivalent glycoconjugate systems 
     255
 
26
.7
11
.7
10
.2
35
.4
33
.3
26
.8
50
.1
53
.0
6.
0
 
 
  
 
 
3.23 1H NMR, 
(400 MHz, CD3OD) 
3.23 13C NMR, 
(100 MHz, CD3OD) 
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3.5.4.9 Trivalent glycodendron 3.24 
A flask was charged with the following reagents in the following order: tris-alkyne 3.5 (8.83 mg, 
0.0247 mmol, 1 eq.), TBTA (2.86 mg, 0.0054 mmol, 0.2 eq.), copper(II) sulphate pentahydrate 
(0.67 mg, 0.0027 mmol, 0.1 eq.), sodium ascorbate (2.13 mg , 0.0108 mmol, 0.4 eq.) and finally 
with bis-amide 2.2f (60 mg, 0.0297 mmol, 3.6 eq.) in 1 mL of THF/H2O (1:1, THF freshly 
distilled and water degassed). The reaction was stirred at room temperature under nitrogen 
atmosphere in dark. After 1 h TLC (silica, hex:EA = 8:2 and C18, H2O: MeOH = 1:1) indicated 
still presence of tris-alkyne 3.5 therefore another portion of sodium ascorbate (2.13 mg , 
0.0108 mmol, 0.4 eq.) was added. After an additional 2 h TLC indicated no 3.5. The reaction 
was charged to a column in order to purify by size exclusion chromatography (Sephadex LH20, 
MeOH) to afford 47.4 mg of product.  
3.23 MALDI MASS 
(matrix: 2,5-dihydroxybenzoic acid 
solvent: MeOH) 
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Yield: 81 % 
MS (MALDI matrix: sinapinic acid, solvent: MeOH):  
calculated for [C114H154ClN15O38]+: 2378.0; found = 2378.5 
1H NMR (400 MHz, CD3OD): δ = 7.98 (s, 3H, H16); 7.28 – 7.16 (m, 24H, H12, H13); 4.89 (br s, 
3H, H1); 4.58 – 4.50 (m, 6H, H8); 4.55 (s, 12H, H15); 4.48 (s, 6H, H18); 4.28 (s, 6H, H10); 4.26 (s, 
6H, H10); 3.99 - 3.80 (m, 15H, H2, H6a, D2, H7); 3.73 - 3.61 (m, 11H, H6b, D1, H3, H25); 3.61 - 
3.44 (m, 12H, H4, H5, H22, H23, H24), 3.42 (br s, 6H, H19), 3.39 (br s, 2H, H21), 2.90 – 2.76 (m, 
6H, D4, D5), 1.96 – 1.68 (m, 12H, D3, D6). 
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.9 (C9), 146.3 (C17), 141.7 (C14), 139.2 (C11), 
128.5, 128.3 (C13, C12), 126.2 (C16), 100.5 (C1), 76.3 (C3); 75.7 (CD1); 72.7 (D2); 72.6 (C24); 72.5, 
72.4  (C2, C5); 72.2, 71.5 (C22, C23); 70.9 (C21); 70.2 (C19); 69.0 (C4); 68.5 (C7); 65.5 (C18); 65.1 
(C15); 63.3 (C6); 51.7 (C8); 46.7 (C20); 44.2 (C25); 43.8 (C10); 41.9, 41.9 (CD4, CD5); 29.9, 29.3 
(CD3, CD6).  
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3.5.4.10 Trivalent glycodendron 3.25 
To a solution of 3.24 (150 mg, 0.0631 mmol, 1 eq.) in DMF (1 mL) sodium azide (25 mg, 0.378 
mmol, 6 eq.) was added. The reaction was stirred at 65ºC for 4 days. The solvent was removed 
under reduced pressure and the resulting crude was purified by reverse phase flash 
chromatography (C18, water with gradient of MeOH from 0% to 70%) to afford 143 mg of pure 
product.  
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Yield: 95 % 
MS (MALDI matrix: sinapinic acid, solvent: MeOH):  
calculated for [C114H154N18O38]+: 2384,5; found = 2385.3 
3.24 MALDI MASS 
(matrix: sinapinic acid 
solvent: MeOH) 
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1H NMR (400 MHz, CD3OD): δ = 7.98 (s, 3H, H16), 7.30 – 7.13 (m, 24H, H12, H13), 4.89 (br s, 
3H, H1), 4.60 – 4.50 (m, 6H, H8), 4.55 (s, 12H, H15), 4.48 (s, 6H, H18), 4.28 (s, 6H, H10), 4.26 (s, 
6H, H10), 3.97 - 3.80 (m, 15H, H2, H6a, D2, H7), 3.73 - 3.62 (m, 9H, H6b, D1, H3), 3.62 - 3.46 (m, 
14H, H4, H5, H22, H23, H24, H25), 3.43 (br s, 6H, H19), 3.40 (br s, 2H, H21), 2.90 – 2.76 (m, 6H, 
D4, D5), 1.96 – 1.69 (m, 12H, D3, D6). 
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.8 (C9), 146.3 (C17), 141.7 (C14), 139.2 (C11), 
128.5, 128.3 (C13, C12), 126.2 (C16), 100.5 (C1), 76.3 (C3); 75.7 (CD1); 72.7 (D2); 72.5, 72.4  (C2, 
C5); 72.3, 71.5, 71.3 (C22, C23, C24); 70.9 (C21); 70.2 (C19); 69.0 (C4); 68.5 (C7); 65.5 (C18); 65.1 
(C15); 63.2 (C6); 51.9 (C25); 51.7 (C8); 46.7 (C20); 43.8 (C10); 41.9, 41.8 (CD4, CD5); 29.9, 29.2 
(CD3, CD6).  
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3.25 1H NMR, 
(400 MHz, CD3OD) 
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3.5.4.11 Nonavalent glycodendrimer 3.26 
A flask was charged with the following reagents in the following order: tris-alkyne 3.1 (0.61 mg, 
0.00838 mmol, 1 eq.), TBTA (0.8 mg, 0.0015 mmol, 0.4 eq.), copper(II) sulphate pentahydrate 
(0.1 mg, 0.00025 mmol, 0.1 eq.), sodium ascorbate (0.3 mg , 0.00025 mmol, 0.4 eq.) and finally 
with glycodendron 3.25 (20 mg, 0.00838 mmol, 3.3 eq.) in 0.8 mL of THF/H2O (1:1, THF 
freshly distilled and water degassed). The reaction was stirred at room temperature under 
nitrogen atmosphere in dark. After 1 h TLC (silica, hex:EA = 8:2 and C18, H2O: MeOH = 1:1) 
indicated still presence of tris-alkyne 3.1 and several new products (probably intermediates) 
3.25 13C NMR, 
(100 MHz, CD3OD) 
3.25 MALDI MASS 
(matrix: 2,5-dihydroxybenzoic acid 
solvent: MeOH) 
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therefore another portion of sodium ascorbate (0.3 mg , 0.00025 mmol, 0.4 eq.) was added and 
the mixture was stirred overnight The reaction was charged to a column in order to purify by size 
exclusion chromatography (Sephadex LH20, MeOH) to afford 14 mg of product 
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Yield: 75 % 
MS (MALDI, matrix: sinapinic acid, solvent: MeOH):  
calculated for [C357H474N54O117]+: 7393,9; found = 7394.5  
MS (ESI-HRMS): calculated for [C357H474N54O117]+: 7389.28007; found = 7393.28658 (after 
deconvolution, error: 0.7 ppm)  
1H NMR (400 MHz, CD3OD): δ = 8.05 (s, 3H, H26), 7.95 (s, 9H, H16), 7.28 – 7.11 (m, 72H, H12, 
H13), 6.29 (br s, 3H, H30), 5.03 (br s, 6H, H28), 4.89 (br s, 9H, H1), 4.63 (s, 6H, H25), 4.55 (s, 
36H, H15), 4.52 – 4.46 (m, 18H, H8), 4.45 (s, 12H, H18), 4.27 (s, 18H, H10), 4.25 (s, 18H, H10), 
3.96 - 3.75 (m, 51H, H2, H6a, D2, H7, H24), 3.75 - 3.62 (m, 27H, H6b, D1, H3), 3.61 - 3.42 (m, 
30H, H4, H5, H22, H23), 3.39 (br s, 18H, H19), 3.36 (br s, 6H, H21), 2.89 – 2.81 (m, 18H, D4, D5), 
1.96 – 1.68 (m, 36H, D3, D6). 
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3.5.4.12 Hexavalent glycodendrimer 3.28 
Pseudotrisahccaride 1.917 (25 mg, 0.04 mmol, 6.6 eq.), hexavalent scaffold 3.3 (2.92 mg, 0.006 
mmol, 1 eq.), copper(II) sulphate pentahydrate (0.15 mg, 0.0006 mmol, 0.1 eq.), sodium 
3.26 1H NMR, 
(400 MHz, CD3OD) 
3.26 MALDI MASS 
(matrix: sinapinic acid 
solvent: MeOH) 
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ascorbate (0.48 mg , 0.0024 mmol, 0.4 eq.) and TBTA (0.63 mg, 0.0012 mmol, 0.2 eq.) were 
dissolved in 1 mL of THF/H2O (1:1). The reaction was stirred overnight, the solvent was 
removed under reduced pressure and the resulting crude was purified by size exclusion 
chromatography (Sephadex LH20, MeOH) to afford 23 mg of product. 
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Yield: 90 % 
[α]D 25 = + 29.4 (c = 0.54, MeOH) 
MS (ESI) calculated for [C172H268N38O206Na]+: 4259.0; found = 4257.9  
                                        [C172H268N38O206Na]+++: 1435.0; found = 1436.1 
1H NMR (400 MHz, D2O): δ = 8.05 (s, 6H, H11), 5.05 (br s, 6H, H1M), 4.84 (br s, 6H, H1M’), 4.74 
– 4.63 (m, 12H, H8), 4.55 (br s, 12H, H13), 4.16 – 4.06 (m, 6H, H7a), 4.06 – 3.99 (m, 12H, HM2, 
D2), 3.99 – 3.94 (m, 6H, H7b), 3.93 - 3.81 (m, 24H, H6aM, H6aM’, H2M’, H3M), 3.82 – 3.57 (m, 84H, 
H10, D1M, H6bM, H6bM’, H3M’, H4M, H4M’, H5M, H5M’), 3.42 (br s, 12H, H14), 3.26 (br s, 4H, H16), 
3.03 – 2.86 (m, 12H, D4, D5), 2.24 – 2.05 (m, 12H, D3eq., D6eq.), 1.92 - 1.67 (m, 12H, D3ax, D6ax). 
13C NMR (100 MHz, D2O): δ = 178.2, 177.9 (C9); 124.6 (C11); 100.5 (C1M’); 99.2 (C1M); 75.1 
(D1); 74.1, 72.7 (C4M, C4M’); 71.6, 71.3, 71.2, 71.2 (C3M, C3M’, C2M, C2M’); 70.6 (D2); 69.2 (C14, 
C16); 68.5 (C6M’); 67.5, 67.3 (C5M, C5M’); 66.5 (C7); 64.4 (C13); 61.7 (C6M); 53.3, 53.2 (C10); 50.7 
(C8); 45.8 (C15); 39.6 (C4, C5); 27.7, 27.3 (D3, D6). 
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3.5.5 Glycodendrimers with rods 3.32 and 3.49-3.51 
3.5.5.1 Rod-like glycoconjugate 3.49 
To a solution of 3.41 (5.5 mg , 0.0043 mmol, 1 eq.) in THF (0.6 mL) a 1M solution of TBAF (1 
drop, cca 10 µl) was added. The reaction was stirred at room temperature. After 1 h TLC 
(DCM:MeOH = 8:2) indicated no starting material. Then, to the reaction mixture the following 
reagents were added in the following order: water (0.6 mL), TBTA (0.46 mg, 0.0008 mmol, 0.2 
eq.), copper(II) sulphate pentahydrate (0.1 mg, 0.0004 mmol, 0.1 eq.), sodium ascorbate (0.34 
mg , 0.0017 mmol, 0.4 eq.) and finally 1.7b (5 mg, 0.0108 mmol, 2.5 eq.). The reaction was 
stirred at room temperature under nitrogen atmosphere in dark. After 2 h TLC (silica, hex:EA = 
8:2 and C18, H2O: MeOH = 1:1) indicated no 3.41, one  major and one minor product. Another 
portion of sodium ascorbate (0.4 eq.) was added and the mixture was stirred overnight. The 
reaction was charged to a column in order to purify by size exclusion chromatography (Sephadex 
LH20, MeOH). The isolated product was further purified by reverse phase chromatography 
(C18, water with gradient of methanol from 0 % to 100 %) to afford 6.2 mg of pure product. 
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Yield: 76 % 
[α]D 25 = 16 (c =  0.27, MeOH)  
MS (HRMS) calculated for [C86H120N6O40]+: 1876.75403; found = 1876.76014 
MS (ESI) calculated for [C86H120N6O40]+: 1877.9; found = 1876.7 
                 calculated for [C86H120N6O40Na]++: 961.9; found = 961.6 
1H NMR (400 MHz, CD3OD): δ = 8.63 (s, 2H, H11), 7.88 (s, 2H, R3), 7.24 (s, 2H, R6), 7.18 (s, 
2H, R11), 4.89 (br s, 2H, H1), 4.68 (t, 4H, H8, J8-7 = 4.7 Hz), 4.39 – 4.31 (m, 4H, G9), 4.31 - 4.22 
(m, 8H, G1, G5), 4.02 - 3.90 (m, 16H, G2, G6, G10, H7), 3.89 - 3.80 (m, 4H, H6a, D2), 3.80 - 3.75 
(m, 6H, H2, G12), 3.75 - 3.59 (m, 26H, H6b, D1, H3, G3, G4, G7, G8, G11), 3.59 – 3.40 (m, 16H, 
H10, H5, H4), 2.81 – 2.56 (m, 4H, D4, D5), 2.04 – 1.88 (m, 4H, D3eq., D6eq.), 1.77 - 1.60 (m, 2H, 
D3ax or D6ax), 1.55 - 1.39 (m, 2H, D3ax or D6ax). 
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13C NMR (100 MHz, CD3OD): δ = 177.1, 176.6 (C9); 155.5, 155.1 (R10, R5); 150.8 (R2); 143.7 
(C12); 127.5 (C11); 122.6 (R1); 119.3 (R11); 118.5 (R6); 116.1, 114.6 (R4, R9); 113.1 (R3); 100.6 
(C1); 92.8, 91.7 (R7, R8); 75.8 (C5); 75.7 (D1); 74.3, 74.3, 73.9 (G3, G7, G11); 72.6, 72.6 (C2, C3); 
72.1 (D2); 71.2, 71.1, 71.0, 71.0, 70.8 (G1 ,G2, G5, G6, G9, G10); 69.6 (C7); 68.7 (C4); 63.2 (C6); 
62.5, 62.5 62.4 (G4 ,G8, G12); 52.5 (C10); 51.7 (C8); 46.8 (C15); 40.3, 40.2 (D4, D5); 29.2, 28.2 
(D3, D6).  
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3.5.5.2 Rod-like glycodendrimer 3.32 
A flask was charged with the following reagents in the following order: rod 3.7a (0.71 mg, 
0.00381 mmol, 1 eq.), TBTA (0.8 mg, 0.0015 mmol, 0.4 eq.), copper(II) sulphate pentahydrate 
(0.1 mg, 0.00038 mmol, 0.1 eq.), sodium ascorbate (0.3 mg , 0.00152 mmol, 0.4 eq.) and finally 
3.49 1H NMR, 
(400 MHz, CD3OD) 
3.49 13C NMR, 
(100 MHz, CD3OD) 
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with glycodendron 3.25 (20 mg, 0.00838 mmol, 2.2 eq.) in 0.8 mL of THF/H2O (1:1, THF 
freshly distilled and water degassed). The reaction was stirred at room temperature under 
nitrogen atmosphere in dark. After 2 h TLC (silica, hex:EA = 1:1 and C18, H2O: MeOH = 1:1) 
indicated still presence of rod 3.7b and two new products (probably mono and distubstituted rod) 
therefore another portion of sodium ascorbate (0.4 eq.) was added and the mixture was stirred for 
another 1h. The reaction was charged to a column in order to purify by size exclusion 
chromatography (Sephadex LH20, MeOH) to afford 17 mg of product which was further 
purified by reverse phase chromatography (C18, water with gradient of methanol from 0 % to 80 
%) to afford 8 mg of pure product. 
O
NN
O N
OHO
HO
OH
O
HO
1
23
4
5
6
7
8
9
10
11
12
13
N
H
O
O
NH
14
15
HO
HO
16
17
18
19
20
O
21 O
N
22
23 24
25
NN
26
27
O
O
R1
R2 R3
R4
3.32
D1D2D3
D4 D5
D6
 
 
Yield: 55 % 
[α]D 25 = -9.5 (c = 0.21, MeOH)  
MS (MALDI, matrix: sinapinic acid, solvent: MeOH):  
calculated for [C240H318N36O78]+: 4955.3; found = 4956.0 
MS (ESI-HRMS): calculated for [C240H318N36O78]+: 4952.20236; found = 4952.20500 (after 
deconvolution, error: 0.5 ppm) 
1H NMR (400 MHz, CD3OD): δ = 8.37 (s, 2H, H26), 7.91 (s, 6H, H16), 7.81 (s, 2H, R2),7.27 – 
7.11 (m, 48H, H12, H13), 4.89 (br s, 6H, H1), 4.59 – 4.54 (m, 4H, H25), 4.53 (s, 24H, H15), 4.51 – 
4.45 (m, 12H, H8), 4.40 (br s, 12H, H18), 4.26 (s, 12H, H10a), 4.24 (s, 12H, H10b), 3.95 - 3.79 (m, 
40H, H2, H6a, D2, H7, H24, R4), 3.72 - 3.57 (m, 18H, H6b, D1, H3), 3.56 - 3.40 (m, 20H, H4, H5, 
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H22, H23), 3.38 – 3.27 (m, 16H, H19, H21), 2.89 – 2.75 (m, 12H, D4, D5), 1.96 – 1.67 (m, 24H, D3, 
D6). 
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.8 (C9); 151.6 (R3); 146.3 (C17); 144.9 (C27); 
141.7, 141.7 (C14); 139.2, 139.2 (C11); 128.5, 128.5 128.3 (C13, C12); 126.4 (C26); 126.0 (C16); 
111.1 (R2); 100.5 (C1); 76.3 (C3); 75.7 (CD1); 72.7 (D2); 72.5, 72.4  (C2, C5); 72.3, 71.6 (C22, 
C23); 70.6, 70.1 (C21, C19); 70.2 (C19); 69.0 (C4); 68.5 (C7); 65.4 (C18); 65.1 (C15); 63.2 (C6); 56.9 
(R4); 51.7 (C25, C8); 46.7 (C20); 43.8 (C10); 41.9, 41.8 (CD4, CD5); 29.9, 29.2 (CD3, CD6).  
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3.5.5.3 Rod-like glycodendrimer 3.50 
A flask was charged with the following reagents in the following order: rod 3.7b (1.27 mg, 
0.00381 mmol, 1 eq.), TBTA (0.8 mg, 0.0015 mmol, 0.4 eq.), copper(II) sulphate pentahydrate 
(0.1 mg, 0.00038 mmol, 0.1 eq.), sodium ascorbate (0.3 mg , 0.00152 mmol, 0.4 eq.) and finally 
with glycodendron 3.25 (20 mg, 0.00838 mmol, 2.2 eq.) in 0.8 mL of THF/H2O (1:1, THF 
freshly distilled and water degassed). The reaction was stirred at room temperature under 
nitrogen atmosphere in dark. After 4 h TLC (silica, hex:EA = 1:1 and C18, H2O: MeOH = 1:1) 
indicated still presence of rod 3.7b and of two new products (probably mono and distubstituted 
rod) therefore another portion of sodium ascorbate (0.4 eq.) was added and the mixture was 
stirred for another 1h. The reaction was charged to a column in order to purify the product by 
size exclusion chromatography (Sephadex LH20, MeOH). The isolated product was further 
purified by reverse phase chromatography (C18, water with gradient of methanol from 0 % to 80 
%) to afford 9.1 mg of pure product. 
 
 
3.32, MALDI MASS 
(matrix: sinapinic acid 
solvent: MeOH) 
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Yield: 45% 
[α]D 25 = -18.9 (c =0.1, MeOH)  
MS (MALDI, matrix: sinapinic acid, solvent: MeOH): 
calculated for [C246H330N36O82]+: 5103.4; found = 5102.6 
MS (ESI-HRMS): calculated for [C246H330N36O82]+: 5100.27592; found = 5100.29384 (after 
deconvolution, error: 3.5 ppm) 
1H NMR (400 MHz, CD3OD): δ = 8.55 (s, 2H, H26), 7.90 (s, 6H, H16), 7.82 (s, 2H, R2), 7.27 – 
7.12 (m, 48H, H12, H13), 4.88 (d, 6H, H1, J1-2 = 1.4 Hz), 4.61 – 4.56 (m, 4H, H25), 4.53 (s, 24H, 
H15), 4.50 – 4.44 (m, 12H, H8), 4.40 (s, 12H, H18), 4.26 (s, 12H, H10a), 4.24 (s, 12H, H10b), 3.94 - 
3.80 (m, 38H, H2, H6a, D2, H7, H24, G1), 3.74 - 3.61 (m, 26H, H6b, D1, H3, G3, G2), 3.60 - 3.38 (m, 
24H, H4, H5, H22, H23, G4), 3.33 (s, 12H, H19), 3.33 – 3.27 (s, 4H, H21), 2.91 – 2.74 (m, 12H, D4, 
D5), 1.96 – 1.66 (m, 24H, D3, D6). 
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.8 (C9); 146.3 (C17); 141.7, 141.7 (C14); 139.2, 
139.2 (C11); 128.6, 128.5, 128.3, 128.3 (C13, C12); 126.4 (C26); 126.1 (C16); 112.6 (R2); 100.6 
(C1); 76.3 (C3); 75.7 (CD1); 73.9 (G3); 72.7 (D2); 72.5, 72.4  (C2, C5); 72.3 – 69.0 (C22, C23, C21, 
C19, G1); 69.0 (C4); 68.5 (C7); 65.5 (C18); 65.1 (C15); 63.3 (C6); 62.5 (G2); 51.7 (C25, C8); 46.7 
(C20); 43.9 (C10); 41.9 (CD4, CD5); 29.7, 29.1 (CD3, CD6).  
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3.5.5.4 Rod-like glycodendrimer 3.51 
To a solution of 3.41 (4.8 mg , 0.00379 mmol, 1 eq.) in THF (0.4 mL) a 1M solution of TBAF (1 
drop, ca 10 µl) was added. The reaction was stirred at room temperature. After 3 h  TLC 
(DCM:MeOH = 8.5:1.5) indicated no starting material. Then, to the reaction mixture the 
following reagents were added in the following order: water (0.6 mL), TBTA (0.8  mg, 
0.0015 mmol, 0.4 eq.), copper(II) sulphate pentahydrate (0.2 mg, 0.00038 mmol, 0.2 eq.), 
sodium ascorbate (0.3 mg , 0.00152 mmol, 0.4 eq.) and finally glycodendron 3.27 (20 mg, 
0.00873 mmol, 2.3 eq.). The reaction was stirred at room temperature under nitrogen atmosphere 
in dark. After 2 h TLC (silica, hex:EA:H2O = 7:3:0.3) indicated no 3.41, one  major and one 
minor product. Another portion of sodium ascorbate (0.4 eq.) was added and the mixture was 
stirred overnight The reaction was charged to a column in order to purify the product by size 
exclusion chromatography (Sephadex LH20, MeOH) to afford 12.5 mg of product. 
 
3.50, MALDI MASS, 
(matrix: sinapinic acid 
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yield: 58% 
[α]D 25 = -8.1 (c = 0.22, MeOH)  
MS (MALDI, matrix: sinapinic acid, solvent: MeOH):  
calculated for [C278H370N36O94Na]+: 5743.1; found = 5744.6 
calculated for [C278H370N36O94]+: 5720.1; found = 5719.9 
MS (ESI-HRMS): calculated for [C278H370N36O94]+: 5716.52790; found = 5719.52543 (after 
deconvolution, error: 2.0 ppm) 
1H NMR (400 MHz, CD3OD): δ = 8.56 (s, 2H, H26), 7.92 (s, 6H, H16), 7.82 (s, 2H, R2), 7.28 – 
7.13 (m, 52H, H12, H13, R5, R10), 4.88 (d, 6H, H1, J1-2 = 1.3 Hz), 4.62 – 4.57 (m, 4H, H25), 4.56 – 
4.48 (m, 36H, H15, H8), 4.39 (s, 12H, H18), 4.32 – 4.17 (m, 36H, H10, G1, G5, G9), 3.95 - 3.79 (m, 
46H, H2, H6a, D2, H7, H24, G2, G6, G8), 3.75 - 3.61 (m, 36H, H6b, D1, H3, G3, G4, G7, G8, G11, 
G12), 3.60 - 3.39 (m, 20H, H4, H5, H22, H23), 3.33 – 3.27 (m, 16H, H21, H19), 2.89 – 2.75 (m, 12H, 
D4, D5), 1.96 – 1.66 (m, 24H, D3, D6). 
13C NMR (100 MHz, CD3OD): δ = 177.1, 176.8 (C9); 146.3 (C17); 143.7 (C27); 141.7(C14); 
139.2, 139.2 (C11); 128.6, 128.5, 128.3, 128.3 (C13, C12); 126.3 (C16); 126.0 (C26); 119.3 (R10, 
R5); 113.5 (R2); 100.6 (C1); 76.3 (C3); 75.7 (CD1); 74.3, 74.3, 73.9 (G3, G7, G11); 72.8 (D2); 72.5, 
72.5  (C2, C5); 72.3 – 69.0 (C22, C23, C21, C19, G1, G5, G9, G2, G6, G10); 69.0 (C4); 68.5 (C7); 65.5 
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(C18); 65.1 (C15); 63.3 (C6); 62.6, 62.5, 62.5 (G4, G8, G12); 51.7 (C25, C8); 46.7 (C20); 43.9 (C10); 
42.0, 41.9 (CD4, CD5); 29.9, 29.2 (CD3, CD6).  
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In this thesis a development of mannobioside mimetics as potential DC-SIGN inhibitors 
in mono and multivalent forms is described.  
The first part (chapter 2) is focusing on structural optimizations of the previously described 
pseudodisaccharide 1.7b (Scheme 4.1). Two major modifications of 1.7b are discussed. In the 
first modification the ester groups on the cyclohexyl ring are replaced by two identical amide 
moieties leading to a focused library of bisamides 2.2a-t. The best ligands exhibited IC50s 
between 150-200 µM, which represents an average improvement by a factor of 3 over the parent 
diester 1.7b, and compound 2.2f was selected as a representative of the 2.2 series. Some of the 
prepared amides were also tested with other lectins besides DC-SIGN to investigate their binding 
selectivity. It was found that bisamides 2.2f binds much better DC-SIGN than Langherin in 
comparison with its counterpart 1.7b. Preliminary studies also showed that multivalent forms of 
bisamide 2.2f have low affinity to the mannose binding lectin (MBL) thus confirming its DC-
SIGN specificity.1 On the other hand, significantly enhanced activity of 2.2f towards the FimH 
adhesion protein was found in comparison with the D-mannose monosaccharide.2 These results 
showed that the replacement of the methylesters in 1.7b by aromatic amides can lead to binding 
specificity of our compounds and further investigations should focus on this issue. 
The second modification of 1.7b, described in the last part of chapter 2, is a replacement of the 
hydroxyl group in position 6 of the mannose residue. Among the prepared molecules 2.48a-c and 
e, the primary amine derivative 2.48a showed an improvement by a factor of 2 in comparison 
with 1.7b having the IC50 at 453 µM (Scheme 4.1).   
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1 Gobbi, M. et. al., unpublished results 
2 Lindhorst, T.; Kolbe, K., unpublished results 
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Scheme 4.1 Brief summary of the two modification of 1.7b described in the second chapter 
 
A merger of 2.2f and 2.48a resulting in compound 4.1 could be a target for further 
investigations.   
 
 
 
Scheme 4.2 compound 4.1, a potential target molecule 
 
The suggested synthetic strategy for the preparation of 4.1 is a combination of approaches 
showed in schemes 2.15 and 2.24 (Chapter 2). In the proposed reaction path glycosyl acceptor 
4.2 (prepared from epoxide 2.29) is functionalized with mannose donor 2.49b bearing an azide in 
position 6 (Scheme 4.3). The p-nitrophenols in compound 4.3 are substituted with benzylamine 
derivative 2.12f followed by deprotection of the benzoyl groups. The azide moiety in 4.5 is 
reduced and subsequently protected by a Boc group in one pot. In the following steps the 
chloride in 4.6 is replaced by an azide and the Boc group is cleaved, resulting in the target 
molecule 4.1 (Scheme 4.3).    
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Scheme 4.3 The proposed reaction route for the synthesis of 4.1 
 
In order to predict the activity improvement of the suggested molecule 4.1, it is important to 
understand the binding modes of 2.2f and 2.48a. If these two molecules interact with the binding 
site of DC-SIGN in a similar fashion, the fusion of 2.2f and 2.48a could lead to a ligand which 
combines the activity and selectivity improvements of both of these molecules. In order to 
understand the interaction of our molecules with the binding site of DC-SIGN, structural studies 
using techniques such as STD–NMR are being carried out by our collaborators within the 
CARMUSYS network. The upcoming results should answer the questions regarding the binding 
modes of 2.2f and 2.48a and possibly predict the binding behavior of 4.1.  
The second part of my thesis (Chapter 3) focused on the preparation of multivalent constructs 
decorated with the previously developed monovalent DC-SIGN ligands. The alkyne containing 
scaffolds 3.1 - 3.5 were functionalized with ligands such as 1.7b, 2.2f and 1.9 via the 1,3 dipolar 
cycloadition (click reaction) leading to a set of multivalent DC-SIGN inhibitors with different 
valency (Scheme 4.4). The prepared molecules were tested by SPR and HIV infection studies 
which showed significant multivalency effect.  
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Scheme 4.4 multivalent constructs described in the third chapter 
 
The most potent ligand 3.23 (hexavalent presentation of 2.2f) have the IC50 value at the level of 
3 µM in the SPR experiment and at 1 µM level in the HIV trans infection studies. This study also 
led to the first molecule able to inhibit DC-SIGN mediated B-cell infections by Dengue virus.  
Further, an approach which tries to combine the simultaneous binding of two DC-SIGN binding 
sites (chelation) with the proximity effects (statistical rebinding) was investigated. Elongated and 
rigid structures consisting of alkyne-aryl unites were proposed as spacers and prepared. These 
rod-like molecules were functionalized at both ends with flexible dendrons decorated with 3 
copies of 2.2f (Figure 4.1).  
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Figure 4.1 Schematic representation of multivalent rod-like structures which are able to inhibit 
two bindig sites within one DC-SIGN tetramer  
 
The initial experiments showed that these molecules are synthetically achievable in a relatively 
simple way. The SPR studies indicated higher multivalency effect for the hexavalent rod-like 
ligand (3.51) in comparison with structures having the same valency but lacking the rigid spacer 
(3.23, see Chapter 3, Graph 3.4). The results concerning the development of multivalent rod-like 
constructs are still preliminary, however the relatively simple synthetic accessibility and the 
significant multivalency effect are encouraging and further studies should be carried out. During 
the development of rod-like ligands several issues have been observed. The first of them is 
related with the low water solubility of the final molecules, whereas the second issue deals with 
the SPR experimental setup. Some suggestions have been already proposed (section 3.4.2, 
chapter 3) to overcome these problems. The low water solubility could be solved by the use of 
more soluble monovalent DC-SIGN ligands such as 1.7b. Another solution could be a 
functionalization of the central aromatic rings with highly polar molecules such as 
monosaccharides, which should improve the water solubility (Scheme 4.5). Moreover, the steric 
hinderance created by the saccharide residues could prevent aggregations between the aromatic 
groups of the rod and 2.2f, and thus keep the molecule elongated and exposed.   
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Scheme 4.5 Functionalisation of rod 3.41 (Chapter 3) with monosacharides in order to increase 
its the water solubility 
 
Regarding the activity determination a modification of the SPR experimental setup was proposed 
in which DC-SIGN is immobilized on the surface of the chip. If the density of the immobilized 
DC-SIGN is appropriately low, the simultaneous binding showed in figure 4.1 should manifest 
as a significant increase of the potency of the measured molecules.  
 
The results obtained in this thesis and the suggestions mentioned above, could help to rationalize 
the design of mono and multivalent DC-SIGN ligands leading to novel and superior inhibitors.   
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